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ABSTRACT  
Mitochondria produce the majority portion of ATP required in eukaryotic cells. ATP is 
generated through a process known as oxidative phosphorylation, through an pathway 
consisting five multi subunit proteins (complex I-IV and ATP synthase), embedded inside 
the mitochondrial membrane. Mitochondrial electron transport chain dysfunction 
increases reactive oxygen species in the cell and causes several serious disorders. 
Described herein are the synthesis of antioxidant molecules to reduce the effects in an 
already dysfunctional system. Also described is the study of the mitochondrial electron 
transport chain to understand the mechanism of action of a library of antioxidants. 
Illustrated in chapter 1 is the general history of research on mitochondrial dysfunction 
and reported ways to ameliorate them. Chapter 2 describes the design and synthesis of a 
series of compounds closely resembling the redox-active quinone core of the natural 
product geldanamycin. Geldanamycin has been reported to confer cytoprotection to 
FRDA lymphocytes in a dose dependent manner under conditions of induced oxidative 
stress. A library of rationally designed derivatives has been synthesized as a part of our 
pursuit of a better neuroprotective drug. Chapter 3 describes the design and synthesis of a 
library of pyrimidinol analogues. Compounds of this type have demonstrated the ability 
to quench reactive oxygen species and sustain mitochondrial membrane potential. 
Described herein are our efforts to increase their metabolic stability and total ATP 
production. It is crucial to understand the nature of interaction between a potential drug 
molecule and the mitochondrial electron transport chain to enable the design and 
synthesis a better therapeutic candidates. Chapter 4 describes a part of the enzymatic 
  ii 
binding studies between a molecular library synthesized in our laboratory and the 
mitochondrial electron transport chain using sub mitochondrial particles (SMP). 
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CHAPTER 1 
INTRODUCTION 
1.1. General Introduction to Mitochondria 
Mitochondrial studies have been at the heart of biochemistry for a long time. 
Although a great deal has been learned in the last few decades, mitochondrial research 
has been fertile for more than a century.1 With the involvement of new techniques and 
researchers having diverse scientific backgrounds, there have been new research 
outcomes reported with increasing frequency. 
Mitochondria (Figure 1.1) are often referred to as the power plants in cells. Most 
human cells have thousands of mitochondria with incredible bioenergetic capacity. 
Mitochondria, being the key to the existence of a eukaryotic cell, are involved in 
numerous cellular processes such as cell growth, cell messaging, aging, replication, 
apoptosis, ion homeostasis, innate immune response and programmed cell death.2-7 
Therefore, faulty mitochondrial function can lead to several diseases involving organs 
and tissues which are demanding energetically; such as heart, brain and skeletal muscles.8 
Impaired mitochondrial function is associated with several pathological conditions such 
as Alzheimer’s disease,9 Parkinson’s disease,10 cancer,11 diabetes,12 epilepsy,13 
Huntington’s disease14 and obesity.15 
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                     A                                             B                                            C 
Figure 1.1. Mitochondria Inside Mammalian Cell, Photographed Using a Zeiss Axiovert 
200M Inverted Microscope, with a 40×40 Oil Objective.  
A) Nucleus Stained with Hoechst 33342 Dye. B) Mitochondria Stained with Mitotracker 
Green. C) Overlay of A and B. 
Figure Courtesy: Dr. Zhiqiang Yu at Arizona State University. 
 
1.2. Discovery of Mitochondria 
 
The earliest report on organelles, which probably were mitochondria, dates back 
to the 1840s, right after the discovery of the nucleus in a cell.8 German scientist Richard 
Altman was the first person to recognize a separate granule shaped entity with metabolic 
and genetic self-sufficiency which he named “bioblasts”.8 Bioblasts were later named 
mitochondria by Karl Benda in 1898 originating from the Greek words “mitos” (granule) 
and “chondros” (granule).8 
Mitochondria are believed to be remnants of an ancient bacteria that were 
incorporated into cytoplasm by early eukaryotic cells about a billion years ago.16 Over 
time, mitochondria evolved to be an essential part of the eukaryotic cell, yielding 
required energy essential for survival. Later in the 1960s, scientists discovered that 
mitochondria still retain their own DNA and layered cell membrane.17 Scientist Peter D. 
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Mitchell was awarded the 1978 Nobel Prize for Chemistry for his discovery of 
the chemiosmotic mechanism for ATP synthesis in mitochondria. 
1.3. The Mitochondrial Structure 
Mitochondria are membrane bound organelles with sizes ranging from 1-10 M 
in length and 0.5 M in diameter.7 Mitochondria can have drastically different 
morphologies depending upon cell type. Even in a single cell mitochondria can appear as 
a sphere, a small rod or as a long tubule. Imaging studies with mitochondria in live cells 
have demonstrated that mitochondria constantly move and undergo structural 
transformations. Mitochondrial tubules move with their long axes aligned along 
cytoskeletal tracts. Individual mitochondria can encounter other mitochondria and 
undergo a fusion reaction resulting in merging of the double membrane and mixing 
between the mitochondrial content. At steady state, mitochondrial shape, length and 
numbers are controlled by a balance between fusion and fission.7 Electron micrographs, 
and therefore texts, sometimes show a misleading picture of a 'typical' mitochondrion as a 
two-dimensional bacterium-sized ellipsoid.   
The mitochondrion is enclosed by two layers, of which the outer layer is the 
simpler and more permeable phospholipid layer containing protein structures called 
porins, and a more complex and less permeable inner layer containing all the proteins 
participating in the mitochondrial electron transport chain.18 The intermembrane space is 
the space between the outer membrane and the inner membrane. The inner mitochondrial 
membrane is compartmentalized into numerous cristae, which expand the surface area of 
the inner mitochondrial membrane, enhancing its ability to produce ATP.19 
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Figure 1.2. Cross-Sectional Image of a Mitochondrion.8 
 1.4. Mitochondrial Electron Transport Chain 
Electrons are transferred through a series of proteins (complexes I-IV) in the 
mitochondrial electron transport chain (ETC) (Figure 1.3). This process is coupled with 
the transfer of protons (H+ ions) across the inner mitochondrial membrane, generating a 
proton gradient, which is utilized by complex V to synthesize adenosine triphosphate 
(ATP) from adenosine diphosphate (ADP) and inorganic phosphate (Pi). The final 
acceptor of electrons in the electron transport chain is molecular oxygen. 




Figure 1.3. Mitochondrial Electron Transport Chain in Action.  
This Figure has been Complied with the Help of the Following Sources: PDB2FUG, 
PDB1NTZ, PDB1OCC. 
 
The initial event involves the transfer of electrons from NADH and succinate (via 
FADH2) to complex I and complex II, respectively. The electrons are then transferred 
from complexes I and II to complex III via coenzyme Q10 (CoQ10). Reduced CoQ10 
reverts to its initial oxidation state when it transfer its electrons to complex III. Complex 
III then transfers the electrons via cytochrome c, which then gets oxidized by transferring 
the electrons to complex IV. Finally, complex IV reduces oxygen to water. Electrons 
passing through complexes I, III and IV create a proton gradient across the inner 
mitochondrial membrane by translocation of protons from the matrix to the 
intermembrane space.  
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Figure 1.4. Reduction-Oxidation Cycle of CoQ10. 
This proton gradient drives ATP synthase to synthesize ATP from ADP and inorganic 
phosphates.20-25 
1.5. Reactive Oxygen Species (ROS) 
The electron transport chain in mitochondria uses nearly 90% of the oxygen 
consumed by the cell.26 The process of electron transfer generates reactive oxygen 
species (ROS) in the form of superoxide anions (O2
 –) as a byproduct, due to the leakage 
of electrons from complex I and complex III to oxygen.27,28  
 
Figure 1.6. Mitochondrial ROS Production 29,30 
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Jensen demonstrated ROS generation inside mitochondria for the first time along with 
other investigators in 1961.31  
Eukaryotic cells normally use ROS for signal transduction as a natural defense 
system against pathogens.32-34  ROS is also used as a signaling molecule in processes such 
as normal vascular diameter regulation, oxygen sensing, certain immunological defense 
pathways, skeletal muscle physiology, genomic stability, transcription regulation and 
signal transduction.35 Excess ROS is harmful and considered to participate in the 
pathogenesis of multiple diseases.34,36-39 
Nature has designed multiple strategies to detoxify O2
 – and its disproportion 
product H2O2 to achieve the appropriate concentration of ROS. This in turn avoids 
generating hydroxyl radical (OH) and peroxynitrite (ONOO–), which are potentially 
more harmful.34,36-39 In the presence of metal ions such as copper and iron, hydrogen 
peroxide can also be further converted to hydroxyl radicals by the Fenton reaction 
(Figure 1.7).40  
 
Figure 1.7. Formation of hydroxyl radical by Fenton reaction 
When electron carriers possess excess electrons due to deregulated electron 
transfer, ROS production is increased. Dysfunctional mitochondria being the major 
source, factors like consumption of excessive amounts of food have also been correlated 
with increased levels of ROS.35 
Highly reactive hydroxyl radicals can react with macromolecules in the 
mitochondria including DNA, RNA, lipid membranes and proteins generating multiple 
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harmful radicals (Figure 1.8).41 Mutations in the mtDNA can lead to defective electron 
transport chain complexes, causing mitochondrial disorders.42-44  
 
 
Figure 1.8. Effects of Oxidative Stress. 
1.6. Mitochondrial Dysfunction and ROS 
Dysfunctional mitochondria produce increased amount of ROS, which exceed the 
capacity for cellular detoxification.5,45-51 Hydroxyl radicals abstract hydrogen atoms from 
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lipids leaving behind a carbon radical, which in turn reacts with an oxygen molecule to 
become a peroxyl radical (Figure 1.8).52,53 This peroxyl radical can potentially generate 
multiple new carbon centered radicals. This process can propagate following a chain 
reaction process, giving rise to multiple lesions in membranes and other macromolecules 
in the cell from a single hydroxyl radical.  
Peroxidation of cardiolipin, for example, is often associated with the etiology of 
several pathological conditions, including cardiac failure, diabetes, ischemia reperfusion 
(IR) injury and neurodegenerative diseases.54 Therapeutic agents, which can protect 
cardiolipin against lipid peroxidation, have been beneficial for patients suffering from 
these diseases.54 
Propagation of lipid peroxidation following radical chain reactions has been 
studied extensively since the 1960s. The detailed mechanism of propagation is 
summarized in Scheme 1.1. Lipid peroxidation can be terminated naturally by quenching 
the propagation of lipid radicals (Scheme 1.1). Antioxidants acting as hydrogen atom 
donors can efficiently trap the peroxyl radical (LOO•) and terminate the chain reaction 
resulting in a stabilized radical (ArO•) (Scheme 1.2).53,55,56 
 
Scheme 1.1. Lipid Peroxidation Chain Reactions in Dysfunctional Mitochondria. 
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Scheme 1.2. Inhibition of Lipid Peroxidation Using -TOH as an Antioxidant. 
1.7. Natural and Synthetic ROS Suppressors 
Nature has its own defense system against oxidative stress. Hydrogen peroxide, 
hydroxyl radicals, and nitrogen based radicals are usually detoxified by a combination of 
antioxidant enzymes including superoxide dismutase, glutathione peroxidase and catalase 
(Figure 1.6).57,58  There are also naturally occurring non-enzymatic chemicals which 
protect cells from oxidative stress, such as ubiquinol-10 (reduced form of CoQ10), 
ascorbic acid, glutathione (GSH) and α- tocopherol (Figure 1.8).57,59  
 
Figure 1.8. Structures of Some Non-Enzymatic Antioxidants. 57,59 
α-TOH has been reported to trap peroxyl radicals faster than the rate of lipid 
peroxidation.60-63 Hence, it can be assumed that other phenolic antioxidants should have a 
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similar behavior. When phenolic hydrogen from an efficient antioxidant molecule (e.g. α-
TOH) is transferred to a peroxyl radical, it results in a resonance stabilized radical 
(ArO•). The resonance stabilization causes the facile stabilized radical (ArO•) formation 
which terminates the propagation of radical chain reaction. 
 
Figure 1.9. Recycling of α -TOH Followed by Quenching of Lipid Peroxidation.  
The resulting α-TOH radicals can be reduced back to α-TOH by endogenous redox 
molecules (e.g. ascorbic acid and NADH) in the cell (Figure 1.9).64 
 Electron scavenging peptides have also been designed to inhibit cardiolipin 
peroxidation by scavenging ROS in mitochondria.65 Szeto-Schiller (SS) peptides (SS-
31and SS-02) have been reported to inhibit cardiolipin peroxidation and restore 
mitochondrial functions.66-68 
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Figure 1.10. Structures of Mitochondria-Targeted Szeto-Schiller Peptides (SS-02 and 
SS-31).  
  
Healthy mitochondrial function, especially as regards the electron transport chain, 
is extremely important in eukaryotes. Since CoQ10 and α-TOH protect cells from 
oxidative stress, the design and synthesis of novel antioxidants and understanding the 
nature of their interaction with the mitochondrial electron transport chain can lead to better 
antioxidants and electron carriers. Improved synthetic antioxidants can potentially be 
beneficial for treating individuals with impaired mitochondrial function. 




DESIGN, SYNTHESIS AND CHARACTERIZATION OF ALKYLAMINOQUINONE 




As mentioned in chapter 1, mitochondria play an essential role in the survival of 
healthy eukaryotic cells. Apart from ATP production through aerobic respiration, there 
are several other major functions that mitochondria play in the cell. Mitochondria are 
essential for the immune response,3 reactive oxygen species (ROS) production 39,40 and 
apoptosis4  in the cell. Due to their extensive involvement in cell functioning, 
dysfunctional mitochondria adversely affect cell survival. Hence, mitochondrial 
dysfunction is linked to the pathogenesis of multiple human diseases.69   
Mitochondria are densely packed close to the energetically demanding structures 
inside cells. In the heart, for example, mitochondria concentrate close to the contractile 
muscle and in sperm cells mitochondria are wrapped tightly around the motile flagellum. 
As a consequence of having a high mitochondrial density, cardiac, neuronal and skeletal 
muscle cells are also the most vulnerable to diseases involving mitochondrial 
dysfunction.69 
2.2. Etiology of Diseases Having a Mitochondrial Origin. 
The key to the aerobic respiration and mitochondrial function lies in the redox 
proteins (complexes I-V) located in the inner membrane of mitochondria. Mitochondrial 
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proteins are encoded in two distinct genetic systems, namely mitochondrial DNA 
(mtDNA) and nuclear DNA (nDNA).  
Mitochondria have a circular, double-stranded DNA (mtDNA). The mtDNA en-
codes proteins and nucleic acids (rRNAs and tRNAs), that are essential for 
intramitochondrial protein synthesis.70-72 Some mitochondrial proteins are also 
synthesized in the cell cytoplasm. They are expressed with an extra protein sequence to 
target mitochondria. After these proteins reach the mitochondria, the targeting sequence 
is then cleaved before the protein is embedded in the inner mitochondrial membrane.73  
The replication, repair, transcription and translation of mtDNA actually depends on the 
functioning of proteins encoded by nDNA. Therefore, ROS mediated damage in 
mitochondrial or nuclear DNA can cause mitochondrial dysfunction and mitochondrial 
disease.69  Mitochondrial diseases can potentially have multi-organ system 
manifestations.74 
2.3. Scheme to Develop Drugs to Treat Mitochondrial Diseases.  
The consequences of oxidative stress are one of the key causes for the 
propagation of mitochondrial diseases. Therefore, multifunctional radical quenchers 
(MRQ), which can reduce oxidative stress and have several beneficial effects, can 
potentially be effective therapeutic agents to blunt the progression of such diseases.75   
Approaches for the therapy of mitochondrial diseases vary considerably depending upon 
the general health and nutritional condition of the patient because physical conditions like 
infection, dehydration, surgery and mental stress can alter the state of the disease. Most 
of the time, a combination of vitamins and co-factors are used for treatment.74  
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2.4. Therapeutic Agents Targeting Mitochondrial Disorder 
There have been different medications used since the 1960s, since mitochondria 
were first recognized as a cause of multiple diseases. Earlier medicines included 
dichloroacetate (DCA), 74,76,77 succinate and menadione.78  
More recent treatments have included idebenone, mitoquinone,79 coenzyme Q10,
80 
riboflavin,81 L-creatine,82,83 L- arginine,84  L- carnitine,36 thiamine (vitamin B1), vitamins 
C, D and E, α-lipoic acid, resveratrol and folinic acid78 (the reduced form of folic acid) 
(Figure 2.1.) have also been used as single therapeutics or as part of a cocktail for the 
treatment of mitochondrial diseases.78  
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Figure 2.1. Therapeutic Agents Used for the Treatment of Mitochondrial Diseases. 
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2.5. CoQ10 and Idebenone. 
CoQ10 has been used in CoQ10 deficient cells therapeutically, to restore electron 
flow in the ETC and avert the accumulation of electrons at complex I.87 This reduces 
oxidative stress due to ROS generation.88 However, the extreme hydrophobicity and 
consequent poor bioavailability has limited the application of CoQ10 as a therapeutic 
agent. CoQ10 is accumulated in the outer mitochondrial membrane (OMM) and cannot 
impart any efficacy without access to the inner mitochondrial membrane (IMM).85-90  
Idebenone is a derivative of CoQ10 with a shorter side chain, which substantially 
improves its solubility. The non-toxic nature of idebenone has encouraged significant 
efforts to improve its pharmacokinetic profile. Idebenone restores the respiration in 
rotenone blocked mitochondria.92-94 Idebenone was initially developed by Takeda 
Pharmaceuticals for treating cognitive disorders and Alzheimer’s disease.91 Idebenone 
has provisional approval in Canada and is sold under the trade name Catena® for the 
treatment of Friedreich’s Ataxia.92-94,95 Idebenone is not yet approved as a prescribed 
drug in North America or Europe.95-99 Conversely, studies have established the inhibitory 
effects of idebenone on complex I in the ETC and documented its poor bioavailability 
after passage through the liver.99-101 
Our research strategy was to invent new drug candidates capable functioning in a 
fashion similar to coenzyme Q10 and also exhibit protective functions.  The putative 
reduction-oxidation cycle of idebenone is depicted in Figure 2.2. Our design focused on 
better resonance stabilization to deal more effectively with electron transport 
malfunction, oxidative stress due to electron leakage, maintaining ATP production, 
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membrane potential and affording protection from lipid peroxidation. These antioxidant 
molecules with multiple functions are called multifunctional radical quenchers (MRQs). 
 
Figure 2.2. Putative Reduction-Oxidation Cycle of Idebenone. 
2.6. Geldanamycin and Related Natural Products. 
Geldanamycin is a naturally occurring benzoquinone ansamycin named 
geldanamycin (Figure 2.3), which shows anti-proliferative effects against a broad range 
of human tumor cell lines.102 An analogue of geldanamycin, denoted (17-AAG), 
possesses the same redox core, undergoes reduction in normal epithelial cells under 
physiological conditions.103 17-AAG forms the reduced hydroquinone in situ and binds to 
the target protein Hsp 90 with greater affinity than the corresponding quinone. Redox 
cores of geldanamycin and 2.1 (a natural product isolated from Embelia ribes, a species 
used in traditional Chinese medicine104) may possibly undergo reduction under 
physiological conditions to the corresponding hydroquinone, potentially enabling it to 
protect cells from oxidative stress. 
 
Figure 2.3. Structures of Geldenamycin, 2.1 and 17-AAG. 
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Considering the structural similarities between the redox cores of 2.1 and geldanamycin, 
it seemed likely that 2.1 and systematically modified analogues of 2.1 might also undergo 
reduction under physiological conditions to afford the corresponding hydroquinone, 
potentially enabling them to protect cells from oxidative stress.  
Optimized derivatives have been synthesized and evaluated in vitro and the most 
promising compounds will ultimately be studied for in vivo efficacy in animal models of 
mitochondrial and neurodegenerative diseases. The structures of the designed and 
synthesized compounds are shown in Figures 2.4 through 2.7. 
  
 
Figure 2.4. Structures of Alkylaminoquinone Analogues with 12-Carbon Side Chain that 
have been Synthesized and Evaluated. 
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Figure 2.5. Structures of Alkylaminoquinone Analogues with 13-Carbon Side Chain that 
have been Synthesized and Evaluated. 
 
Figure 2.6. Structures of Alkylaminoquinone Analogues with 16-Carbon Side Chain that 
have been Synthesized and Evaluated. 
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Figure 2.7. Structure of an Alkylaminoquinone Analogue with a 12-Carbon Side Chain 
and Hydrophobic Amine that have been Synthesized and Evaluated. 
 
2.7. Results. 
In order to synthesize the alkylaminoquinones shown in Figures 2.4 through 2.7 
(2.2-2.16), commercially available 3,4,6-trimethoxycyclohexa-1,4-dienecarbaldehyde 
was oxidized followed by methylation of the corresponding phenol. Appropriate aliphatic 
side chains were attached by n-BuLi mediated alkylation. Subsequent oxidation 
transformed the core to the quinone, to which -aminobutyric esters were inserted to 
obtain the requisite analogues. A retrosynthetic approach is illustrated in Figure 2.8. 
 
Figure 2.8. Retrosynthetic Analysis for Alkylaminoquinone Analogues 2.2-2.16. 
 
In order to synthesize the derivative shown in Figure 2.7, commercially available 3,4,6-
trimethoxycyclohexa-1,4-dienecarbaldehyde was oxidized followed by the methylation of 
corresponding phenol. Aliphatic side chains were attached where applicable; subsequent 
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oxidation transformed the core to the quinone, to which a long chain aliphatic amine was 




Figure 2.9. Retrosynthetic Analysis for the Alkylaminoquinone Analogue 2.17. 
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2.7.1. Synthesis of Alkylaminoquinone Analogues. 
Synthesis of Alkylaminoquinone Analogues with 12-Carbon Aliphatic Side Chain 
(Illustrated in Figure 2.4). 
As an extension of our structure-activity relationship (SAR) study of 
alkylaminoquinone analogues synthesized previously,105,106 new analogues were 
synthesized (Figure 2.4-2.7) to ascertain the importance of the side chain length to the 
antioxidant properties of the quinones. The synthesis of alkylaminoquinone analogues 
with 12-carbon aliphatic side chains (Figure 2.4), shown in Scheme 2.1, began with 
2,4,5-trimethoxybenzaldehyde by appropriate functional group transformations. As 
outlined in Scheme 2.1, the synthesis of compound 2.2 began with the H2O2-mediated 
oxidation of commercially available 2,4,5-trimethoxybenzaldehyde to yield 2,4,5-
trimethoxyphenol (2.19) in 78% yield.107 The n-BuLi-mediated alkylation of compound 
2.19 with purified 1-bromododecane to yield compound 2.20 in 75% yield.108 The 
alkylated tetramethoxybenzene 2.20 was then subjected to cerium(IV) ammonium nitrate 
(CAN) oxidation to give crude quinone (2.21).108 The aminocarboxypropyl group was 
introduced by treating methoxyquinone (2.21) with γ-aminobutyric acid ester tosylate 
salts 2.22, 2.23 and 2.24 in the presence of a large excess of sodium bicarbonate to yield 
compounds 2.2, 2.3 and 2.4 in 15%, 18% and 20% yields, respectively.109  γ-
Aminobutyric acid (GABA) ester tosylate salts (2.23, 2.24) were obtained by treating γ-
aminobutyric acid with the corresponding alcohols in a Dean-Stark distilling receiver, 
containing p-toluenesulfonic acid and toluene at reflux. The salts were crystallized in 
70% (2.22), 65% (2.23), 75% (2.24) yields, respectively.109 
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Scheme 2.1. Route Employed for the Synthesis of Alkylaminoquinone Analogues with 
12-Carbon Aliphatic Side Chain (2.2- 2.4). 
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Synthesis of Alkylaminoquinone Analogues with 13-Carbon Aliphatic Side Chains 
(illustrated in Figure 2.5) 
As an extension of compounds previously synthesized and studied,105,106 saturated 
alkylaminoquinone derivatives were synthesized, methylating the potentially electrophilic 
positions (Figure 2.5). The synthesis of alkylaminoquinone analogues with 13-carbon 
aliphatic side chains, shown in Scheme 2.2, began with n-BuLi-mediated alkylation of 
compound 2.19 with purified 1-bromotridecane to yield compound 2.25 in 70% yield.108 
Compound 2.25 was further subjected to n-butyllithium-mediated C-methylation to yield 
2.26 in 90% yield.108 The C-methylated tetramethoxybenzene (2.26) was then subjected 
to cerium(IV) ammonium nitrate oxidation to give crude quinone (2.27) in 60% yield.108 
The aminocarboxypropyl group was introduced by treating 2.27 with an equivalent of γ-
aminobutyric acid ester tosylate salts (2.22, 2.23 and 2.24) in the presence of an 
equivalent amount of sodium bicarbonate to yield the compounds 2.5, 2.7 and 2.9 in 
30%, 12% and 32% yields, respectively. Treating 2.27 with excess of γ-aminobutyric 
acid ester tosylate salts 2.22, 2.23 and 2.24 in the presence of a large excess of sodium 
bicarbonate yielded compounds 2.6, 2.8 and 2.10 in 23%, 8% and 26% yields, 
respectively.106 
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Scheme 2.2. Route Employed for the Synthesis of Alkylaminoquinone Analogues with 
13-Carbon Aliphatic Side Chains (2.5- 2.10). 
 
Synthesis of Alkylaminoquinone Analogues with 16-Carbon Aliphatic Side Chains 
(Illustrated in Figure 2.6). 
In order to study the effect of the side chain on the antioxidant activity of the 
alkylaminoquinones,105,106 a longer side chain was attached to the redox core and a new 
series of derivatives (Figure 2.6) (2.11, 2.13 and 2.15) were synthesized. The synthesis of 
alkylaminoquinone analogues with 16-carbon aliphatic side chains, shown in Scheme 2.3, 
began with n-butyllithium-mediated alkylation of compound 2.19 with purified 1-
bromohexadecane. As a result, compound 2.28 was obtained in 67% yield.108 The 
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tetramethoxybenzene derivative (2.28) was then subjected to cerium(IV) ammonium 
nitrate oxidation to yield quinone 2.29 in 68% yield.108 The aminocarboxypropyl group 
was introduced by treating 2.29 with excess γ-aminobutyric acid ester tosylate salts 2.22, 
2.23 and 2.24 in the presence of a large excess of sodium bicarbonate to obtain the 
compounds 2.11, 2.13 and 2.15 in 15%, 18% and 22% yields, respectively.106 
Scheme 2.3. Route Employed for the Synthesis of Alkylaminoquinone Analogues with 
16-Carbon Aliphatic Side Chains. (2.11, 2.13 and 2.15). 
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Synthesis of Methylated Alkylaminoquinone Analogues with 16-Carbon Aliphatic 
Side Chains (Illustrated in Figure 2.6). 
 
To study the effect of a C-methylated alkylaminoquinone with a longer side chain 
on antioxidant properties, the longer side chain analogue was modified by methylation of 
the core and new series of derivatives (2.12, 2.14 and 2.16) were synthesized (Figure 
2.6). The synthesis of saturated alkylaminoquinone analogues with 16-carbon aliphatic 
side chains, shown in Scheme 2.4, began with n-BuLi-mediated alkylation of compound 
2.19 with purified 1-bromohexadecane to obtain compound 2.28 in 67% yield.108 
Compound 2.28 was further subjected to n-BuLi-mediated methylation to obtain 2.30 in 
87% yield.108 The C-methylated tetramethoxybenzene derivative 2.30 was then subjected 
to cerium(IV) ammonium nitrate oxidation to yield quinone 2.30 in 62% yield.108  
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Scheme 2.4. Route Employed for the Synthesis of Alkylaminoquinone Analogues with a 
16-Carbon Aliphatic Side Chains with a Methyl Group on the Ring (2.12, 2.14 and 2.16). 
 
The aminocarboxypropyl group was introduced by treating 2.30 with γ-aminobutyric acid 
ester tosylate salts 2.22, 2.23 and 2.24 (Scheme 2.1) in the presence of a large excess of 
sodium bicarbonate to yielded the compounds 2.12, 2.14 and 2.16 in 23%, 8% and 26% 
yields, respectively.105 
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Synthesis of Hydrophobic Alkylaminoquinone Analogues with 12-Carbon Aliphatic 
Side Chains (Illustrated in Figure 2.7). 
To study the effect of hydrophobicity on the antioxidant activity of the 
alkylaminoquinones, a longer side chain and a hydrophobic amine were attached to the 
core simultaneously, affording 2.17 (Figure 2.7). The synthesis of hydrophobic 
alkylaminoquinone analogues with 16-carbon aliphatic side chains, shown in Scheme 2.5, 
began by treating 2.29 with commercially available octadecylamine in excess in the 




Scheme 2.5. Route Employed for the Synthesis of Hydrophobic Alkylaminoquinone 
Analogues with a 12-Carbon Aliphatic Side Chain (2.17). 
 
2.7.2. Biochemical and Biological Evaluation of Alkylaminoquinone Analogues. 
Mitochondrial Electron Transport Chain Function  
The antioxidants were designed to interact with the mitochondrial electron 
transport chain complexes. In the course of electron transfer, the compounds might 
irreversibly bind to any of the mitochondrial respiratory chain complexes, thus having the 
undesired effect of inhibiting respiratory chain function. Accordingly, the most desirable 
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analogues would have minimal inhibitory effects on the respiratory chain. As an initial 
screening measure, the effects of the compounds on NADH oxidase activity have been 
studied this includes the functions of mitochondrial complexes I, III and IV. The 
importance of side chain length to achieve improved bio-energetic and antioxidant 
activity, especially depending on the interaction of the MRQs with the mitochondrial 
respiratory chain, have been well documented.106,109-113 In the light of those findings, 
analogues having different side chain lengths attached to the redox core have been 
designed and synthesized (Figures 2.4-2.7). Inhibition of NADH oxidase (complexes I, 
III and IV) by the compounds under evaluation was studied (Table 2.1) using 
submitochondrial particles (SMP). The results, presented in Table 2.1, show that the 
inhibitory behavior of these compounds was dose dependent.  
Compound 2.7, having a butyl ester, inhibited the NADH oxidase activity among 
the most strongly at higher concentration. Hence, the inhibition of NADH oxidase 
activity depends on the chain length of the antioxidant molecule as shown before.111,112 
Elongated n-hexyl esters or tertiary butyl esters (2.5, 2.6, 2.9 and 2.10) resulted in a 
slightly lesser inhibitory effect than was observed for compound 2.7. 
Both the mono substituted (2.5, 2.7 and 2.9) and bis substituted core analogues 
(2.6, 2.8 and 2.10) inhibited NADH oxidase activity. Modification in the linear alkyl side 
chain in the aminocarboxypropyl ester resulted in a greater inhibition when linear carbon 
chains were attached compared to branched counterparts.  
Compounds 2.9-2.10 afforded no significant improvement over compounds 2.5-
2.6 in terms of inhibition of the complexes. Increased hydrophobicity of a branched 
carbon chain has the same kind of inhibitory effect compared to a longer carbon side 
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chain. The bis-substituted hexyl ester analogue (2.10) had a significantly greater 
inhibitory effect compared to the bis substituted tertiary-butyl derivative (2.6). 
Table 2.1. The Inhibitory Effect of Compounds on Bovine Heart Mitochondrial NADH 
Oxidase Activity (Complexes I, III and IV).  
 
  ______________________________________________________ 
 
                             NADH oxidase activity (%)a             
         ________________________________________ 
 
       Compound    1 μM                   5 μM                10 μM 
   ______________________________________________________ 
  
       Control                   100                     100              100 
       2.5                            87 ± 2         85 ± 1             80 ± 1    
       2.6                 95 ± 2                  92 ± 3             84 ± 3 
       2.7                            86 ± 2                  84 ± 4                  68 ± 1               
       2.8                            77 ± 1                  68 ± 1                  69 ± 2        
       2.9                 96 ± 1         83 ± 2                  74 ± 2  
       2.10                          85 ± 1                  78 ± 6                  70 ± 3  
   ______________________________________________________ 
a- Relative to untreated control. 
 
Inhibition of Lipid Peroxidation 
 
The ability to quench lipid peroxidation of the alkylaminoquinone analogues was 
studied in FRDA lymphocytes that had been depleted of glutathione by diethylmaleate 
(DEM) treatment. A hydrophobic fatty acid fluorophore, C11-BODIPY581/591, which 
preferentially inserts in membranes, has been previously shown to quantify fatty acid 
oxidation and antioxidant activity in live cells.114 Oxidized polyunsaturated butadienyl 
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portion of the dye results in a shift of the fluorescence emission peak from red to green. 
Oxidation can be followed using flow cytometer as reported before.13,106,110,111,113 A shift 
of the fluorescence emission peak from red to green is considered to be a measure of 
oxidation with excitation/emission wavelengths of 490/510 nm. The median mean 
fluorescence values were used for further analysis. An increase in green fluorescence 
intensity is interpreted as lipid peroxidation. The results in presence of compounds in 
Figure 2.5 are presented in Table 2.2. 
Compounds 2.5 and 2.7 showed the most potent lipid peroxidation quenching activity 
among compounds 2.5-2.10. Compounds 2.6, 2.8, 2.9 and 2.10 had lower activity for 
suppressing lipid peroxidation in comparison with the analogues having same side chain 
length and a longer carbon chain in the ester region. A significant difference in the lipid 
peroxidation scavenging activity was noted for the pairs of alkylaminoquinone analogues 
with mono or bis-aminocarboxypropyl ester substituents. Having greater hydrophobicity 
in terms of increasing the number of substituents in bis-substituted compounds and 
compounds with longer carbon chain esters had reduced amount of scavenging activity. 
The mono-substituted analogues having n-butyl ester (2.7) and tertiary butyl ester (2.5) 
showed the best results, 2.5 being the best in this series. The results of this experiment 
clearly shows a dose dependence, with higher concentrations resulting in better 
scavenging activity. 
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Table 2.2.  Suppression of Lipid Peroxidation by Alkylaminoquinone Antioxidants in 
Cultured FRDA Lymphocytes Treated with DEM.b  
______________________________________________________ 
 
                      Lipid Peroxidation Scavenging Activity (%)a         
         ________________________________________ 
 
       Compound   2.5 μM                   5 μM                10 μM 
   ______________________________________________________ 
 
Untreated control       100                     100               100 
       2.5                                -                   61 ± 4             75 ± 2    
       2.6                     -                     12 ± 2              6 ± 2 
       2.7                                -                     60 ± 1       70 ± 3 
       2.8                                -                       7 ± 1              19 ± 2 
       2.9                     -                     8 ± 3        13 ± 3  
       2.10                              -                     18 ± 1       23 ± 4 
   ______________________________________________________ 
a- Relative to untreated control. 
b- The experiment was performed by Dr. Omar M. Khdour. 
 
Suppression of Reactive Oxygen Species 
The ability to suppress ROS induced by glutathione depletion using 
alkylaminoquinone analogues 2.5–2.10 (Figure 2.5) were evaluated in FRDA lymphocyte 
cells. The ROS-induced formation of the highly fluorescent product 2′,7′-
dichlorofluorescein (DCF) from the non-fluorescent dye 2′,7′-dichlorodihydrofluorescein 
diacetate (DCFH-DA) formed the basis for intracellular ROS measurement.115 The results 
from this experiment are presented in Table 2.3 and fairly closely paralleled those found 
for lipid peroxidation.  
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Compounds with mono-substituted tertiary butyl and n-butyl substituents (2.5 and 
2.7) were the most potent in suppressing ROS. Compounds 2.2, 2.3 and 2.7-2.10 were not 
very efficient in suppressing ROS, while bis-substituted compounds with longer ester 
carbon chains were poorly active.  Mono-substituted butyl ester derivative 2.7 was the 
most efficient in this series.  
Table 2.3. Suppression of ROS Production by Alkylaminoquinone Antioxidants in 
Cultured FRDA Lymphocytes Pretreated with DEM.b  
   ______________________________________________________ 
 
                              ROS Scavenging Activity (%)a 
         ________________________________________ 
 
       Compound   2.5 μM                   5 μM                10 μM 
   ______________________________________________________ 
 
Untreated control       100                    100               100 
       2.2                                -                      5 ± 2                         - 
       2.3                                -                     35 ± 3                        - 
       2.5                                -                   35 ± 6                  -    
       2.6                                -                          -                  - 
       2.7                                -                     50 ± 5            - 
       2.8                                -                     25 ± 1                   - 
       2.9                     -                   16 ± 8             -  
       2.10                              -                     14 ± 1            - 
   ______________________________________________________ 
a- Relative to untreated control. 
b- The experiment was performed by Dr. Omar M. Khdour. 
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Cytoprotection 
The ability of the test compounds (2.2-2.16) (Figure 2.4-2.7) to confer 
cytoprotection was evaluated using FRDA lymphocytes. The cells were treated with 
diethyl maleate to induce oxidative stress through depletion of glutathione. Compounds 
that can protect cells from apoptosis to a greater extent were considered to provide better 
protection. The cytoprotection results obtained with the FRDA lymphocytes are shown in 
Tables 2.4 and 2.5.  
The cytoprotective effects of the compounds under investigation were dose 
dependent in the concentration range from 1 μM to 5 μM (Table 2.4) and 0.1 μM to 2.5 
μM (Table 2.5). In the series of compounds 2.5-2.10 and the series 2.11-2.16 the 
behaviors were different. None of the compounds in the former series (2.5-2.10) provided 
significant cytoprotection from DEM-induced stress when employed at 1 μM 
concentration with the exception of 2.5. However, all others (except 2.8) provided 
significant (>75%) cytoprotection when employed at 5 μM concentration. Bis-
aminocarboxypropyl substituted alkylaminoquinones were generally more effective 
compared to the mono aminocarboxypropyl substituted analogues, with 2.8 being the 
worst in the series. Compounds 2.6, 2.7 and 2.10 were the best compounds in this series 
in the cytoprotection assay.  
 Compounds 2.11-2.16 did not perform well in the cytoprotection assay even at 
0.1 μM concentration. Compound 2.11 showed minimal cytoprotection at any test 
concentration. Alkylaminoquinones with 16-carbon side chains show an overall negative 
effect towards the viability of cultured FRDA cells treated with DEM. 
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Table 2.4. Cytoprotective Effects of Alkylaminoquinone Analogues on the Viability of 
Cultured FRDA Cells Treated with DEM.b  
   ______________________________________________________ 
 
                                      Viable cells (%)a 
         ________________________________________ 
 
       Compound      1 μM                   2.5 μM                 5 μM 
   ______________________________________________________ 
 
Untreated control       100                     100               100 
       2.5                             67 ± 5             -                        91 ± 6                   
       2.6                  15 ± 2                     -                        98 ± 6 
       2.7                             63 ± 4                    -                 95 ± 3 
       2.8                               9 ± 2                    -                 7 ± 3 
       2.9                  16 ± 4             -         87 ± 4  
       2.10                           11 ± 2                    -        91 ± 3 
   ______________________________________________________ 
a- Relative to untreated control. 
b- The experiment was performed by Dr. Omar M. Khdour. 
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Table 2.5. Cytoprotective Effects of Alkylaminoquinone Analogues on the Viability of 
Cultured Cultured FRDA Cells Treated with DEM.b 
   
 
Compound                                                         Viable Cells (%)a 
                                              ____________________________________________________________________________________________________________________________________________________________________________ 
 
                                           0.1 μM      0.5 μM          2.5 μM 
_______________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________ 
 
   
    2.11                                14 ± 2                        11 ± 2                              10 ± 3                                                                    
 
    2.12                     12 ± 1                          9 ± 2                        8 ± 4 
 
    2.13                         11 ± 1                   8 ± 1                  8 ± 1 
 
    2.14                            8 ± 3                   8 ± 1                  9 ± 6 
 
    2.15                                 8 ± 1                8 ± 1                   8 ± 1 
 
    2.16                                 6 ± 1         8 ± 3               8 ± 4 
                                          
a- Relative to untreated control 
b- The experiment was performed by Dr. Yana Chen 
 
Microsomal Stability 
The ability of test compounds (2.2-2.17) (Figure 2.4-2.7) to survive incubation 
with activated bovine liver microsomes were studied to infer their metabolic stability in 
animal models. Compounds with medicinal interest; having potentially useful in vitro 
activity, are sometimes found to be metabolically unstable, eliminating their potential 
utility as molecules of interest for in vivo studies. The test compounds were incubated 
with bovine liver microsomes for 30 min at 37 °C followed by extraction using 1-
propanol. The final microsomal preparation was reconstituted in minimal volume of 
HPLC grade methanol and used for HPLC analyses. Microsomal stability was determined 
by comparison of the area under the curve for the test compound between the HPLC 
traces of the compound with and without microsomal treatment. All of the compounds 
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showed relatively good stability in presence of bovine liver microsomes (Table 2.6). 
Compounds with 12-carbon side chains (2.2 and 2.4) show good results with the bis-
substituted aminocarboxypropyl tertiary butyl ester compared to the corresponding n-
hexyl ester. Bis substituted aminocarboxypropyl tertiary butyl esters (2.11 and 2.12) 
differed in stability, significantly. The methyl group present in 2.12 rendered it less 
stable. Compounds 2.13 and 2.14 differ in the aminocarboxypropyl ester moiety. 2.13 
Having an n-butyl ester, is more stable than 2.14 with an n-hexyl ester.  
Table 2.6. Microsomal Activity of Alkylaminoquinone Analogues on the Bovine Liver 
Microsomes.b  
  ______________________________________________________                                           
   
       Compound                Recovery (Activated/deactivated %)a 
   ______________________________________________________ 
 
Untreated control                                   100 
       2.2                                           91            
       2.4                                                           87                 
       2.11                                                 94 
       2.12                                                         80                                                       
       2.13                                                97                       
       2.14                                                         73                  
       ______________________________________________________ 
a- Relative to untreated control. 
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2.8. Discussion 
 
2.8.1. Synthesis of Alkylaminoquinone Analogues 
 
As part of our efforts to identify compounds having potential utility in treating 
neurodegenerative and mitochondrial disorders, a number of “geldanamycin analogues” 
have been synthesized. The ROS scavenging activity of natural antioxidants like α-
tocopherol and coenzyme Q10 depend not only on its redox core but also on the length of 
its lipophilic side chain. For α-TOH, the lipophilic side chain facilitates the insertion of 
the redox core into the liposomes and suppresses its migration between liposomal 
membranes.112 It has previously been reported that the alkyl side chain length plays an 
important role in the activity of an antioxidant molecule.110-113 In this study, different side 
chains have been attached (Figure 2.4-2.7) to achieve optimal antioxidant activity. 
Another important variable in the structures of the analogues of the natural product 2.1 
were the number of aminocarboxypropyl substituents (Figure 2.4-2.7). 
Aminocarboxypropyl can either replace one or both methoxy groups in the precursor 
quinone (2.21, 2.27, 2.29 and 2.31). In a given side chain length, varied ester groups on 
aminocarboxypropyl group can change the antioxidant activity of the molecule. Natural 
product 2.1 and molecules previously reported in literature106 had an electrophilic 
position in the ring, which could make the molecules subject to possible nucleophilic 
attack. Derivatives of natural product 2.1 have been prepared in which the electrophilic 
position had been methylated. On the other hand, redox-core methylation makes the 
compounds unstable to microsome mediated enzyme degradation.105,106 The analogues 
synthesized (Scheme 2.2-2.7) have only electron donating substituents. 
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Attaching a long chain alkyl group to core 2.19 was initially challenging, 
achieving very low yields. silica gel column purification of the commercially available 
alkyl bromide helped in achieving a better yield. Since there were two possible positions 
on the ring to deprotonate, n-BuLi mediated deprotonation was initially done carefully 
with an equivalent amount of the base. Later in the process, it was found that adding 2.5 
equivalents of base actually improved the yield drastically and it did not yield a bis-
alkylated product, possibly because forming a di-anion was energetically unfavorable. 
Adding extra equivalents of base probably pushed the deprotonation reaction toward 
completion (Scheme 2.1).  
The ultimate step in the synthesis of the final product 2.5 (Scheme 2.2) was based 
on an NaHCO3-mediated conversion of a vinylogous ester into the corresponding 
vinylogous amide,91 mono-aminocarboxypropyl substituted analogues were challenging 
because dimethoxy substituted quinone cores were more inclined to bis-substitution, 
adding less than equivalent amount of 2.22, 2.23 and 2.24 (Scheme 2.2) could not push 
the reaction to completion, any alteration in condition such as increased temperature or 
equivalents yielded bis-substituted product. So, the yield could not further be improved. 
Biological results show that mono or bis-substituted aminocarboxypropyl substituted 
derivatives can change electronic and hydrophobic effects, which reflected clearly in the 
outcome (Table 2.3). 
Analogues with 16-carbon side chains were also made in C-methylated ring 
systems to verify whether methylation had any effect on the activity, but they were in 
general bad as an antioxidant (Table 2.5). 
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2.8.2. Discussion of Biochemical Results. 
 
Mitochondrial Electron Transport Chain Function   
 
The antioxidant molecules proposed in this effort had been subjected to the 
mitochondrial electron transport chain. Alkylaminoquinone analogues that inhibited the 
mitochondrial respiratory chain (Table 2.1); may function well as protective agents in 
protecting cells and their membrane against oxidative stress, but are less likely to be able 
to confer cytoprotection or to augment ATP production in cells with (partially) 
dysfunctional mitochondria. Inhibition of the mitochondrial electron transport chain 
usually involves binding irreversibly to mitochondrial complex I; a number of 
compounds also inhibit complex III and IV.  Accordingly, an assay was employed which 
measures NADH oxidase activity, encompassing complexes I, III and IV.110-113 
It is important to note that interpretation of the results in a NADH oxidase assay is not 
straight-forward. The assay gives a result that reflects interaction with three individual 
mitochondrial complexes (I, III, IV) (complex II, being a part of the Krebs’s cycle, is not 
considered here), does not interact with antioxidants, indicating both the ease of electron 
transfer between the complexes and possible inhibition of the complexes through 
irreversible binding. Hence the results in the NADH oxidase assay can be potentially 
misleading. A compound that fails to bind to any of the mitochondrial complexes, will 
show no inhibition of NADH oxidase, but has no chance of augmenting ATP production. 
Thus lack of any inhibitory activity in the NADH oxidase assay may not be the most 
desired effect, rather limited inhibition shows potential interaction with the mitochondrial 
electron transport chain. Additionally, further mechanistic studies can quantify their 
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interaction with individual complexes. Oxygen consumption studies can also serve as an 
useful tool to study the effect from other complexes in the ETC. 
It may also be noted that the concentrations of the compounds employed in Table 
2.1 are purposefully higher (e.g. 10 μM, which is unlikely to be achieved physiologically) 
than those used in the other assays (in order to provide mechanistic insights).  
As shown in Table 2.1, most of the compounds (Figure 2.5) tested were not 
inhibitory to NADH oxidase. Notably, 2.6 and 2.9 had little effect on NADH oxidase 
presumably because they were not interacting well with the complexes. In comparison, 
2.5, 2.7 and 2.8, showed reasonable activity in the range that shows considerable 
interaction with the mitochondrial complexes. Bis-aminocarboxypropyl substituted 
compounds having greater hydrophobicity may possibly exhibit poor solubility, which 
may affect the results in this assay.  
Inhibition of Lipid Peroxidation 
 
As shown in Table 2.2, alkylaminoquinone derivatives have been tested for their 
ability to quench lipid peroxidation in FRDA lymphocytes. The cells are initially 
subjected to oxidative challenge with diethyl maleate (DEM). DEM reacts with 
glutathione irreversibly inactivating it in a way such that it can no longer provide 
protection against oxidative stress.111-113 ROS levels increase as a result, and in turn, lipid 
peroxidation also increases.  
The individual compounds (Figure 2.4-2.7) improve the lipid peroxidation 
scavenging activity in a dose dependent fashion. Mono-substituted compounds 2.5 and 
2.7 show good results compared to their bis-substituted analogues. This may possibly 
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reflect the increased hydrophobicity resulting from the aliphatic chains. The results of 
compounds 2.9 and 2.10 show a similar trend.  
ROS Scavenging Activity 
 
A selection of alkylaminoquinones (Figure 2.4-2.7) were also tested for their 
ability to suppress ROS in FRDA lymphocytes (Table 2.3). The results closely paralleled 
those found for lipid peroxidation. The analogues were tested at 5 µM concentration; the 
results reflect ROS suppression abilities which was most interesting for compound 2.7. 
Contrary to the lipid peroxidation quenching assay, 2.5 did not show very impressive 
results and 2.9 also did not function well in this regard. Similar to the previous case, the 
bis-substituted compounds were not very potent, possibly due to lesser solubility in the 
aqueous medium. Compounds 2.2 and 2.3 had shorter side chains compared to the 
compounds 2.5 and 2.7. Compounds with shorter side chains in general show lesser 
protection against ROS. Compound 2.3 having, an n-butyl ester (linear aliphatic), on it 
shows better ROS protection than 2.2. 2.3 being a bis-substituted compound suffers from 




FRDA lymphocytes were used in the assay to assess the cytoprotective ability of 
the analogues (Figures 2.4-2.7). This cell line was derived from lymphocytes 
obtained from a patient with Friedreich’s ataxia, a disease associated with a significant 
mitochondrial dysfunction.  Compounds having favorable properties as multifunctional 
radical quenchers were evaluated for cytoprotection in the FRDA cell line. Compounds 
2.5-2.10 (Figure 2.5) showed impressive results with the exception of compound 2.8. 
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Surprisingly, the bis-substituted compounds showed impressive results as well. 
Surprisingly compounds with longer side chains (2.11-2.16) (Figure 2.6) (having 16-
carbon aliphatic side chains) failed to provide any significant protection in the FRDA 
lymphocytes. As a whole, compounds with 13-carbon side chains provided the maximum 
protection in FRDA lymphocytes in this series. 
Microsomal Stability Assay 
 
Potential drug candidates are expected to exhibit pharmacokinetic parameters 
enabling reasonable biochemical activity. The metabolic fate of many orally 
administered drugs are often a function of clearance in the liver.116,117 Accordingly, in 
vitro microsomal incubations were performed on alkylaminoquinone analogues (Figure 
2.4-2.7) to assess their percentage recovery after incubation with activated bovine liver 
microsomes. Reinforcement of drug discovery and lead identification can be done by 
assessing the metabolic fate of orally administered drugs. In vitro microsomal studies on 
compounds 2.2-2.17 (Figure 2.4-2.7) yielded interesting results (Table 2.6). Most of the 
compounds that were subjected to microsomal stability assay exhibited reasonable 
stability. The differences in the side chain length between 2.2, 2.4 and 2.11-2.14 did not 
result in a big difference in the microsomal stability, indicating that side chain length was 
not a deciding factor between the compounds. The difference in stability between 
methylated ring systems (2.12, 2.14) and the nonmethylated analogues (2.11, 2.13) 
proved that methyl group attached to the aromatic system reduces vulnerability to 
potential metabolic degradation. 
2.9. Experimental 
 
Anhydrous grade solvents were purchased from Sigma-Aldrich Inc. (St. Louis, 
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MO) and from Fisher Scientific. Most of the chemical reagents were used without further 
purification, except for 1-bromotridecane and undecyl bromide, 1- bromododecane and 1-
bromohexadecane, which were purified by silica gel flash column chromatography prior 
to use. The reactions were carried out under an atmosphere of argon. The glassware and 
needle were pre-dried in an oven at 120 °C prior to use. All reactions were performed 
under a stream of argon. Flash column chromatography was carried out using silica gel 
(Silicycle R10030B, 60 particle size, 230-400 mesh), applying a low pressure stream of 
nitrogen. Analytical thin layer chromatographic separations were carried out on glass 
plates coated with silica gel (60 particle size F254, SiliCycle TLG-R10011B-323). The 
TLC chromatograms were developed by immersing the plates in 2.5% potassium 
permanganate in ethanol or 2% anisaldehyde + 5% sulfuric acid + 1.5% glacial acetic 
acid in ethanol, followed by heating, or else visualized by UV irradiation (254 nm). 
Tetrahydrofuran was distilled from sodium/benzophenone ketyl and dichloromethane 
from calcium hydride.118 1H and 13C NMR spectra were recorded on a Gemini 300 or 
Varian Inova 400, or on a Varian Inova 500 spectrometer, using CDCl3 as solvent and 
internal standard, unless otherwise indicated. 1H NMR chemical shifts were reported 
relative to residual CHCl3 at 7.26 ppm, or to residual DMSO-d6 at 2.50 ppm; 
13C NMR 
shifts were reported relative to the central line of CDCl3 at 77.16 ppm, or to 
13C DMSO-
d6 at 39.51 ppm. Splitting patterns are designated as s, singlet; br s, broad singlet; d, 
doublet; dd, doublet of doublets; dt, doublet of triplets; m, multiplet; q, quartet; quin, 
quintet. High resolution mass spectrometric data were obtained at the Arizona State 
University CLAS High Resolution Mass Spectrometry Facility.  
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2,4,5-Trimethoxyphenol (2.18).107,108 To a solution containing 5.00 g of 2,4,5-
trimethoxybenzaldehyde (25.0 mmol) and 3.20 mL of H2O2 (35% wt solution in H2O) in 
51.0 mL of methanol was added 0.50 mL (9.20 mmol) of conc. H2SO4 dropwise under an 
atmosphere of argon at room temperature. The reaction mixture was heated to reflux for 2 
h, diluted with water and extracted with three 100-mL portions of dichloromethane.  The 
combined organic layer was washed successively with brine, distilled water and dried 
(MgSO4). The excess solvent was concentrated under diminished pressure. The crude 
residue was applied to silica gel column (12 × 4 cm) Step gradient elution with 1:4→1:2 
ethyl acetate–hexane afforded 2.18 as a yellow solid:  yield is 3.6 g (78%). Silica gel 
TLC Rf 0.45 (1:1 ethyl acetate–hexanes);  1H NMR (CDCl3) δ 3.48 (s, 6H), 3.52  (s, 3H) 
6.08 (br.s, 1H), 6.33 (s, 1H) and 6.36 (s, 1H);  13C NMR (CDCl3) δ 56.4, 57.0, 57.2, 99.6, 
100.9, 139.6, 142.1 and 143.8. 
        
1.2.4.5-Tetramethoxybenzene (2.19).108 To a solution of 0.60 g sodium hydride (57.0 
mmol ) washed with several portions of hexane (60% in oil dispersion) in dry N,N-
dimethylformamide  was added a solution of 3.50 g (19.0 mmol) of alcohol 2.18 in 62.0 
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mL of dry N,N-dimethylformamide.  The mixture was stirred at 0 oC for 30 min under 
argon atmosphere and 2.30 mL (38.3 mmol) of methyl iodide was added dropwise.  The 
reaction mixture was then stirred at room temperature for 13 h and quenched upon 
addition of 10 mL of methanol. The solvent was concentrated under diminished pressure 
to afford a crude residue. The crude residue was extracted with five 10-mL portions of 
dichloromethane, washed successively with 50 mL of 3% aq HCl, distilled water, brine 
and dried (MgSO4). The solvent was concentrated under diminished pressure to afford a 
crude residue. The crude residue was applied to a silica gel column (8 × 4 cm). Elution 
with 1:4 ethyl acetatehexanes gave 2.19 as a colorless solid: yield 3.60 g (95%); silica 
gel TLC Rf 0.32 (1:2 ethyl acetatehexanes); 1H NMR (CDCl3) δ 3.70 (s, 12H) 
and6.47(s, 2H); 13C NMR (CDCl3) δ 57.1, 100.7 and 143.2. 
 
3-Dodecyl-1,2,4,5-tetramethoxybenzene (2.20).119 To a solution containing 1.20 g (6.00 
mmol) of 1,2,4,5-tetramethoxybenzene 2.19  and 90.0 μL (0.60 mmol) 
tetramethylethylenediamine in 30.0 mL dry THF was added 2.70  mL (2.5 M in hexanes, 
6.60  mmol) of n-butyllithium dropwise at 78 oC over 5 min. The reaction mixture was 
warmed to 0 oC over 2 h, 1.6 mL (6.60 mmol) of purified 1-bromododecane was added 
and the reaction mixture was stirred at room temperature under an atmosphere of argon 
for 15 h. The reaction mixture was quenched with 20 mL of saturated NH4Cl and 
extracted with five 10-mL portions of diethyl ether. The organic layer was washed 
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successively with distilled water, brine and dried (MgSO4). The excess solvent was 
concentrated under diminished pressure to afford a crude residue. The crude residue was 
applied to a silica gel column (6 × 3 cm). Elution with 1:9 ethyl acetatehexanes afforded 
3 as a colorless solid: yield 1.73 g (75%); silica gel TLC Rf 0.45 (1:1 ethyl 
etherhexanes); 1H NMR (CDCl3) δ 0.85 (t, 3H,  J = 6.8 Hz), 1.231.29 (m, 18H), 
1.471.58 (m, 2H), 2.61 (dd, 2H, J = 8.8 and 6.9 Hz), 3.74 (s, 6H), 3.80 (s, 6H) and 6.38 
(s, 1H); 13C NMR (CDCl3) δ 14.1, 22.7, 24.6, 29.3, 29.5, 29.6, 29.6, 29.7, 29.7, 30.0, 
30.7, 32.0, 56.1, 60.8, 60.9, 96.7, 131.1, 141.1 and 148.8.   
 
2,5-Dimethoxy-3-dodecyl-1,4-benzoquinone (2.21).108 To a solution containing 0.10 g 
(0.20 mmol) of 1,2,4,5-tetramethoxy-3-methyl-6-tridecylbenzene (2.20) in 2.60 mL of  
acetonitrile was added 2.60 mL (0.20 g, 0.50 mmol) of a 7 (1.82  mL) :3 (0.78 mL) 
solution of cerium(IV) ammonium nitrate in  acetonitrilewater dropwise at 7 ºC 
(saltice bath) over a period of 30 min. The reaction mixture was stirred at room 
temperature for 3 h and then diluted with 10 mL of diethyl ether. The organic layer was 
washed successively with distilled water, brine and dried (MgSO4). The excess solvent 
was concentrated under diminished pressure to afford crude quinone (2.21).  The crude 
residue was applied to a silica gel column (7 × 2 cm). Elution with 1:4 ethyl 
acetatehexanes gave 2.21 as a yelloworange solid: yield 55 mg (60%); silica gel TLC 
Rf 0.68 (1:4 ethyl acetatehexanes); 1H NMR (CDCl3) δ 0.82 (t,  3H, J = 6.8 Hz), 
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1.201.25 (m, 18H), 1.321.41 (m, 2H), 2.33 (t, 2H, J = 8 Hz) and 3.93 (s, 6H); 13C 
NMR (CDCl3) δ 14.0, 22.7, 23.0, 24.5, 28.9, 29.3, 29.4, 29.4, 29.5, 29.6, 29.6, 29.6, 31.1, 
31.8, 60.1, 126.3, 130.9, 147.4, 155.4, 184.0 and 184.5.  
 
Tert-butyl 4-aminobutanoate (2.22).120 CBz-GABA-O-t-Bu (170 mg, 0.60 mmol) in 
15.0 mL methanol was hydrogenated under 5 atm pressure in the presence of 10% Pd/C 
(40.0 mg), overnight. The reaction mixture was filtered through Celite and solvent was 
concentrated under diminished pressure to provide GABA-O-t-Bu as a colorless oil: yield 
83.4 mg (91%); 1H NMR (CDCl3) δ 6.00 (br, s, 2H), 3.08 (t, J = 6.8 Hz, 2H), 2.40 (t, J = 
7.0 Hz, 2H), 2.14-1.95 (m, 2H), 1.44 (s, 9H); 13C NMR (CDCl3) δ 28.0, 28.8, 32.9, 41.4, 
80.2 and 172.8.  
                                            
4-Butoxy-4-oxobutan-1-aminium 4-methylbenzenesulfonate (2.23).120 A solution of 
1.00 g (9.70 mmol) of 4-aminobutanoic acid, 2.00 g (1.00 mmol) p-toluenesulfonic acid 
monohydrate and 1.10 mL (1.20 mmol) of 1-butanol in 20 mL of toluene was heated 
under reflux, using a Dean-Stark distilling receiver, for 24 h. The reaction mixture was 
cooled to room temperature and diluted with 20 mL of anhydrous diethyl ether to afford 
p-toluenesulfonate 2.23 as a crystalline, colorless solid: yield 2.96 g (92%); silica gel 
TLC Rf 0.25 (9:1 chloroform-methanol);
1H NMR (CD3OD) δ 0.94 (t, 3H, J = 7.4 Hz), 
1.331.46 (m, 2H), 1.551.67 (m, 2H), 1.92 (dt, 2H, J = 20.0 and 7.3 Hz), 2.37 (s, 3H), 
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2.44 (t, J = 7.2 Hz, 2H), 2.923.02 (m, 2H), 4.09 (t, 2H, J = 6.6 Hz), 4.86 (s, 3H), 7.24 
(d, 2H, J= 10.5 Hz) and 7.71 (d, 2H, J = 10 Hz); 13C NMR (CD3OD) δ 14.0, 20.1, 21.4, 
23.7, 31.6, 31.8, 40.1, 65.6, 126.8, 129.5, 141.6, 143.3 and 174.1. 
                                         
4-(Hexyloxy)-4-oxobutan-1-aminium 4-methylbenzenesulfonate (2.24).120                                                                     
A solution of 1.00g (9.70 mmol) of 4-aminobutanoic acid, 2.00 g (1.00 mmol) p-
toluenesulfonic acid monohydrate and 1.50 mL (1.20 mmol) of 1-hexanol in 20.0 mL of 
toluene was heated under reflux, using a Dean-Stark distilling receiver, for 24 h. The 
reaction mixture was cooled to room temperature and diluted with 20 mL of anhydrous 
diethyl ether to afford p-toluenesulfonate 2.24 as a crystalline colorless solid: yield 2.50 g 
(72%); silica gel TLC Rf 0.22 (9:1 chloroformmethanol); 1H NMR (CDCl3) δ 0.88 (t, J 
= 7.2 Hz , 3H), 1.211.35 (m, 6H), 1.55 (quin, 2H, J = 14.0 and 7.2 Hz), 1.85 (quin, 2H, 
J = 14.8 and 7.30 Hz), 2.27 (t, 2H, J = 7.34 Hz), 2.36 (s, 3H), 2.802.92 (m, 2H), 3.98 (t, 
2H, J = 6.9 Hz), 7.18 (d, 2H, J = 7.9 Hz) and 7.727.83 (m, 5H); 13C NMR (CDCl3) δ 
14.2, 21.5, 22.67, 22.71, 25.7, 28.6, 31.0, 31.6, 39.4, 65.0, 126.1, 129.2, 140.9, 141.2 and 
172.6. 
 
2,5-Bis-(tert-butyloxycarbonylpropylamino)-3-dodecyl-1,4-benzoquinone (2.2). To a 
solution of 47.0 mg (0.10 mmol) of 2,5-dimethoxy-3-dodecyl-1,4-benzoquinone (2.21) 
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and 0.30 g (3.00 mmol) of sodium bicarbonate  in 9.70 mL of ethanol was added 14.0 mg 
(0.07 mmol) of γ-aminobutyric acid tert-butyl ester hydrochloride salt (2.22). The 
reaction mixture was stirred for 27 h at room temperature. The reaction mixture was then 
diluted with 5 mL of water and extracted with seven 2-mL portions of dichloromethane. 
The organic layer was washed successively with water, brine and dried (Na2SO4). The 
excess solvent was concentrated under diminished pressure to afford a crude residue. The 
residue was purified by flash column chromatography on a silica gel column (24 × 2 cm). 
Elution with 1:5 ethyl acetatehexane afforded 2.2 as a bright red amorphous solid: yield 
12.0 mg (15%) (2.2); silica gel TLC Rf 0.32 (2.2) (1:2 ethyl acetatehexanes); 1H NMR 
(CDCl3) (2.2) δ 0.87 (t, 3H, J = 6.8 Hz), 1.251.36 (m, 22H), 1.43 (s, 18H), 1.861.91 
(m, 4H), 2.32 (m, 4H), 2.42 (t, 2H), 3.47 (t, 2H, J = 5.6), 3.55 (t, 2H, J = 6.0) and 5.94 
(m, 2H); 13C NMR (CDCl3) 14.1, 22.7, 24.2, 25.8, 26.1, 28.1, 29.4, 29.6, 29.7, 29.7, 29.7, 
30.7, 31.9, 32.48, 43.8, 44.1, 80.7, 80.7, 101.44, 106.78, 146.16, 147.1, 171.9, 171.9, 
180.2 and 180.6; mass spectrum (APCI), m/z 591.4383 (M + H)+ (C34H59N2O6 requires 
m/z 591.4373).  
 
2,5-Bis-(butyloxycarbonylpropylamino)-3-dodecyl-1,4-benzoquinone (2.3). To a 
solution of 135 mg (0.40 mmol) of 2,5-dimethoxy-3-dodecyl-1,4-benzoquinone (2.21) 
and 0.20 g (1.70 mmol) of sodium bicarbonate  in 9.70 mL of ethanol was added 120 mg 
(0.70 mmol) of γ-aminobutyric acid butyl ester tosylate salt (2.23). The reaction mixture 
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was stirred for 27 h at room temperature. The reaction mixture was then diluted with 5 
mL of water and extracted with seven 2-mL portions of dichloromethane. The organic 
layer was washed successively with water, brine and dried (Na2SO4). The excess solvent 
was concentrated under diminished pressure to afford a crude residue. The residue was 
purified by flash column chromatography on a silica gel column (24 × 2 cm). Elution 
with 1:5 ethyl acetatehexane gave  2.3 as a bright red amorphous solid: yield 12.0 mg 
(18%); silica gel TLC Rf 0.36 (1:2 ethyl acetatehexanes); 1H NMR (CDCl3) δ 0.87 (t, 
3H, J = 6.8 Hz), 0.93 (t, 6H, J = 7.5 Hz), 1.161.46 (m, 18H), 1.35-1.39 (q, 2H, J = 8 Hz 
), 1.591.62 (m, 6H), 1.93-1.95 (m, 4H), 2.382.41 (m, 8H), 3.51 (m, 4H), 4.074.10 (m, 
4H) and 6.58 (m, 2H); 13C NMR (CDCl3) 13.6, 14.1, 19.1, 22.7, 24.2, 25.8, 26.1, 29.4, 
29.6, 29.7, 29.7, 30.6, 30.7, 31.3, 31.3, 31.9, 43.8, 44.1, 64.6, 64.6, 101.6, 106.9, 146.1, 
147.0, 172.6, 171.7, 180.2 and 180.7; mass spectrum (APCI), m/z 591.4379 (M + H)+ 
(C34H59N2O6 requires m/z 591.4373).  
 
 
2,5-Bis-(hexyloxycarbonylpropylamino)-3-dodecyl-1,4-benzoquinone (2.4). To a 
solution of 44.0 mg (0.10 mmol) of 2,5-dimethoxy-3-dodecyl-1,4-benzoquinone (2.21) 
and 0.28 g (2.40 mmol) of sodium bicarbonate  in 9.70 mL of ethanol was added excess 
of γ-aminobutyric acid hexyl ester tosylate salt (2.24). The reaction mixture was stirred 
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for 27 h at room temperature. The reaction mixture was then diluted with 5 mL of water 
and extracted with seven 2-mL portions of dichloromethane. The organic layer was 
washed successively with water, brine and dried (Na2SO4). The excess solvent was 
concentrated under diminished pressure to afford a crude residue. The residue was 
purified by flash column chromatography on a silica gel column (24 × 2 cm). Elution 
with 1:5 ethyl acetatehexane gave 2.4 as a bright red amorphous solids: yield- 20%; 
silica gel TLC Rf 0.42 (1:2 ethyl acetatehexanes); 1H NMR (CDCl3) δ 0.850.90 (m, 
12H), 1.201.32 (m, 26H), 1.591.62 (m, 4H), 1.96 (m, 4H), 2.372.42 (m, 8H), 3.47 (t, 
3H, J = 9 Hz), 3.57 (t, 2H, J = 9 Hz), 4.024.21 (m, 4H) and 5.876.06 (m, 2H); 13C 
NMR (CDCl3) 14.0, 14.1, 19.8, 22.5, 22.7, 24.1, 25.5, 25.728.5, 29.3, 29.6, 29.6, 29.6, 
30.6, 31.3, 31.3, 31.3, 31.9, 43.8, 44.0, 53.3, 64.6, 101.5, 104.9, 106.9, 146.02, 147.0, 
172.6, 172.6, 180.2 and 180.6; mass spectrum (APCI), m/z 647.4986 (M + H)+ 
(C38H67N2O6 requires m/z 647.4999).  
 
1,2,4,5-Tetramethoxy-3-tridecylbenzene (2.25).108 To a solution containing 1.20 g (6.00 
mmol) of 1,2,4,5-tetramethoxybenzene 2.19  and 90.0 μL (0.60 mmol) 
tetramethylethylenediamine in 30.0 mL dry THF was added 2.70  mL (2.5 M in hexanes, 
6.60  mmol) of n-butyllithium dropwise at 78 oC over 5 min. The reaction mixture is 
warmed to 0 oC over 2 h, 1.70 mL (6.60 mmol) of purified 1-bromotridecane added and 
the reaction mixture stirred at room temperature under an atmosphere of argon for 15 h. 
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The reaction mixture was quenched with 20 mL of saturated NH4Cl and extracted with 
five 10-mL portions of diethyl ether. The organic layer was washed successively with 
distilled water, brine and dried (MgSO4). The excess solvent was concentrated under 
diminished pressure to afford a crude residue. The crude residue was applied to a silica 
gel column (6 × 3 cm). Elution with 1:9 ethyl acetatehexanes afforded 2.19 as a 
colorless solid: yield 1.61 g (70%); silica gel TLC Rf 0.45 (1:1 ethyl etherhexanes); 
unreacted 1,2,4,5-tetramethoxybenzene (2.19) was recovered; 1H NMR (CDCl3) δ 0.85 (t, 
3H, J = 6.8 Hz), 1.231.29 (m, 20H), 1.471.58 (m, 2H), 2.61 (dd, 2H, J = 8.8 and 6.9 
Hz), 3.74 (s, 6H), 3.80 (s, 6H) and 6.38 (s, 1H); 13C NMR (CDCl3) δ 14.1, 22.7, 24.6, 
29.3, 29.5, 29.6, 29.6, 29.7, 29.7, 30.0, 30.7, 32.0, 56.1, 60.8, 60.9, 96.7, 131.1, 141.1 and 
148.8.   
 
1,2,4,5-Tetramethoxy-3-methyl-6-tridecylbenzene (2.26).106 To a solution containing 
1.20 g (6.00 mmol) of 1,2,4,5-tetramethoxy-3-tridecylbenzene  2.25 and 75.0 μL (0.50 
mmol) tetramethylethylenediamine in 25.0 mL dry THF was added 2.70  mL (2.5 M in 
hexanes, 7.40  mmol) of n-butyllithium dropwise at 78 oC over 5 min. The reaction 
mixture is warmed to 0 oC over 2 h. 0.50 mL (7.50 mmol) of purified methyliodide was 
added and the reaction mixture was stirred at room temperature under an atmosphere of 
argon for 15 h. The reaction mixture was quenched with 20 mL of saturated NH4Cl and 
extracted with five 10-mL portions of diethyl ether. The organic layer was washed 
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successively with distilled water, brine and dried (MgSO4). The excess solvent was 
concentrated under diminished pressure to afford a crude residue. The crude residue was 
applied to a silica gel column (6 × 3 cm). Elution with 1:9 ethyl acetatehexanes afforded 
2.26 as a colorless solid: yield 0.98 g (90%); silica gel TLC Rf 0.55 (1:1 ethyl 
etherhexanes); 1H NMR (CDCl3) δ 0.87 (t, 3H, J = 6.8 Hz), 1.251.29 (m, 20H), 
1.471.58 (m, 2H), 2.14 (s, 3H) 2.61 (dd, 2H, J = 8.8 and 6.9 Hz), 3.74 (s, 6H) and 3.80 
(s, 6H); 13C NMR (CDCl3) δ 9.02, 14.1, 22.7, 24.6, 29.3, 29.5, 29.6, 29.6, 29.7, 29.7, 
30.0, 30.7, 32.0, 56.1, 60.8, 60.9, 96.7, 131.1, 141.1 and 148.8. mass spectrum (APCI+), 
m/z 395.3161 (M + H)+ (C24H43O4 requires m/z 395.3161). 
 
 
2,5-Dimethoxy-3-tridecyl-6-methyl-1,4-benzoquinone (2.27). To a solution containing 
0.10 g (0.20 mmol) of 1,2,4,5-tetramethoxy-3-methyl-6-tridecylbenzene (2.26) in 2.60 
mL of  acetonitrile was added 2.60 mL (0.20 g, 0.50 mmol) of a 7 (1.82  mL) :3 (0.78 
mL) solution of cerium(IV) ammonium nitrate in  acetonitrilewater dropwise at 7 ºC 
(saltice bath) over a period of 30 min. The reaction mixture was stirred at room 
temperature for 3 h and then diluted with 10 mL of diethyl ether. The organic layer was 
washed successively with distilled water, brine and dried (MgSO4). The excess solvent 
was concentrated under diminished pressure to afford crude quinone 2.27.  The crude 
residue was applied to a silica gel column (7 × 2 cm). Elution with 1:4 ethyl 
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acetatehexanes gave 2.27 as a yelloworange solid: yield 55 mg (60%); silica gel TLC 
Rf 0.68 (1:4 ethyl acetatehexanes); 1H NMR (CDCl3) δ 0.82 (t,  3H, J = 6.8 Hz), 
1.201.25 (m, 20H), 1.321.41 (m, 2H), 1.84 (s, 3H), 2.33 (t, 2H, J = 8 Hz) and 3.93 (s, 
6H); 13C NMR (CDCl3) δ 9.02, 14.0, 22.7, 23.0, 24.5, 28.9, 29.3, 29.4, 29.4, 29.5, 29.6, 
29.6, 29.6, 31.1, 31.8, 60.1, 126.3, 130.9, 147.4, 155.4, 184.0 and 184.5. mass spectrum 
(APCI), m/z 365.2692 (M + H)+ (C22H37O4 requires m/z 365.2692). 
 
2-Methoxy-3-tridecyl-5-tert-butyloxycarbonylpropylamino-6-methyl-1,4-
benzoquinone (2.5) and 2,5-bis(tert-butyloxycarbonylpropylamino)-3-tridecyl-6-
methyl-1,4-benzoquinone (2.6). To a solution of 52.0 mg (0.10 mmol) of 2,5-
dimethoxy-3-tridecyl-6-methyl-1,4-benzoquinone (2.7) and 0.90 g (12.0 mmol) of 
sodium bicarbonate  in 9.70 mL of ethanol was added 14.0 mg (0.07 mmol) of γ-
aminobutyric acid tert-butyl ester hydrochloride salt. The reaction mixture was stirred for 
27 h at room temperature. The reaction mixture was then diluted with 5 mL of water and 
extracted with seven 2-mL portions of dichloromethane. The organic layer was washed 
successively with water, brine and dried (Na2SO4). The excess solvent was concentrated 
under diminished pressure to afford a crude residue. The residue was purified by flash 
column chromatography on a silica gel column (24 × 2 cm). Elution with 1:5 ethyl 
acetatehexane yielded  2.5 and 2.6 as a bright red amorphous solids: yield- 21 mg (2.5) 
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30%, (2.6) 23% ; silica gel TLC Rf 0.63 (2.5) and 0.32 (2.6) (1:2 ethyl acetatehexanes); 
1H NMR (CDCl3) (2.5) δ 0.87 (t, 3H, J = 6.8 Hz), 1.251.36 (m, 22H), 1.45 (s, 9H), 
1.851.89 (q, 2H, J = 9 Hz), 2.03 (s, 3H), 2.32 (q, 2H, J = 6.8 Hz), 2.352.39 (m, 2H), 
3.14 (dd, 2H, J = 13.0 and 6.8 Hz), 4.10 (s, 3H) and 5.94 (m, 1H); 13C NMR (CDCl3) 
(2.5) δ 10.3, 14.3, 22.8, 23.1, 23.6, 28.2, 28.8, 29.5, 29.6, 29.7, 29.81, 29.83, 32.1, 32.9, 
42.1, 61.8, 81.1, 96.1, 127.6, 146.9, 158.5, 172.2, 181.8 and 183.9; mass spectrum 
(APCI), m/z 492.3692 (M + H)+ (C29H50NO5 requires m/z 492.3692). 
1H NMR (CDCl3) (2.6) δ 0.87 (t, 3H, J = 6.8 Hz), 1.251.36 (m, 22H), 1.43 (s, 18H), 
1.861.91 (m, 4H), 2.03 (s, 3H), 2.32 (m, 4H), 2.42 (t, 2H), 3.47 (t, 2H, J = 5.6), 3.55 (t, 
2H, J =6) and 5.94 (m, 2H); 13C NMR (CDCl3) (2.6) 10.3, 14.1, 22.7, 24.2, 25.8, 26.1, 
28.1, 29.4, 29.6, 29.7, 29.7, 29.7, 30.7, 31.9, 32.48, 43.8, 44.1, 80.7, 80.7, 101.44, 106.78, 
146.16, 147.1, 171.9, 171.9, 180.2 and 180.6; mass spectrum (APCI), m/z 619.4691 (M + 
H)+ (C36H63N2O6 requires m/z 619.4691).  
                               
2-Methoxy-3-tridecyl-5-butyloxycarbonylpropylamino-1,4-benzoquinone (2.7) and 
2,5-bis(butyloxycarbonylpropylamino)-3-tridecyl-6-methyl-1,4-benzoquinone (2.8). 
To a solution of 150 mg (0.40 mmol) of 2,5-dimethoxy-3-tridecyl-6-methyl-1,4-
benzoquinone (2.27) and 1.10 g (13.9 mmol) of sodium bicarbonate  in 9.70 mL of 
ethanol was added 40.0 mg (0.30 mmol) of γ-aminobutyric acid butyl ester tosylate salt 
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(2.23). The reaction mixture was stirred for 27 h at room temperature. The reaction 
mixture was then diluted with 5 mL of water and extracted with seven 2-mL portions of 
dichloromethane. The organic layer was washed successively with water, brine and dried 
(Na2SO4). The excess solvent was concentrated under diminished pressure to afford a 
crude residue. The residue was purified by flash column chromatography on a silica gel 
column (24 × 2 cm). Elution with 1:5 ethyl acetatehexane yielded  2.7 and 2.8 as a 
bright red amorphous solid: yield- 21 mg (2.7) 12 %, (2.8) 8% ; silica gel TLC Rf 0.69 
(2.7) and 0.36 (2.8) (1:2 ethyl acetatehexanes); 1H NMR (CDCl3) (2.7) δ 0.87 (t, 3H, J = 
6.8 Hz), 0.93 (t, 3H, J = 7.5 Hz), 1.161.46 (m, 23H), 1.591.61 (m, 3H), 1.91 (t, 2H, J = 
7.5 Hz), 2.03 (s, 3H), 2.322.40 (m, 4H), 3.51 (t, 2H, J = 7.0 Hz), 4.04 (s, 3H), 4.074.09 
(m, 2H) and 5.95 (t, 1H, J = 5.6 Hz); 13C NMR (CDCl3) (2.7) δ 10.0, 13.69, 14.1, 19.1, 
22.7, 22.9, 26.0, 28.7, 29.4, 29.4, 29.6, 29.7, 29.7, 30.6, 31.3, 31.9, 44.4, 61.5, 64.6, 
106.3, 127.1, 143.9, 157.9, 172.8, 172.8, 182.35 and 184.9; mass spectrum (APCI), m/z 
492.3689 (M+H)+ (C29H50NO5 requires 492.3689). 
1H NMR (CDCl3) (2.8) δ 0.87 (t, 3H, J = 6.8 Hz), 0.93 (t, 6H, J = 7.5 Hz), 1.161.46 (m, 
20H), 1.351.39 (q, 2H, J = 8 Hz ), 1.591.62 (m, 6H), 1.931.95 (m, 4H), 2.03 (s, 3H), 
2.382.41 (m, 8H), 3.51 (m, 4H), 4.074.10 (m, 4H) and 6.58 (m, 2H); 13C NMR 
(CDCl3) (2.8) 10.3,13.6, 14.1, 19.1, 22.7, 24.2, 25.8, 26.1, 29.4, 29.6, 29.7, 29.7, 30.6, 
30.7, 31.3, 31.3, 31.9, 43.8, 44.1, 64.6, 64.6, 101.6, 106.9, 146.07, 147.0, 172.6, 171.7, 
180.2 and 180.7; mass spectrum (APCI), m/z 619.4690 (M + H)+ (C36H63N2O6 requires 
m/z 619.4690).  
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2-Methoxy-3-tridecyl-5-hexyloxycarbonylpropylamino-1,4-benzoquinone (2.9) and 
2,5-bis(hexyloxycarbonylpropylamino)-3-tridecyl-6-methyl-1,4-benzoquinone (2.10). 
To a solution of 44.0 mg (0.10 mmol) of 2,5-dimethoxy-3-tridecyl-6-methyl-1,4-
benzoquinone (2.27) and 0.30 g (3.00 mmol) of sodium bicarbonate  in 9.70 mL of 
ethanol was added 5.60 mg (0.10 mmol) of γ-aminobutyric acid hexyl ester tosylate salt 
2.24. The reaction mixture was stirred for 27 h at room temperature. The reaction mixture 
was then diluted with 5 mL of water and extracted with seven 2-mL portions of 
dichloromethane. The organic layer was washed successively with water, brine and dried 
(Na2SO4). The excess solvent was concentrated under diminished pressure to afford a 
crude residue. The residue was purified by flash column chromatography on a silica gel 
column (24 × 2 cm). Elution with 1:5 ethyl acetatehexane gave  2.9 and 2.10 as a bright 
red amorphous solids: yield- (2.9) 32 %, (2.10) 26% ; silica gel TLC Rf 0.75 (2.9) and 
0.42 (2.10) (1:2 ethyl acetatehexanes); 1H NMR (CDCl3) (2.9) δ 0.850.89 (m, 6H), 
1.201.32 (m, 28H), 1.551.63 (m, 2H), 1.96 (m, 2H), 2.02 (s, 3H), 2.252.33 (t, 2H, J= 
8 Hz), 2.36- 2.39 (t, 2H, J= 9.5 Hz ) 3.50 (q, 2H, J = 6.5 Hz), 4.024.21 (m, 2H), 4.03 (s, 
3H) and 5.876.06 (m, 1H); 13C NMR (CDCl3) (2.9) δ 10.0, 13.9, 14.1, 14.2, 21.0, 22.5, 
22.7, 23.0, 25.6, 26.5, 28.7, 29.3, 29.4, 29.5, 29.7,29.7, 31.3, 31.4, 31.9, 44.4, 60.4, 61.7, 
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64.9, 106.3, 127.1, 143.8, 157.8, 171.1, 172.8, 182.3 and 184.9; mass spectrum (APCI), 
m/z 520.4002 (M+H)+ (C31H54NO5 requires 520.4002). 
1H NMR (CDCl3) (2.10) δ 0.850.90 (m, 12H), 1.201.32 (m, 28H), 1.591.62 (m, 4H), 
1.96 (m, 4H), 2.02 (s, 3H), 2.372.42 (m, 8H), 3.47 (t, 3H, J = 9 Hz), 3.57 (t, 2H, J = 9 
Hz), 4.024.21 (m, 4H) and 5.876.06 (m, 2H); 13C NMR (CDCl3) (2.10) 10.3,14.0, 
14.1, 19.8, 22.5, 22.7, 24.1, 25.5, 25.728.5, 29.3, 29.6, 29.6, 29.6, 30.6, 31.3, 31.3, 31.3, 
31.9, 43.8, 44.0, 53.3, 64.6, 101.5, 104.9, 106.9, 146.02, 147.0, 172.6, 172.6, 180.2 and 
180.6; mass spectrum (APCI), m/z 675.5308 (M + H)+ (C40H71N2O6 requires m/z 
675.5308).  
 
3-Hexadecyl-1,2,4,5-tetramethoxybenzene (2.28). To a solution containing 300 mg 
(1.50 mmol) of 1,2,4,5-tetramethoxybenzene 2.19  and 29.0 μL (0.20 mmol) 
tetramethylethylenediamine in 5.00 mL dry THF was added 1.00  mL (2.5 M in hexanes, 
2.60  mmol) of n-butyllithium dropwise at 78 oC over 5 min. The reaction mixture was 
warmed to 0 oC over 2 h, 500 L (1.90 mmol) of purified 1-bromotridecane added and 
the reaction mixture was stirred at room temperature under an atmosphere of argon for 15 
h. The reaction mixture was quenched with 20 mL of saturated NH4Cl and extracted with 
five 10-mL portions of diethyl ether. The organic layer was washed successively with 
distilled water, brine and dried (MgSO4). The excess solvent was concentrated under 
diminished pressure to afford a crude residue. The crude residue was applied to a silica 
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gel column (6 × 3 cm). Elution with 1:9 ethyl acetatehexanes afforded 2.28 as a 
colorless solid: yield 67% ; silica gel TLC Rf 0.40 (1:1 ethyl etherhexanes); unreacted 
1,2,4,5-tetramethoxybenzene (2.19) was recovered; 1H NMR (CDCl3) δ 0.88 (t, 3H, J = 
7.2 Hz), 1.251.37 (m, 26H), 1.501.52 (m, 2H), 2.61 (t, 2H, J = 8Hz), 3.77 (s, 6H), 3.84 
(s, 6H), 6.41 (s, 1H); 13C NMR (CDCl3) δ 14.3, 22.8, 24.7, 24.8, 29.5, 29.6, 29.8, 29.8, 
30.2, 30.3, 30.9, 31.3, 32.1, 56.4, 60.7, 61.1, 96.8, 131.3, 141.3 and 149.0; mass spectrum 
(APCI), m/z 423.3474 (M + H)+ (C26H47O4 requires m/z 423.3474).  
 
3-Hexadecyl-2,5-dimethoxy-1,4-benzoquinone (2.29). To a solution containing 0.10 g 
(0.20 mmol) of 3-hexadecyl-1,2,4,5-tetramethoxybenzene  (2.28) in 2.60 mL of  
acetonitrile was added 2.60 mL (0.30 g, 0.50 mmol) of a 7 (1.80  mL) :3 (0.80 mL) 
solution of cerium(IV) ammonium nitrate in  acetonitrilewater dropwise at 7 oC 
(saltice bath) over a period of 30 min. The reaction mixture was stirred at room 
temperature for 3 h and then diluted with 10 mL of diethyl ether. The organic layer was 
washed successively with distilled water, brine and dried (MgSO4). The excess solvent 
was concentrated under diminished pressure to afford crude quinone 2.29.  The crude 
residue was applied to a silica gel column (7 × 2 cm). Elution with 1:4 ethyl 
acetatehexanes gave  2.29  as a yelloworange solid: yield 60 mg (68%); silica gel TLC 
Rf 0.68 (1:4 ethyl acetatehexanes); 1H NMR (CDCl3) δ 0.88 (t,  3H, J = 7.2 Hz), 
1.251.32 (m, 26H), 1.381.42 (m, 2H), 2.43 (t, 2H, J = 8 Hz), 3.81 (s, 3H), 4.05 (s, 3H) 
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and 5.73 (s, 1H); 13C NMR (CDCl3) δ 14.1, 22.7, 23.1, 28.6, 29.3, 29.4, 29.5, 29.6, 29.7, 
31.2, 31.9, 38.1, 56.3 61.3, 105.4, 130.7, 155.9, 158.7, 182.4 and 183.6. mass spectrum 
(MALDI), m/z 393.48 (M + H)+ (C24H41O4 requires m/z 393.48). 
 
2,5-Bis(tert-butyloxycarbonylpropylamino)-3-hexadecyl-1,4-benzoquinone (2.11). To 
a solution of 25.0 mg (0.07 mmol) of 3-hexadecyl-2,5-dimethoxy-1,4-benzoquinone 
(2.29) and 0.20 g (2.50 mmol) of sodium bicarbonate  in 9.70 mL of ethanol was added 
12.3 mg (0.10 mmol) of γ-aminobutyric acid tert-butyl ester hydrochloride salt (2.22). 
The reaction mixture was stirred for 27 h at room temperature. The reaction mixture was 
then diluted with 5 mL of water and extracted with seven 2-mL portions of 
dichloromethane. The organic layer was washed successively with water, brine and dried 
(Na2SO4). The excess solvent was concentrated under diminished pressure to afford a 
crude residue. The residue was purified by flash column chromatography on a silica gel 
column (24 × 2 cm). Elution with 1:5 ethyl acetatehexane gave  2.11  as a bright red 
amorphous solids: yield- 12 mg (15 %); silica gel TLC Rf 0.35 (1:2 ethyl 
acetatehexanes); 1H NMR (CDCl3) δ 0.87 (t, 3H, J = 7.2 Hz), 1.241.37 (m, 28H), 1.44 
(s, 18H), 1.871.94 (m, 4H), 2.32 (q, 4H, J = 7.6 Hz), 2.46 (t, 2H, J = 8.8 Hz), 3.17 (q, 
2H, J = 6.4 Hz), 3.52 (q, 2H, J = 6.4 Hz), 5.25 (s, 1H) and 6.60-6.65 (m, 2H); 13C NMR 
(CDCl3) δ14.1, 22.7, 23.6, 24.1, 25.8, 28.1, 29.3, 29.6, 29.6, 29.7, 30.6, 31.9, 32.5, 32.6, 
32.8, 41.8, 43.8, 80.7, 80.8, 92.1, 107.8, 146.6, 150.5, 171.8, 171.9, 179.0 and 179.5; 
mass spectrum (APCI), m/z 647.4999(M + H)+ (C38H67N2O6 requires m/z 647.4999). 
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2,5-Bis(butyloxycarbonylpropylamino)-3-hexadecyl-1,4-benzoquinone (2.13). To a 
solution of 25.0 mg (0.10 mmol) of 3-hexadecyl-2,5-dimethoxy-1,4-benzoquinone (2.29) 
and 0.20 g (2.00 mmol) of sodium bicarbonate  in 9.70 mL of ethanol was added 12.20 
mg (0.10 mmol) of γ-aminobutyric acid n-butyl ester hydrochloride salt. The reaction 
mixture was stirred for 27 h at room temperature. The reaction mixture was then diluted 
with 5 mL of water and extracted with seven 2-mL portions of dichloromethane. The 
organic layer was washed successively with water, brine and dried (Na2SO4). The excess 
solvent was concentrated under diminished pressure to afford a crude residue. The 
residue was purified by flash column chromatography on a silica gel column (24 × 2 cm). 
Elution with 1:5 ethyl acetatehexane gave  2.13  as a bright red amorphous solids: yield 
15 mg (18%); silica gel TLC Rf 0.30 (1:2 ethyl acetatehexanes); 1H NMR (CDCl3) δ 
0.87 (t, 3H, J = 7.2 Hz), 0.93 (t, 6H, J = 7.6 Hz), 1.251.32 (m, 26H), 1.38 (q, 2H, J= 7.2 
Hz), 1.56 (m, 4H), 1.61 (t, 4H, J = 7.2 Hz ), 1.97 (m, 4H), 2.40 (q, 4H, J = 9.6 Hz), 2.44 
(t, 2H, J = 8.8 Hz), 3.18 (q, 2H, J = 6.4 Hz), 3.52 (q, 2H, J = 6.4 Hz),4.09 (t, 4H, J = 6.8 
Hz ) 5.25 (s, 1H) and 6.60-6.65 (m, 2H); 13C NMR (CDCl3) 13.7, 14.1, 19.1, 22.7, 23.5, 
24.1, 25.7, 29.3, 29.6, 29.6, 29.7, 30.6, 30.6, 30.6, 31.3, 31.5, 31.9, 41.8, 43.8, 64.6, 64.6, 
92.21, 107.9, 146.5, 150.4, 172.6, 172.7, 179.1 and 179.6 ; mass spectrum (APCI), m/z 
647.49999 (M + H)+ (C38H67N2O6 requires m/z 647.4999). 
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2,5-Bis(hexyloxycarbonylpropylamino)-3-hexadecyl-1,4-benzoquinone (2.15). To a 
solution of 25.0 mg (0.06 mmol) of 3-hexadecyl-2,5-dimethoxy-1,4-benzoquinone (2.29) 
and 0.10 g (1.30 mmol) of sodium bicarbonate  in 9.70 mL of ethanol was added 14.1 mg 
(0.06 mmol) of γ-aminobutyric acid n-hexyl ester hydrochloride salt. The reaction 
mixture was stirred for 27 h at room temperature. The reaction mixture was then diluted 
with 5 mL of water and extracted with seven 2-mL portions of dichloromethane. The 
organic layer was washed successively with water, brine and dried (Na2SO4). The excess 
solvent was concentrated under diminished pressure to afford a crude residue. The 
residue was purified by flash column chromatography on a silica gel column (24 × 2 cm). 
Elution with 1:5 ethyl acetatehexane gave  2.15  as a bright red amorphous solids: yield 
10 mg (22%); silica gel TLC Rf 0.30 (1:2 ethyl acetatehexanes); 1H NMR (CDCl3) δ 
0.87 (m, 9H), 1.251.38 (m, 36H), 1.61 (m, 4H), 1.97 (m, 4H), 2.40 (q, 8H, J = 9.6 Hz), 
2.46 (t, 2H, J = 8.8 Hz), 3.18 (q, 2H, J = 6.4 Hz), 3.52 (q, 2H, J = 6.4 Hz), 4.07 (t, 4H, J 
= 6.8 Hz ), 5.25 (s, 1H) and 6.60-6.65 (m, 2H); 13C NMR (CDCl3) 13.7, 14.1, 19.1, 22.7, 
23.5, 24.1, 25.7, 29.3, 29.6, 29.6, 29.7, 30.6, 30.6, 30.6, 31.3, 31.5, 31.9, 41.8, 43.8, 64.6, 
64.6, 92.21, 107.9, 146.5, 150.4, 172.6, 172.7, 179.1 and 179.6 ; mass spectrum (APCI), 
m/z 703.5625 (M + H)+ (C42H75N2O6 requires m/z 703.5625). 
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1-Hexadecyl-2,3,5,6-tetramethoxy-4-methylbenzene (2.30). To a solution containing 
0.30 g (1.60 mmol) of 1,2,4,5-tetramethoxy-3-hexadecylbenzene  2.28 and 30.0 μL (0.20 
mmol) tetramethylethylenediamine in 8.00 mL dry THF was added 1.00  mL (2.5 M in 
hexanes, 3.0  mmol) of n-butyllithium dropwise at 78 oC over 5 min. The reaction 
mixture is warmed to 0 oC over 2 h, 1.00 mL (15.0 mmol) of purified methyliodide added 
and the reaction mixture stirred at room temperature under an atmosphere of argon for 15 
h. The reaction mixture was quenched with 20 mL of saturated NH4Cl and extracted with 
five 10-mL portions of diethyl ether. The organic layer was washed successively with 
distilled water, brine and dried (MgSO4). The excess solvent was concentrated under 
diminished pressure to afford a crude residue. The crude residue was applied to a silica 
gel column (6 × 3 cm). Elution with 1:9 ethyl acetatehexanes afforded 2.30 as a 
colorless solid: yield 0.15 g (48%); silica gel TLC Rf 0.65 (1:1 ethyl etherhexanes); 
unreacted 1,2,4,5-tetramethoxy-3-hexadecylbenzene  (2.28) was recovered; 1H NMR 
(CDCl3) δ 0.87 (t, 3H, J = 6.8 Hz), 1.241.28 (m, 26H), 1.471.58 (m, 2H), 2.14 (s, 3H) 
2.61 (dd, 2H, J = 8.8 and 6.9 Hz), 3.76 (s, 6H) and 3.80 (s, 6H); 13C NMR (CDCl3) δ 9.0, 
14.1, 22.7, 24.5, 29.3, 29.5, 29.6, 29.6, 29.7, 30.1, 31.1, 31.9, 60.1, 60.6, 122.9, 127.8 and 
147.5; ; mass spectrum (APCI), m/z 437.3671 (M + H)+ (C27H49O4 requires m/z 
437.3631). 
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2,5-Dimethoxy-3-hexadecyl-6-methyl-1,4-benzoquinone (2.31). To a solution 
containing 0.10 g (0.20 mmol) of 3-hexadecyl-1,2,4,5-tetramethoxybenzene  (2.30) in 
2.60 mL of  acetonitrile was added 2.60 mL (0.30 g, 0.50 mmol) of a 7 (1.80  mL) :3 
(0.80 mL) solution of cerium(IV) ammonium nitrate in  acetonitrilewater dropwise at 7 
oC (saltice bath) over a period of 30 min. The reaction mixture was stirred at room 
temperature for 3 h and then diluted with 10 mL of diethyl ether. The organic layer was 
washed successively with distilled water, brine and dried (MgSO4). The excess solvent 
was concentrated under diminished pressure to afford crude quinone 2.31.  The crude 
residue was applied to a silica gel column (7 × 2 cm). Elution with 1:4 ethyl 
acetatehexanes gave  2.31  as a yelloworange solid: yield 59 mg (62%); silica gel TLC 
Rf 0.72 (1:4 ethyl acetatehexanes); 1H NMR (CDCl3) δ 0.88 (t,  3H, J = 7.2 Hz), 
1.241.28 (m, 26H), 1.381.42 (m, 2H), 1.90 (s, 3H), 2.43 (t, 2H, J = 8 Hz) and 3.97 (s, 
6H); 13C NMR (CDCl3) δ 8.4, 14.1, 22.7, 23.0, 28.9, 29.3, 29.4, 29.5, 29.5, 29.6, 29.6, 
29.7, 29.7, 31.9, 61.0, 61.1, 126.4, 130.9, 155.4, 184.0 and 184.5; mass spectrum (APCI), 
m/z 407.3170 (M + H)+ (C25H43O4 requires m/z  407.3165). 
 
  68 
2,5-Bis(tert-butyloxycarbonylpropylamino)-3-hexadecyl-5-methyl-1,4-benzoquinone 
(2.12). To a solution of 25.0 mg ( 0.06 mmol) of 2,5-dimethoxy-3-hexadecyl-6-methyl-
1,4-benzoquinone (2.31) and 0.10 g (1.50 mmol) of sodium bicarbonate  in 9.70 mL of 
ethanol was added 12.0 mg (0.06 mmol) of γ-aminobutyric acid tert-butyl ester 
hydrochloride salt. The reaction mixture was stirred for 27 h at room temperature. The 
reaction mixture was then diluted with 5 mL of water and extracted with seven 2-mL 
portions of dichloromethane. The organic layer was washed successively with water, 
brine and dried (Na2SO4). The excess solvent was concentrated under diminished 
pressure to afford a crude residue. The residue was purified by flash column 
chromatography on a silica gel column (24 × 2 cm). Elution with 1:5 ethyl 
acetatehexane gave  2.12  as a bright red amorphous solids: yield 20 mg (23%); silica 
gel TLC Rf 0.40 (1:2 ethyl acetatehexanes); 1H NMR (CDCl3) δ 0.86 (t, 3H, J = 7.2 Hz), 
1.231.37 (m, 28H), 1.42 (s, 18H), 1.871.94 (m, 4H), 2.01 (s, 3H), 2.29 (m, 4H), 2.46 
(t, 2H, J = 8.8 Hz), 3.45 (q, 2H, J = 6.4 Hz), 3.54 (q, 2H, J = 6.4 Hz) and 6.60-6.65 (m, 
2H); 13C NMR (CDCl3) δ14.1, 22.7, 23.6, 24.1, 25.8, 28.1, 29.3, 29.6, 29.6, 29.7, 30.6, 
31.9, 32.5, 32.6, 32.8, 41.8, 43.8, 80.7, 80.8, 92.1, 107.8, 146.6, 150.5, 171.8, 171.9, 
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2,5-Bis(butyloxycarbonylpropylamino)-3-hexadecyl-5-methyl-1,4-benzoquinone. 
(2.14). To a solution of 25.0 mg (0.06 mmol) of 2,5-dimethoxy-3-hexadecyl-6-methyl-
1,4-benzoquinone (2.31) and 0.20 g (2.30 mmol) of sodium bicarbonate  in 9.70 mL of 
ethanol was added 12.0 mg (0.06 mmol) of γ-aminobutyric acid n-butyl ester 
hydrochloride salt. The reaction mixture was stirred for 27 h at room temperature. The 
reaction mixture was then diluted with 5 mL of water and extracted with seven 2-mL 
portions of dichloromethane. The organic layer was washed successively with water, 
brine and dried (Na2SO4). The excess solvent was concentrated under diminished 
pressure to afford a crude residue. The residue was purified by flash column 
chromatography on a silica gel column (24 × 2 cm). Elution with 1:5 ethyl 
acetatehexane gave  2.14  as a bright red amorphous solids: yield 6 mg (8%); silica gel 
TLC Rf 0.35 (1:2 ethyl acetatehexanes); 1H NMR (CDCl3) δ 0.87 (t, 3H, J = 7.2 Hz), 
0.93 (t, 6H, J = 7.6 Hz), 1.251.32 (m, 26H), 1.38 (q, 2H, J = 7.2 Hz), 1.58 (m, 8H), 1.95 
(t, 4H, J = 7.2 Hz ), 2.02 (s, 3H), 2.40 (m, 6H), 3.48 (q, 2H, J = 6.4 Hz), 3.57 (q, 2H, J = 
6.4 Hz), 4.08 (t, 4H, J = 6.8 Hz ) and 6.60-6.65 (m, 2H); 13C NMR (CDCl3) 13.7, 14.1, 
19.1, 22.7, 23.5, 24.1, 25.7, 29.3, 29.6, 29.6, 29.7, 30.6, 30.6, 30.6, 31.3, 31.5, 31.9, 41.8, 
43.8, 64.6, 64.6, 92.2, 107.9, 146.5, 150.4, 172.6, 172.7, 179.1 and 179.6 ; mass spectrum 
(APCI), m/z 661.5156 (M + H)+ (C39H69N2O6 requires m/z 661.5156).   
 




(2.16) To a solution of 22.0 mg (0.06 mmol) of 2,5-dimethoxy-3-hexadecyl-6-methyl-
1,4-benzoquinone (2.31) and 0.50 g (5.00 mmol) of sodium bicarbonate  in 9.70 mL of 
ethanol was added 13.6 mg (0.06 mmol) of γ-aminobutyric acid n-hexyl ester 
hydrochloride salt. The reaction mixture was stirred for 27 h at room temperature. The 
reaction mixture was then diluted with 5 mL of water and extracted with seven 2-mL 
portions of dichloromethane. The organic layer was washed successively with water, 
brine and dried (Na2SO4). The excess solvent was concentrated under diminished 
pressure to afford a crude residue. The residue was purified by flash column 
chromatography on a silica gel column (24 × 2 cm). Elution with 1:5 ethyl 
acetatehexane gave  2.16  as a bright red amorphous solids: yield 15 mg (34%); silica 
gel TLC Rf 0.36 (1:2 ethyl acetatehexanes); 1H NMR (CDCl3) δ 0.87 (m, 9H), 
1.251.38 (m, 36H), 1.61 (m, 8H), 1.95 (m, 4H), 2.02 (s, 3H), 2.40 (q, 6H, J = 9.6 Hz), 
3.49 (q, 2H, J = 6.4 Hz), 3.57 (q, 2H, J = 6.4 Hz), 4.07 (t, 4H, J = 6.8 Hz ) and 6.60-6.65 
(m, 2H); 13C NMR (CDCl3) 10.3, 14.0, 14.1, 22.5, 22.7, 24.1, 22.5, 25.7, 26.0, 28.5, 29.3, 
29.5, 29.6, 29.7, 30.6, 31.3, 31.3, 31.3, 31.9, 43.8, 44.0, 64.9, 101.5, 106.9, 146.1, 1467.0, 
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172.6, 172.7, 180.2 and 180.6 ; mass spectrum (APCI), m/z 718.5782 (M + H)+ 
(C43H77N2O6 requires m/z 718.5782). 
 
2,5-Bis(octadecylamino)-3-dodecyl-1,4-benzoquinone (2.17). To a solution of 201 mg 
(0.60 mmol) of 2,5-dimethoxy-3-hexadecyl-6-methyl-1,4-benzoquinone (2.31) and 1.00 g 
(13.0 mmol) of sodium bicarbonate  in 9.70 mL of ethanol was added 538  mg (1.20 
mmol) of octadecylamine. The reaction mixture was stirred for 24 h at room temperature. 
The reaction mixture was then diluted with 5 mL of water and extracted with seven 2-mL 
portions of dichloromethane. The organic layer was washed successively with water, 
brine and dried (Na2SO4). The excess solvent was concentrated under diminished 
pressure to afford a crude residue. The residue was purified by flash column 
chromatography on a silica gel column (24 × 2 cm). Elution with 1:5 ethyl 
acetatehexane gave  2.17  as a bright red amorphous solids: yield 111 mg (23%); silica 
gel TLC Rf 0.36 (1:2 ethyl acetatehexanes); 1H NMR (CDCl3) δ 0.87 (m, 12H), 
1.251.38 (m, 77H), 1.61 (m, 7H), 1.95 (m, 3H), 5.27 (s, 1H) and 6.60-6.65 (m, 2H); 13C 
NMR (CDCl3) 14.1, 22.7, 24.6, 28.1, 28.3, 28.8, 29.2, 29.3, 29.3, 29.4, 29.4, 29.5, 29.5, 
29.5, 29.6, 29.6, 29.7, 30.2, 31.1, 31.9, 31.9, 32.8, 34.0, 42.5, 43.1, 44.6, 60.5, 107.3, 
127.9, 146.9, 147.3, 150.6, 178.8, 179.3 and 179.7; mass spectrum (APCI), m/z 811.8024 
(M + H)+ (C54H103N2O2 requires m/z 811.8020). 
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Cell Lines and Culture Conditions.106 
Friedreich’s ataxia lymphocytes (GM15850), were obtained from Coriell Cell 
Repositories (Camden, NJ). The lymphocytes were cultured in RPMI-1640 medium 
(Gibco, Life Technologies, Grand Island, NY) containing 15% fetal calf serum, 2 mM 
glutamine (HyClone, South Logan, UT) and 1% penicillin–streptomycin antibiotic 
supplement (Cellgro, Manassas, VA). Cells were kept at a nominal concentration of 5-
10×105 cell/mL. The lymphocytes were cultured in RPMI 1640 glucose free medium 
(Gibco, Grand Island, NY) supplemented with 25 mM galactose, 2 mM glutamine and 
1% penicillin–streptomycin, and 10% dialyzed fetal bovine serum (FBS) (<0.5 μg/mL) 
(Gemini Bio- Product, West Sacramento, CA). 
Cytoprotection.109  
FRDA lymphocytes were grown in RPMI 1640 medium (Gibco) supplemented 
with 15% fetal calf serum, 2 mM glutamine (HyClone) and 1% penicillin–streptomycin 
mix (Cellgro). Cells were seeded at a density of 5×105 cells/mL and treated with different 
concentrations of the indicated compounds. Cells were incubated at 37 °C in a humidified 
atmosphere of 5% CO2 in air for 17 h. After pre-incubation, the cells were treated with 5 
mM DEM. Cell viability were determined by staining cells with 0.4% trypan blue and 
counting the cells using a hemacytometer. At least 500 cells were counted in each 
experimental group. At the time of assay, < 20% of DEM treated cells were viable 
(trypan blue negative), whereas in non DEM-treated controls, > 90% of the cells were 
viable. Cell viability was expressed as the percentage of control. Data are expressed as 
means ± S.E.M. (n = 3).  
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Inhibition of Lipid Peroxidation106  
Lipid peroxidation was determined in FRDA lymphocyte cells depleted of 
glutathione. Following pretreatment with the indicated compounds at 5 μM or 10 μM 
concentration for 16 h, the cells were treated with 500 nM C11-BODIPY581/591 in the 
dark at 37 °C for 30 min before inducing lipid peroxidation with 5 mM diethyl maleate 
(DEM) for 140 min, and then subjected to flow cytometry analysis using the FL1-H 
channel for C11-BODIPY581/591-green (oxidized form). In each analysis, 10,000 events 
were recorded. Increased C11-BODIPY581/591–green fluorescence, a measure of 
intracellular lipid peroxidation, was determined by a shift in BODIPY581/59 –green 
fluorescence to the right on the X-axis of the FACS histogram relative to the untreated 
control. 
Inhibition of NADH Oxidase Activity121 
Beef heart mitochondria were obtained by a large-scale procedure. Inverted 
submitochondrial particles (SMP) were prepared by the method of Matsuno-Yagi and 
Hatefi21 and stored in a buffer containing 0.25 M sucrose and 10 mM Tris–HCl, pH 7.4, 
at −80 °C. The inhibitory effects of quinone analogues on bovine heart mitochondrial 
complex I (NADH: ubiquinone oxidoreductase) were evaluated by modification of a 
method described previously.133 Stock solutions (2 mg/mL in ethanol) of quinone 
analogues were prepared and kept in the dark at −80 °C. Maximal ethanol concentration 
never exceeded 2% and had no influence on the control enzymatic activity. The 
enzymatic activities were assayed at 30 °C and monitored spectrophotometrically with a 
Molecular Devices SPECTRA Max-M5 (340 nm, ε = 6.22 mM-1 cm-1). NADH oxidase 
activity was determined in a reaction medium (2.5 mL) containing 50 mM Hepes, pH 7.5, 
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containing 5 mM MgCl2. The final amount of mitochondrial protein was 30 μg. The 
reaction was initiated by adding 50 μM NADH after the pre-equilibration of SMP with 
inhibitor for 5 min. The initial rates were calculated from the linear portion of the traces. 
The inhibition of NADH:Q oxidoreductase (complex I) activity was also determined 
under the same experimental conditions except that the reaction medium (2.5 mL) 
contained 0.3 M sucrose, 1 mM MgCl2, 2 μM antimycin A, 2 mM KCN, 50 μM 
ubiquinone Q1 and 50 mM phosphate buffer, pH 7.4. IC50 values were taken as the final 
compound concentrations in the assay cuvette that yielded 50% inhibition of the 
enzymatic activity. 
Microsomal Stability Assay111 
Bovine liver microsomes were prepared from liver of a freshly slaughtered 
animal. Briefly, liver tissues were diced into small pieces and then washed with isotonic 
sucrose buffer (0.25 M sucrose, 10 mM Tris-HCl, 0.5 mM EDTA, pH 7.8). The diced 
tissue was passed through a precooled meat grinder and mixed with three-fold ice cold 
sucrose buffer supplemented with a mixture of protease inhibitors. The suspension was 
homogenized in a Waring blender for 25 sec at high speed. At this stage, the pH of the 
suspension was adjusted to 7.4 with 1 M Tris base. The homogenate was centrifuged for 
20 min at 1200 × g to remove cell debris. The supernatant suspension was homogenized 
in a tight fitting Teflon-glass Potter-Elvejhem homogenizer and then centrifuged twice at 
10,000 × g for 20 min, collecting the supernatant each time to remove mitochondria. The 
floating fat layer was carefully removed by filtering the supernatant through layers of 
cheesecloth. The supernatant was centrifuged at 150,000 × g for 30 min (Beckman-
Coulter ultracentrifuge, XL-100K -01, 
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SW-55 Ti rotor). The pellet (microsomal fraction) was suspended in 0.25 M sucrose 
buffer containing 10 mM Tris-HCl, pH 7.4, with 20% (v/v) glycerol, and centrifuged 
once more at 150,000 × g. The pellet was resuspended in sucrose buffer with 20% (v/v) 
glycerol. The protein concentration after resuspension was approximately 20 mg/mL, as 
determined by BCA protein assay (Pierce Chemical) using bovine serum albumin as a 
standard. Aliquots of microsomal suspensions were stored at –80 °C. 
In vitro metabolic stability was determined in bovine liver microsomes at a 
protein concentration of 1 mg/mL in 50 mM phosphate buffer, pH 7.4, containing 5 mM 
MgCl2 in a final incubation volume of 0.5 mL. Each test compound was added to a final 
concentration of 25 μM. This mixture was pre-warmed to 37 °C prior to starting the 
reaction by the addition of β-NADPH to 1 mM final concentration. After incubation for 
30 min at 37 °C, the reaction was quenched by the addition of 1 mL of propanol, 
vortexed for 2 min and centrifuged at 15,000 × g for 20 min to pellet the precipitated 
protein. The resulting supernatant was removed by pipetting and then concentrated under 
diminished pressure. A parallel incubation of the test compound with deactivated 
microsomes lacking β-NADPH and quenched immediately with propanol served as a 
control and was run for each test agent to detect microsome-independent degradation. 
The sample was reconstituted in 130 μL of MeOH and centrifuged again at 15,000 × g 
for 3 mins. The supernatant was removed and 4 μM fluorine was added as an internal 
standard prior to HPLC analysis. HPLC analyses were performed on a reversed phase 
Zorbax SBPhenyl reversed phase analytical (150 × 4.6 mm, 5 μm) HPLC column using a 
mobile phase consisting of MeOH/H2O. A linear gradient of (50:50 MeOH/H2O→100:0 
MeOH/H2O) was employed over a period of 14 min at a flow rate of 1 mL/min. 
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Metabolic stability was expressed as percent of control remaining. The experiments were 
carried out in duplicate to verify the results for some of the compounds. 
Reactive Oxygen Species (ROS) Assay105 
Quantitative analysis of intracellular ROS levels in FRDA lymphocytes, 
challenged with 5 mM diethyl maleate (DEM) in presence or absence of the test 
compounds, was obtained by FACS analysis using a dichlorodihydrofluorescein diacetate 
probe (DCFH-DA), as described previously.112-117 Briefly, 1 mL of FRDA lymphocytes 
(5 × 105 cells) were plated in a 24-well plate, treated with the test compounds and 
incubated at 37 °C for 16 h in a humidified atmosphere containing 5% CO2 in air. Cells 
were treated with 5 mM diethyl maleate (DEM) for 80 min, collected by centrifugation at 
300 × g for 3 min and then washed with phosphate buffered saline (Life Technologies). 
Cells were resuspended in PBS containing 20 mM glucose and incubated at 37 °C in the 
dark for 25 min with 10 μM DCFH-DA. Cells were collected by centrifugation at 300 × g 
for 3 min and then washed with PBS. The samples were analyzed immediately by flow 
cytometry (C6 Accuri, BD Biosciences, San Jose, CA), using a 488 nm excitation laser 
and the FL1-H channel 530 ±15 nm emission filter. The generation of ROS, mainly 
peroxides, was detected as a result of the oxidation of DCFH. In each analysis, 10,000 
events were recorded after cell debris was electronically gated out. Results obtained were 
verified by running duplicates and repeating experiments in three independent runs. 
Results were expressed as a percentage of ROS scavenging activity. 
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CHAPTER 3 
DESIGN, SYNTHESIS AND CHARACTERIZATION OF A LIBRARY OF 
PYRIMIDINOL ANALOGUES AS MULTIFUNCTIONAL RADICAL QUENCHERS. 
 
3.1. Introduction 
Aerobic organisms must consume oxygen as a terminal electron acceptor during 
oxidative phosphorylation in order to produce, and thereby maintain, ATP levels.113 
When oxygen is involved in an electron transfer process, production of reactive oxygen 
species (ROS) is inevitable. Mitochondrial ROS is a potential threat to healthy cellular 
metabolism.39 The physical accumulation of ROS in the mitochondria can produce 
unwanted effects such as cancer, aging and neurodegenerative diseases.122 Natural 
lipophilic antioxidants like vitamin E and coenzyme Q10 are probably the best known 
natural antioxidants. Efforts have been made in our laboratory to discover improved, 
metabolically stable multi-functional radical quenchers.110-113 
3.2. Friedreich’s Ataxia  
Friedreich’s ataxia (FRDA) is mainly observed in caucasian populations.123 
Approximately 1 in 50,000 people in United States are affected by this disease. There is 
currently no proven strategy to cure FRDA. The main cause of FRDA is believed to be 
reduced expression of a nuclear protein called frataxin. If the level of frataxin falls below 
5-30% of the normal level, signs of the disease are observed.46 Frataxin is believed to be 
responsible for trafficking of iron and the assembly of iron-sulfur (Fe-S) clusters within 
the mitochondria.124 In the presence of low levels of frataxin iron accumulates, and Fe-S 
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clusters are not assembled properly, hence there is a high incidence of Fenton like 
reactions, resulting in high levels of ROS.123,124 
3.3. Radical Properties 
The stability of phenoxide radicals are typically measured indirectly by the bond 
dissociation energy (BDE) of the O-H bond. The lower the BDE, the higher is the 
stability of the resulting radical. It has been shown previously that the higher the electron 
density in the ring, the lower is the bond dissociation energy.125,126 
 
Figure 3.1.  A) Experimental ESR Signal and Simulation of a Pyridinol Core MRQ (5 
mM) in Dry De-aerated Benzene at 25 °C. B) Resonance Stabilized 3-Pyridinoxyl 
Radical Resulting from Abstraction of the O-H Hydrogen Atom. 
The experiment was Performed by Dr. Ruth Goldschmidt and Dr. Manikandadas M. 
Madathil.  
Adopted from the Dissertation of Dr. Pablo M. Arce Amezquita at Arizona State 
University. 
 
 The increased electron density in the ring also makes the ring vulnerable to the air 
oxidation.127 The redox functionality of an antioxidant molecule can also be correlated to 
the ease of abstracting an electron from the molecule. The minimum amount of energy 
needed to remove the outermost (highest energy) electron from a neutral atom in the 
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gaseous state is called ionization potential (IP). The lower the IP, the easier it is to 
transfer the electron to an ambient electron acceptor. Multifunctional radical quenchers 
can easily traffic electrons to and from reactive radicals which would otherwise 
contribute to oxidative stress, resulting in a stabilized/quenched radical. 
 
Figure 3.2. Radical Quenching (ROS and Carbon Centered Lipid Peroxidation) 
Mechanism in Pyrimidinol MRQs. 
 
The resonance stabilized radicals (such as those formed from MRQs) are more stable and 
less reactive, therefore less damaging. This concept has been utilized previously to design 
a series of amino-pyrimidinol derivatives in our laboratory.128,129 Amino-pyrimidinols can 
quench lipid peroxidation faster than α-tocopherol and have enhanced stability in air. The 
electron donating group in the ring lowers the BDE and the nitrogen atoms in the ring 
increase the IP (more stable toward oxidation).129 
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Figure 3.3. Redox Cores of the Earlier Generation Pyrimidinol Antioxidants  
The efforts in our laboratory went from optimizing the reduction potential of the MRQ 
core to enhancing the metabolic stability of antioxidant molecules by optimizing 
structural variables in the molecule. 2-(dimethylamino)-4-methoxy-6-methylpyrimidin-5-
ol derivatives were shown to be antioxidants with considerable stability and redox 
properties. (Figure 3.4.) 




Figure 3.4. Cyclic Voltammogram of Pyrimidinol Antioxidants in 0.1 M 
Tetrabutylammonium Perchlorate in Acetonitrile, Using an Ag/AgCl Electrode as a 
Reference. This experiment was Performed by Dr. Manikandadas M. Madathil.  




The metabolic stability of the first generation pyrimidinol antioxidants were poor, despite 
their excellent antioxidant activities. Described herein are our efforts (compounds 3.2-
3.8) (Figure 3.6, 3.7 and 3.8) toward optimization of stability and antioxidant activity in 
support of our pursuit of better multi-functional radical quenchers. 
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Figure 3.5. Pyridinol Analogue Chosen for Further Structural Optimization. 
 
Figure 3.6. Series of Pyridinol Analogues with Linear Alkyl Side Chains of Different 
Length; Synthesized and Evaluated. The Methoxy Group on the Redox Core of the Lead 
Compound has been Replaced with Cyclic O-Alkyl Substituents. 
 
 
Figure 3.7. Pyridinol Analogues with Linear Alkyl Side Chains; Synthesized and 
Evaluated. The Methoxy Group on the Redox Core of the Lead Compound has been 
Replaced with Cyclic O-Alkyl Substituents. The Dimethylamine Group on the Lead 
Compound has been Replaced with Pyrrolidine and Piperidine, Respectively. 
 
 
Figure 3.8. Pyridinol Analogue with Long Chain Linear Aliphatic Alcohol Synthesized 
and Evaluated. The Methoxy Group on the Redox Core of the Lead Compound has been 
Replaced with Long Chain Aliphatic Alcohol.
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3.4. Results 
In order to synthesize pyrimidinol analogues with different alkyl side chain 
lengths, and substituents (compounds 3.2-3.8) (Figure 3.6, 3.7 and 3.8), a commercially 
available and appropriately halogen substituted heterocyclic redox core (2,4-dichloro-6-
methylpyrimidine) was used as a starting material. Cyclobutanol and dimethylamine were 
introduced to the ring by aromatic nucleophilic and C-N coupling reactions at appropriate 
positions. Long chain aliphatic side chains were attached after the core was complete. 
Bromination followed by incorporation of hydroxyl group lead to the synthesis of the 
proposed analogues (compounds 3.2-3.8) (Figure 3.6, 3.7 and 3.8). 
 
Figure 3.9. Retrosynthetic Analysis for the Pyrimidinol Analogues (compounds 3.2-3.8) 
(Figure 3.6, 3.7 and 3.8). 
 
3.4.1. Synthesis of Pyrimidinol Analogues 
Synthesis of Pyrimidinol Analogues with Cyclic Alcohol and Variable Side Chain 
Lengths 3.2-3.5. 
The route employed for the synthesis of pyrimidinol analogues 3.2-3.5 (Figure 
3.6) is illustrated in Scheme 3.1.  
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Scheme 3.1. Route Employed for the Synthesis of Pyrimidinol Analogues with Linear 
Alkyl Side Chains of Different Length and Variable Cyclic Alcohols (3.2-3.5). 
 
Initially, 2, 4- dichloro-6-methylpyrimidine was treated with 1-cyclobutanol and 
NaH in anh THF to afford crude 2-chloro-4-cyclobutoxy-6-methylpyrimidine. After the 
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workup and purification, 2-chloro-4-cyclobutoxy-6-methylpyrimidine was coupled with 
dimethylamine hydrochloride using CuI, 3,4,7,8-tetramethyl-1,10-phenanthroline 
(Me4Phen) and Cs2CO3 to afford 3. 9 in 35% yield over two steps.
130,131 Compound 3.9 
was then treated with n-BuLi and 1-bromotridecane to attach a n-tetradecyl side chain 
resulting in 3.11 in 65 % yield. Treatment of 3.11 with N-bromosuccinimide in the dark 
afforded 3.15 in 92% yield in the penultimate step. The final product (3.2) was obtained 
in 22% yield by treatment of 3.15 with n-BuLi in THF on ice, then with trimethyl borate 
and hydrogen peroxide.110 
Compound 3.9 was treated with  n-BuLi and 1-bromotetradecane to attach a 
pentadecyl side chain affording 3.12 in 55% yield. Treatment of 3.12 with N-
bromosuccinimide in the dark afforded 3.16 in 87% yield in the penultimate step. The 
final product (3.3) was obtained in 25% yield by treatment of 3.16 with n-BuLi in THF 
on ice, then with trimethyl borate and hydrogen peroxide.110 
Compound 3.9 was treated with  n-BuLi and 1-bromopentadecane to attach a n-
hexadecyl side chain yielding 3.13 in 48% yield. Treatment of 3.13 with N-
bromosuccinimide in the dark afforded 3.17 in 95% yield in the penultimate step. The 
final product, 3.4 was obtained in 28% yield by treatment of 3.17 with n-BuLi in THF on 
ice, then with trimethyl borate, hydrogen peroxide.132 
2,4- Dichloro-6-methylpyrimidine was  treated with 1-cyclopentanol and NaH in 
anh. THF to afford crude 2-chloro-4-cyclopentoxy-6-methylpyrimidine. After the workup 
and purification, 2-chloro-4-cyclopentoxy-6-methylpyrimidine was coupled with 
dimethylamine hydrochloride using CuI, 3,4,7,8-tetramethyl-1,10-phenanthroline 
(Me4Phen) and Cs2CO3 to afford 3. 10 in 40% yield over two steps.
130,131 Compound 3.10 
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was then treated with  n-BuLi and 1-bromopentadecane to attach a hexadecyl side chain 
affording 3.14 in 59% yield. Treatment of 3.14 with N-bromosuccinimide in the dark 
afforded 3.18 in 82% yield in the penultimate step. The final product (3.5) was obtained 
in 18% yield by treatment of 3.18 with n-BuLi in THF on ice, then with trimethyl borate 
and hydrogen peroxide.132 
Synthesis of Pyrimidinol Analogues 3.6-3.7 
The route used for the synthesis of pyrimidinol analogues 3.6-3.7 (Figure 3.7) is 
illustrated in Scheme 3.2. 
 
Scheme 3.2. Route Employed for the Synthesis of Pyrimidinol Analogues with Different 
Cyclic Amines (3.6 and 3.7). 
 
Initially, 2,4- dichloro-6-methylpyrimidine was  treated with 1-cyclobutanol and 
NaH in anh THF to afford crude 2-chloro-4-cyclobutoxy-6-methylpyrimidine. After the 
workup and purification, 2-chloro-4-cyclobutoxy-6-methylpyrimidine was coupled to 
pyrrolidine using CuI, 3,4,7,8-tetramethyl-1,10-phenanthroline (Me4Phen) and Cs2CO3 to 
  87 
afford 3. 19 in 35 % yield over two steps.130,131 Compound 3.19 was then treated with  n-
BuLi and 1-bromopentadecane to attach a n-hexadecyl side chain, giving in 3.21 in 58% 
yield. Treatment of 3.21 with N-bromosuccinimide in the dark then afforded 3.23 in 90% 
yield. The final product, 3.6, was obtained in 19% yield by treatment of 3.23 with n-BuLi 
in THF on ice, then treated with trimethyl borate, and hydrogen peroxide.132 
2,4-Dichloro-6-methylpyrimidine was  treated with 1-cyclobutanol and NaH in 
anh THF to afford crude 2-chloro-4-cyclobutoxy-6-methylpyrimidine. After the workup 
and crude purification, 2-chloro-4-cyclobutoxy-6-methylpyrimidine was coupled with 
piperidine using CuI, 3,4,7,8-tetramethyl-1,10-phenanthroline (Me4Phen) and Cs2CO3 to 
afford 3. 22 in 65% yield over two steps.130,131 Compound 3.20 was then treated with  n-
BuLi and 1-bromopentadecane to attach a hexadecyl side chain affording 3.22 in 58% 
yield. Treatment of 3.22 with N-bromosuccinimide in the dark afforded 3.24 in 95% 
yield. The final product, 3.7, was obtained in 12% yield by treatment of 3.24 with n-BuLi 
in THF on ice, then with trimethyl borate, hydrogen peroxide.132 
 
Synthesis of Pyrimidinol Analogue 3.8 
The route involved for the synthesis of pyrimidinol analogues 3.8 (Figure 3.8) is 
illustrated in Scheme 3.3.  
  88 
 
Scheme 3.3. Route Employed for the Synthesis of Pyrimidinol Analogues having Long 
Chain Aliphatic Alcohol as Side Chain (3.8). 
 
Initially, 2,4- dichloro-6-methylpyrimidine was  treated with 1-pentadecaanol and 
NaH in anh THF to afford crude 2-chloro-4-methyl-6-(pentadecyloxy)pyrimidine. After 
the workup and purification, 2-chloro-4-methyl-6-(pentadecyloxy)pyrimidine was treated 
with dimethylamine hydrochloride using CuI, 3,4,7,8-tetramethyl-1,10-phenanthroline 
(Me4Phen) and Cs2CO3 to afford N,N,4-trimethyl-6-(pentadecyloxy)pyrimidin-2-amine 
(3.25) in 56% yield over two steps.130,131 Treatment of 3.25 with N-bromosuccinimide in 
the dark afforded 3.26 in 90% yield in the penultimate step. The final product, 3.8 was 
obtained in 22% yield by treatment of 3.26 with n-BuLi in THF on ice, then with 
trimethyl borate, hydrogen peroxide.132 
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3.4.2. Biochemical and Biological Evaluation of Pyrimidinol Analogues 
Mitochondrial Electron Transport Chain Function 
Inhibition of electron transfer in the mitochondrial respiratory chain complexes 
can limit the therapeutic utility of potential antioxidant molecules. Compounds that do 
not inhibit the electron transfer mechanism can potentially be considered for further 
assessments. Accordingly, we assessed the activity of our new analogues (Figure 3.6-
3.8). This was done by measuring inhibition of NADH oxidase activity.  NADH oxidase 
activity encompasses the functions of mitochondrial complexes I, III and IV, and 
measured using submitochondrial particles (SMP). The results are presented in Table 3.1. 
The results show dose dependence. 
Compound 3.4 is a pyrimidinol analogue with a 16-carbon side chain having 
cyclobutanol and dimethylamine substituents. The results indicate that the compound 
interacted with the complexes. It inhibited electron transfer, but possibly not strongly 
enough to eliminate the compound as a therapeutic candidate. 
Compound 3.5 is a pyrimidinol analogue having a 16-carbon side chain and a 
cyclopentanol group on the redox core. It showed results similar to 3.4 inhibiting one or 
more of the mitochondrial complexes and was probably too inhibitory to be used as a 
potential therapeutic agent. Compound 3.8 is another pyrimidinol analogue with a long 
chain aliphatic group attached to the O-atom in the side chain. This potentially 
differentiated the compound from the previous two. This compound also inhibited the 
electron transport chain to an extent between 3.4 and 3.5.  
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Table 3.1. The Inhibitory Effect of Pyrimidinol Analogues on Bovine Heart 
Mitochondrial NADH Oxidase Activity (Complexes I, III and IV).a  
______________________________________________________ 
 
                                NADH oxidase activity (%)b             
         ________________________________________ 
 
       Compound    1 μM                   5 μM                10 μM 
   ______________________________________________________ 
  
       Control                    100                  100               100 
       3.4                               86 ± 2              69 ± 2                   60 ± 1             
       3.5                               73 ± 2        40 ± 1              34 ± 1    
       3.8                    77 ± 1              47 ± 2              41 ± 3      
 
   ______________________________________________________ 
a- The experiments were performed by Dr. Yana Chen. 
b- Relative to untreated control. 
 
Cellular ATP Levels 
Finding drug molecules which can augment ATP production over control in 
addition to decreasing oxidative stress represents a novel approach to the therapy of 
mitochondrial diseases. This property can potentially improve, or at least stabilize, 
disease status in a patient. For measurement of ATP levels in presence of antioxidant 
molecules (Figure 3.6-3.8) synthesized in our laboratory, cells were grown in glucose-
free media to block ATP production via glycolysis. Thus, cells grown in a galactose rich 
environment should exhibit maximal ATP production through oxidative phosphorylation, 
and should also become more sensitive to mitochondrial respiratory chain inhibitors than 
cells grown on glucose medium.133,134  
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As shown in Table 3.2, compound 3.4, 3.5 and 3.8 supported ATP production, 
albeit at different concentrations. Compound 3.4 was perhaps the most promising of all 
the analogues evaluated in this assay. It supported ATP production at1, 5 and 20 μM 
concentrations. At 5 μM concentration, it enhanced the ATP production by 11% above 
the control. At 20 μM concentration, it was 9% above control. Compound 3.5 also 
enhanced ATP levels at 1 μM concentration by 6% above the control. Compound 3.8 
maintained ATP production relative to the control at 1 μM concentration. At 5 μM 
concentration, it supported the ATP production to an extent of 18% over the control.  
Table 3.2. Total ATP Concentration in CoQ10 Deficient Lymphocytes Following 
Incubation with Pyrimidinol Antioxidants for 48 h.a        
______________________________________________________ 
 
                                            Total ATP (%)b             
         ________________________________________ 
 
       Compound    1 μM                   5 μM                 20 μM 
   ______________________________________________________ 
  
       Control                    100                  100            100 
        3.4                              103 ± 2            111 ± 3                109 ± 3             
        3.5                              106 ± 4        100 ± 6             75 ± 4    
        3.8                    100 ± 10          118 ± 4             58 ± 6  
   ______________________________________________________ 
a- The experiment was performed by Dr.Omar M. Khdour. 
b- Relative to untreated control. 
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Inhibition of Lipid Peroxidation 
 
The pyrimidinol analogues were evaluated for their ability to quench lipid 
peroxidation. The study was done in diethyl maleate (DEM)-treated, glutathione-depleted 
FRDA lymphocytes. C11-BODIPY581/591 is a hydrophobic fatty acid fluorophore, 
which inserts preferentially in membranes, and has been shown previously to enable 
quantification of fatty acid oxidation and antioxidant activity in live cells.114 Oxidation of 
the polyunsaturated butadienyl moiety of the dye results in a fluorescence shift of the 
emission peak from red to green. Flow cytometric methods were used to measure the 
degree of oxidation as reported before.110-113 The shift of the fluorescence emission peak 
occurs with excitation/emission wavelengths of 490/510 nm from red to green. The 
median mean fluorescence values were used for analysis. Enhancement of green 
fluorescence intensity indicates lipid peroxidation. Compound 3.4 (Figure 3.6) was the 
only pyrimidinol analogue from the current analogues to be evaluated in this assay. The 
result of the experiment is shown in Table 3.3. Compound 3.4 provided good protection 
from lipid peroxidation, at higher (500 nM) concentration, but to a much lesser extent at 
two lower concentrations (100 nM, 250 nM) tested.  
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Table 3.3. Suppression of Lipid Peroxidation by Pyridinol Antioxidants in Cultured 
FRDA Lymphocytes Treated with DEM.a  
  ______________________________________________________ 
 
                   Lipid peroxidation scavenging activity (%)b             
         ________________________________________ 
 
       Compound    100 nM           250 nM          500 nM 
   ______________________________________________________ 
  
       Control                    100                  100               100 
          3.4                           41 ± 2       58 ± 4              92 ± 1    
          ______________________________________________________ 
 
a- The experiment was performed by Dr. Omar Khdour. 




The ability of the compounds (Figure 3.6-3.8) to protect cells subjected to 
oxidative insult were evaluated. The results are summarized in Table 2.3. The experiment 
was performed in FRDA lymphocytes (GM 15850). The experiment was performed at 
0.1, 0.5 and 2.5 μM concentrations. The results showed dose dependent behavior, with 
the exception of the higher doses of 3.2 and 3.4 tested. Compound 3.2 protected the cells 
at 0.1 μM concentration and 0.5 μM concentration to the extent of 70% relative to 
control. At 2.5 μM concentration, it protected the cells only to the extent of 50%. 
Compound 3.3 protected the cells in a dose dependent fashion, with the protection 
increasing steadily from 56 to 73%. Compound 3.4 was only weakly protective at all 
tested concentrations. Compound 3.5 was also weakly cytoprotective at all tested 
concentrations, exhibiting only 44% protection at 2.5 μM concentration.  Finally, 
compound 3.6 showed promising cytoprotection results conferring 83% protection at 0.1 
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μM concentration, 92 % protection at 0.5 μM concentration and 97% protection at 2.5 
μM concentration.  
Table 3.4. Cytoprotective Effects of Pyrimidine Analogues on the Viability of Cultured 
FRDA Lymphocytes Treated With DEM.a  
  ______________________________________________________ 
 
                                         Viable cells (%)b          
         ________________________________________ 
 
       Compound    0.1 μM              0.5 μM              2.5 μM 
   ______________________________________________________ 
  
       Control                   100                    100              100 
       3.2                              71 ± 3                71 ± 3                   50 ± 2 
       3.3                              56 ± 3                58 ± 4                   73 ± 3 
       3.4                              5 ± 2         11 ± 4                 4 ± 1    
       3.5                   14 ± 3                16 ± 4               44 ± 15   
       3.6                              83 ± 4                92 ± 5                    97 ± 5 
       ______________________________________________________ 
 
a- The experiments were performed by Chenhong Tang and Bobbie Le. 
b- Relative to untreated control. 
 
Microsomal Stability Assay. 
 
The ability of test compounds 3.4, 3.5 and 3.8 (Figure 3.6-3.8) to survive the 
metabolic effects of bovine liver microsomes were studied and the results are 
summarized in Table 3.5. The results of this assay roughly define how well an orally 
administered compound is likely to survive enzymatic conditions in an animal. 
Compound 3.4 performed fairly well in this experiment; 72% of the tested compound was 
recovered after the incubation. Compound 3.5 gave a similar result, affording 77% 
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recovery after the experiment. Compound 3.8 also gave a similar result with 74% 
recovery.   
Table 3.5. Stability of Pyridinol Analogues in the presence of Bovine Liver 
Microsomes.a. 
  ______________________________________________________                                           
    
       Compound                Recovery (Activated/deactivated %)b 
   ______________________________________________________ 
 
Untreated control                                    100 
       3.4                                                 72.4 
       3.5                                                           77.3 
       3.8                                           74.0                              
  ______________________________________________________ 
 
a- The experiments were performed by Dr. Yana Chen  
b- Relative to untreated control. 
 
3.5. Discussion 
3.5.1. Synthesis of Pyrimidinol Analogues 
The pursuit of a better antioxidant for neurodegerative diseases has led us to 
synthesize and evaluate a series of pyrimidinol analogues (Figure 3.6-3.8). Previous 
experiences showed that altered hydrophobicity affected the antioxidant capabilities in a 
molecule with therapeutic interest. Side chains of different lengths were attached to 
balance any possible addition in hydrophobicity due to a cyclobutanol substituent, which 
had been introduced to confer metabolic stability. The route employed for the syntheses 
was easily workable although, due to lower yields in some steps, the overall yields were 
low. The syntheses of molecules 3.2-3.5 were initially troublesome due to an unknown 
impurity in the NMR spectra, which did not allow the bromination reaction to proceed in 
  96 
the penultimate step. Changing the source of starting material solved the problem. 2,4-
Dichloro-6-methylpyrimidine was subjected to a NaH mediated addition reaction with 
cyclobutanol to form the intermediate 2-chloro-4-cyclobutoxy-6-methylpyrimidine. The 
crude intermediate was used in the next step and 3.9 was obtained and identified. The n-
BuLi mediated alkylations to obtain compounds 3.11, 3.12 and 3.13 was efficient 
enough. Attachment of hexadecyl alkyl side chain proceeded in a somewhat lower yield 
(Scheme 3.1). Compounds 3.11, 3.12 and 3.13 were brominated via N-bromosuccinimide 
with high (92, 87 and 95%) yields. Compounds 3.15, 3.16 and 3.17 were treated with n-
BuLi, B(OMe)3 and hydrogen peroxide to obtain the final products 3.2, 3.3 and 3.4 
(Scheme 3.1). 2,4-Dichloro-6-methylpyrimidine was subjected to a NaH mediated 
addition reaction with cyclopentanol to form the intermediate 2-chloro-4-cyclopentoxy-6-
methylpyrimidine. The crude intermediate was used in the next step and 3.10 was 
isolated and identified. The intermediate was subjected to a similar route to obtain final 
product 3.5 (Scheme 3.1).  
Compound 3.6 was synthesized from the intermediate 2-chloro-4-cyclobutoxy-6-
methylpyrimidine. This intermediate was treated with pyrrolidine to obtain intermediate 
3.19. Side chain was attached to the redox core to obtain the intermediate 3.21. The 
intermediate was then brominated to obtain 3.23 in the penultimate step. The final step 
provided compound 3.6 (Scheme 3.2).   
Compound 3.7 was synthesized from the intermediate 2-chloro-4-cyclobutoxy-6-
methylpyrimidine. This intermediate was treated with piperidine to obtain intermediate 
3.20. Side chain was attached to the redox core to obtain the intermediate 3.22. The 
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intermediate was then brominated to obtain 3.24 in the penultimate step. The final step 
provided compound 3.7 (Scheme 3.2).     
The synthesis of compound 3.8 was designed to achieve a higher yield because it 
avoided the low yielding n-BuLi mediated alkylation step. In fact the initial steps were 
achieved in fairly good yields to obtain intermediate 3.25, which was then brominated in 
90% yield obtain 3.26. The final step involving hydroxylation of the brominated 
analogue, still proceeded in low yield to obtain final product 3.8 (Scheme 3.3).  
3.5.2. Biological Results 
It is important for a multifunctional radical quencher to have considerable 
antioxidant activity along with metabolic stability in biological systems. The antioxidant 
molecules in the previous generation were excellent, but they lacked the stability in the 
microsomal assay which could potentially affect their ability to function as a therapeutic 
agent. Multiple pyrimidinol molecules were designed (Figure 3.6-3.8) which could 
potentially improve antioxidant activity and the ATP production, as well as improving 
the stability in the microsomal assay. Methoxyl groups are often targets for enzymatic 
degradation.135,136 Therefore, analogues were designed to protect the methoxy substituent 
from oxidative degradation by replacement with a cyclobutyl group (Figure 3.6). 
Likewise, dimethylamine was replaced by a pyrrolidine or piperidine groups (Figure 3.7). 
The NADH oxidase assay (Table 3.1) on the derivatives 3.3, 3.4 and 3.8 showed that the 
new molecules did not strongly inhibit electron transfer in the electron transport chain. 
The ATP production data (Table 3.2) showed that 3.4 did enhance the ATP production 
compared to the control. Compounds 3.5 and 3.8 showed favorable results in ATP 
production as well. Compound 3.4 was also investigated for its ability to protect against 
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lipid peroxidation (Table 3.3). It showed 92% protection at higher (500 nM) 
concentration and 56% protection at 250 nM concentration. The microsomal stability data 
(Table 3.5) showed that the compounds 3.4, 3.5 and 3.8 are fairly stable to microsomal 
degradation with 72, 77 and 74%, respectively. The cytoprotection assay also provided 
crucial data (Table 3.4). While 3.4 enhanced the ATP production, protected cells against 
lipid peroxidation and it was stable to microsomes, it showed little cytoprotection. 
Compound 3.5 also provided only modest cytoprotection at best. Compound 3.6, which is 
a different analogue of 3.4, showed much better cytoprotective values. Compound 3.6 has 
cyclic substituents, which may well confer favorable microsomal stability. Accordingly, 
compound 3.6 needs to be evaluated further for its antioxidant capabilities, and for ATP 
production.  
3.6 Experimental 
Anhydrous grade solvents were purchased from Sigma-Aldrich Inc. (St. Louis, 
MO) and from Fisher Scientific. Most of the chemical reagents were used without further 
purification, except for 1-bromotridecane, undecyl bromide, 1- bromododecane and 1-
bromohexadecane, which were purified by silica gel flash column chromatography prior 
to use. Reactions were carried out under an atmosphere of argon. The glassware and 
needles used for material transfer were pre-dried in an oven at 120 °C prior to use. Flash 
column chromatography was carried out using silica gel (Silicycle R10030B, 60 particle 
size, 230-400 mesh), applying a low pressure stream of nitrogen. Analytical thin layer 
chromatographic separations were carried out on glass plates coated with silica gel (60 
particle size F254, SiliCycle TLG-R10011B-323). The TLC chromatograms were 
developed by immersing the plates in 2.5% potassium permanganate in ethanol or 2% 
  99 
anisaldehyde + 5% sulfuric acid + 1.5% glacial acetic acid in ethanol, followed by 
heating, or else visualized by UV irradiation (254 nm). Tetrahydrofuran was distilled 
from sodium/benzophenone ketyl and dichloromethane from calcium hydride.118 1H and 
13C NMR spectra were recorded on a Gemini 300 or Varian Inova 400, or on a Varian 
Inova 500 spectrometer, using CDCl3 as solvent and internal standard, unless otherwise 
indicated. 1H NMR chemical shifts were reported relative to residual CHCl3 at 7.26 ppm, 
or to residual DMSO-d6 at 2.50 ppm; 
13C NMR shifts were reported relative to the central 
line of CDCl3 at 77.16 ppm, or to 
13C DMSO-d6 at 39.51 ppm. Splitting patterns are 
designated as s, singlet; br s, broad singlet; d, doublet; dd, doublet of doublets; dt, doublet 
of triplets; m, multiplet; q, quartet; quin, quintet. High resolution mass spectrometric data 
were obtained at the Arizona State University CLAS High Resolution Mass Spectrometry 
Facility. 
 
4-Cyclobutoxy-2-N, N-dimethylamino-6-pyrimidine (3.9).131 To a solution of 117 mg 
(0.50 mmol) of cyclobutanol and 120 mg sodium hydride in 3.00 mL of THF stirred for 
10 min at 0 ºC; was added 200 mg (3.07 mmol) of 2,4-dichloro-6-methylpyrimidine. The 
reaction mixture was stirred at room temperature for 27 h. The reaction mixture was then 
diluted with 5 mL of water and extracted with seven 2-mL portions of dichloromethane. 
The organic layer was washed successively with water, brine and dried (Na2SO4). The 
excess solvent was concentrated under diminished pressure to afford a crude residue as a 
yellow oil. The crude material was used directly in the next step. 
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To a solution of 200 mg (0.56 mmol) of 2-chloro-4-cyclobutoxy-6-methylpyrimidine in 
6.00 mL of DMF was added 13.0 mg (0.05 mmol) of 3,4,7,8-tetramethyl-1,10-
phenanthroline, 10.0 mg (0.06 mmol) of CuI, 137 mg (1.69 mmol) dimethylamine.HCl 
salt, 641 mg (1.90 mmol) cesium carbonate in ice. The reaction mixture was then stirred 
for 5 h at 50 ºC. The reaction mixture was then diluted with 5 mL of water and extracted 
with several 2-mL portions of dichloromethane. The organic layer was washed 
successively with water, brine and dried (Na2SO4). The excess solvent was concentrated 
under diminished pressure to afford 3.9 as a crude residue. The residue was purified by 
flash column chromatography on a silica gel column (24 × 2 cm). Elution with 1:9 ethyl 
acetatehexane gave  3.9  as a colorless oil: yield 120 mg (47%); silica gel TLC Rf 0.25 
(1:9 ethyl acetatehexanes); 1H NMR (CDCl3) δ 1.631.65 (m, 1H), 1.661.80 (m, 1H), 
2.082.14 (m, 2H) 2.14 (s, 3H), 2.352.43 (m, 3H), 3.11 (m, 6H), 5.065.09 (m, 1H); 13C 
NMR (CDCl3) δ 13.5, 24.1, 30.6, 36.8, 69.7, 93.8, 162.2, 167.8 and 169.1; mass spectrum 
(APCI), m/z 208.1446 (M + H)+ (C11H18N3O requires m/z 208.1450). 
 
4-(Cyclopentyloxy)-2-N,N-dimethylamino-6-pyrimidine (3.10).131 To a solution of 234 
mg (2.72 mmol) of cyclopentanol and 120 mg sodium hydride (5.00 mmol) in 3.00 mL of 
THF at 0 ºC; was added 250 mg (1.55 mmol) of 2,4-dichloro-6-methylpyrimidine. The 
reaction mixture was stirred for 27 h at room temperature. The reaction mixture was then 
diluted with 5 mL of water and extracted with seven 2-mL portions of dichloromethane. 
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The organic layer was washed successively with water, brine and dried (Na2SO4). The 
excess solvent was concentrated under diminished pressure to afford a crude residue. The 
crude residue was used directly in the next step. 
To a solution of 400 mg (1.80 mmol) of 2-chloro-4-(cyclopentyloxy)-6-
methylpyrimidine in 2.00 mL of DMF was added 13.0 mg (0.06 mmol) of 3,4,7,8-
tetramethyl-1,10-phenanthroline, 10.0 mg (0.06 mmol), dimethylamine, HCl salt 137 mg 
(1.69 mmol), cesium carbonate 641 mg (1.90 mmol) in ice. The reaction mixture was 
stirred for 5 h at 50 ºC. The reaction mixture was then diluted with 5 mL of water and 
extracted with seven 2-mL portions of dichloromethane. The organic layer was washed 
with water, brine and dried (Na2SO4). The excess solvent was concentrated under 
diminished pressure to afford a crude. The crude was purified by flash column 
chromatography on a silica gel column (24 × 2 cm). Elution with 1:5 ethyl 
acetatehexane gave  3.10  as a colorless oil: yield 125 mg (40%); silica gel TLC Rf 0.30 
(1:2 ethyl acetatehexanes); 1H NMR (CDCl3) δ 1.631.65 (m, 1H), 1.661.80 (m, 1H), 
2.082.14 (m, 4H) 2.14 (s, 3H), 2.352.43 (m, 3H), 3.11 (m, 6H), 5.065.09 (m, 1H); 13C 
NMR (CDCl3) δ 14.0,23.8, 23.9, 24.1, 32.7, 32.8, 32.8, 36.8, 94.5, 164.6, 167.5 and 
169.6; mass spectrum (APCI), m/z 222.1987 (M + H)+ (C12H20ClN3O requires m/z 
222.1987). 
 
4-Cyclobutoxy-N,N-dimethyl-6-tetradecylpyrimidin-2-amine (3.11).112 To a solution 
containing 200 mg (0.96  mmol) of 4-cyclobutoxy-2-N,N-dimethylamine-6-
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methylpyrimidine 3.10  and 160 μL (112 mg, 0.96 mmol) tetramethylethylenediamine in 
4 mL dry THF was added 1.22 mL (1.6 M in hexanes, 2.17 mmol) of n-butyllithium 
dropwise at 40 ºC over 5 min. The reaction mixture is warmed to 0 ºC over 2 h, 0.70 mL 
(0.70 g, 2.75 mmol) of purified 1-bromotridecane added and the reaction mixture stirred 
at room temperature under an atmosphere of argon for 3 h. The reaction mixture was 
quenched with 20 mL of saturated NH4Cl and extracted with five 10-mL portions of 
diethyl ether. The organic layer was washed successively with distilled water, brine and 
dried (MgSO4). The excess solvent was concentrated under diminished pressure to afford 
a crude residue. The crude residue was applied to a silica gel column (6 × 3 cm). Elution 
with 1:9 ethyl acetatehexanes afforded 3.11 as a colorless solid: yield 135 mg (65%); 
silica gel TLC Rf 0.45 (1:1 ethyl etherhexanes); 1H NMR (CDCl3) δ 0.840.87 (t, 3H, J 
= 7.2 Hz), 1.28 (m, 23H), 1.601.76 (m, 2H), 1.781.83 (q, 1H, J = 10 Hz), 2.072.14 (q, 
2H, J = 10 Hz), 2.362.40 (m, 2H), 2.442.48 (t, 2H, J = 8 Hz), 3.12 (s, 6H), 5.075.13 
(q, 1H, J = 8 Hz), 6.40 (s, 1H); 13C NMR (CDCl3) δ 14.1, 14.5, 23.1, 28.9, 29.7, 29.8, 
29.9, 30.0, 30.1, 30.1, 31.1, 32.3, 37.2, 38.3, 70.2, 93.6, 162.6, 169.5 and 172.4; mass 
spectrum (APCI), m/z 390.3486 (M + H)+ (C24H44N3O requires m/z 390.3484).  
 
 
4-cyclobutoxy-N,N-dimethyl-6-tridecylpyrimidin-2-amine (3.12).112 To a solution 
containing 148 mg (0.71 mmol) of 4-cyclobutoxy-N,N,6-trimethylpyrimidin-2-amine 3.9  
and 118 μL (83.0 mg, 0.71 mmol) tetramethylethylenediamine in 4.00 mL dry THF was 
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added 0.80  mL (1.6 M in Hexanes, 1.08  mmol) of n-butyllithium dropwise at 40 ºC 
over 5 min. The reaction mixture is warmed to 0 ºC over 2 h, 0.40 mL (0.47 g, 1.70 
mmol) of purified 1-bromotetradecane added and the reaction mixture stirred at room 
temperature under an atmosphere of argon for 3 h. The reaction mixture was quenched 
with 20 mL of saturated NH4Cl and extracted with five 10-mL portions of diethyl ether. 
The organic layer was washed successively with distilled water, brine and dried 
(MgSO4). The excess solvent was concentrated under diminished pressure to afford a 
crude. The crude was applied to a silica gel column (6 × 3 cm). Elution with 1:9 ethyl 
acetatehexanes afforded 3.12 as a colorless solid: yield 158 mg (55%); silica gel TLC Rf 
0.45 (1:1 ethyl etherhexanes); 1H NMR (CDCl3) δ 0.84-0.87 (t, 3H, J = 7.2 Hz), 1.28 
(m, 25H), 1.601.76 (m, 2H), 1.78-1.83 (q, 1H, J = 10 Hz), 2.072.14 (q, 2H, J = 10 Hz), 
2.362.40 (m, 2H), 2.442.48 (t, 2H, J = 8 Hz), 3.12 (s, 6H), 5.07-5.13 (q, 1H, J = 8 Hz), 
6.40 (s, 1H); 13C NMR (CDCl3) δ 14.0, 14.5, 23.1, 28.9, 29.7, 29.8, 29.9, 30.01, 30.1, 
30.1, 31.1, 32.3, 37.2, 38.3, 70.2, 93.6, 162.6, 169.5 and 172.4; mass spectrum (APCI), 
m/z 404.5158 (M + H)+ (C25H46N3O requires m/z 404.5155). 
                 
 
4-Cyclobutoxy-6-heptadecyl-N,N-dimethylpyrimidin-2-amine (3.13).112 To a stirred 
solution containing 933 mg (5.58 mmol) of 4-cyclobutoxy-2-N,N-dimethylamino-6-
pyrimidine 3.9 and 120 μL (87.0 mg, 0.80 mmol) tetramethylethylenediamine in 10.0 mL 
anh THF was added 5.23 mL (8.37 mmol) of 1.6 M n-BuLi in hexanes. The reaction 
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mixture was stirred at 23 °C for 20 min. 0.55 mL (0.57 g, 2.10 mmol) of purified 1-
bromopentadecane was added to the mixture. The reaction was then stirred for 30 more 
min. The reaction mixture was quenched with satd aq ammonium chloride and poured 
into 100 mL of water. The compound was extracted with two 80-mL portions of ethyl 
acetate. The combined organic layer was washed with 80 mL of brine, dried (MgSO4) 
and concentrated under diminished pressure. The residue was purified by 
chromatography on a silica gel column (15 × 5 cm). Elution with 9:1 hexanes–ethyl 
acetate afforded compound 3.13 as a colorless solid: yield 902 mg (48%); silica gel TLC 
Rf 0.45 (9:1 hexanes–ethyl acetate); 1H NMR (CDCl3) δ 0.87 (t, 3H, J = 7.2 Hz),  
1.251.32 (m, 27H), 1.631.65 (m, 1H), 1.661.80 (m, 1H), 2.082.14 (m, 2H) 2.14 (s, 
3H), 2.352.43 (m, 3H), 3.11 (m, 6H), 5.065.09 (m, 1H); 13C NMR (CDCl3) δ 13.9, 
14.5, 23.1, 28.9, 29.7, 29.8, 29.9, 30.0, 30.1, 30.1, 31.1, 32.3, 37.2, 38.3, 70.2, 93.6, 
162.6, 169.5 and 172.4; mass spectrum (APCI), m/z 418.3800 (M + H)+ (C26H48ClN3O 
requires m/z 418.3797).




4-(Cyclopentyloxy)-6-hexadecyl-N,N-dimethylpyrimidin-2-amine (3.14).112 To a 
stirred solution containing 633 mg (2.86 mmol) of compound 4-(cyclopentyloxy)-2-N,N-
dimethylamino-6-methylpyrimidine 3.10 in 6.00 mL anh THF was added 1.79  mL (8.37 
mmol) of 1.6 M n-BuLi in hexanes. The reaction mixture was stirred at 80 °C for 20 
min. 1.20 mL (4.10 mmol) 1-bromopentadecane was added to the mixture. The reaction 
was then stirred for 30 more mins. The reaction mixture was quenched with saturated 
aqueous ammonium chloride and poured into 100 mL of water. The compound was 
extracted with two 80-mL portions of ethyl acetate. The combined organic layer was 
washed successively with 80 mL of brine, dried (MgSO4) and concentrated under 
diminished pressure. The residue was purified by chromatography on a silica gel column 
(15 × 5 cm). Elution with 9:1 hexanes–ethyl acetate afforded compound 3.14 as a 
colorless solid: yield 735 mg (59%); silica gel TLC Rf  0.45 (9:1 hexanes–ethyl acetate); 
1H NMR (CDCl3) δ 0.87 (t, 3H, J = 7.2 Hz),  1.251.32 (m, 27H), 1.631.65 (m, 1H), 
1.661.80 (m, 1H), 2.082.14 (m, 4H) 2.14 (s, 3H), 2.352.43 (m, 3H), 3.11 (m, 6H), 
5.065.09 (m, 1H); 13C NMR (CDCl3) δ14.1, 22.6, 24.0, 28.4, 29.3, 29.4, 29.5, 29.6, 
29.6, 29.7, 31.9, 32.8, 36.8, 50.25, 93.8, 163.3, 169.6 and 172.7; mass spectrum (APCI), 
m/z 432.3955 (M + H)+ (C27H50ClN3O requires m/z 432.3954). 




5-Bromo-4-cyclobutoxy-N,N-dimethyl-6-tetradecylpyrimidin-2-amine (3.15).112 To a 
solution containing 150 mg (0.38 mmol) of 4-cyclobutoxy-N,N-dimethyl-6-
tetradecylpyrimidin-2-amine (3.11) in 5.00 mL chloroform was added 71.0 mg (0.40 
mmol) of N-bromosuccinimide slowly at 0 ºC over 5 min. The reaction mixture was 
stirred at room temperature under an atmosphere of argon for 15 min. The reaction 
mixture was quenched with 20 mL of saturated NH4Cl and extracted with three 10-mL 
portions of diethyl ether. The organic layer was successively washed with distilled water, 
brine and dried (MgSO4). The excess solvent was concentrated under diminished pressure 
to afford a crude residue. The crude residue was applied to a silica gel column (6 × 3 cm). 
Elution with 1:20 ethyl acetatehexanes afforded 3.15 as a colorless solid: yield 165 mg 
(92%); silica gel TLC Rf 0.45 (1:10 ethyl etherhexanes); 1H NMR (CDCl3) δ 0.840.87 
(t, 3H, J = 7.2 Hz), 1.28 (m, 23H), 1.601.76 (m, 2H), 1.781.83 (q, 1H, J = 10 Hz), 
2.072.14 (q, 2H, J = 10 Hz), 2.362.40 (m, 2H), 2.442.48 (t, 2H, J = 8 Hz), 3.12 (s, 
6H), 5.075.13 (q, 1H, J = 8 Hz); 13C NMR (CDCl3) δ22.6, 24.9, 27.6, 29.1, 29.3, 29.3, 
29.3, 29.4, 29.4, 29.5, 29.5, 29.6, 29.6, 29.7, 29.8, 29.8, 29.8, 30.5, 30.5, 30.6, 31.8, 35.9, 
36.7, 36.7, 36.7, 36.8, 36.8, 36.9, 36.9, 36.9, 51.1, 70.9, 90.5, 160.1, 164.9 and 168.9; 
mass spectrum (APCI), m/z 468.5265  (M + H)+ (C24H43BrN3O2 requires m/z 468.5259).  
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5-Bromo-4-cyclobutoxy-N,N-dimethyl-6-tridecylpyrimidin-2-amine (3.16).112 To a 
solution containing 120 mg (0.30 mmol) of 4-cyclobutoxy-N,N-dimethyl-6-
tridecylpyrimidin-2-amine 3.12 in 5.00 mL chloroform was added 53.3 mg (0.30 mmol) 
of N-Bromosuccinimide slowly at 0 ºC over 5 min. The reaction mixture was stirred at 
room temperature under an atmosphere of argon for 15 min. The reaction mixture was 
quenched with 20 mL of saturated NH4Cl and extracted with three 10-mL portions of 
diethyl ether. The organic layer was washed successively with distilled water, brine and 
dried (MgSO4). The excess solvent was concentrated under diminished pressure to afford 
a crude. The crude was applied to a silica gel column (6 × 3 cm). Elution with 1:20 ethyl 
acetatehexanes afforded 3.16 as a colorless solid: yield 116 mg (82%); silica gel TLC Rf 
0.45 (1:10 ethyl etherhexanes); 1H NMR (CDCl3) δ 0.840.87 (t, 3H, J = 7.2 Hz), 1.28 
(m, 25H), 1.601.76 (m, 2H), 1.781.83 (q, 1H, J = 10 Hz), 2.072.14 (q, 2H, J = 10 
Hz), 2.362.40 (m, 2H), 2.442.48 (t, 2H, J = 8 Hz), 3.12 (s, 6H), 5.075.13 (q, 1H, J = 8 
Hz); 13C NMR (CDCl3) δ 14.1, 22.7, 27.6, 29.3, 29.4, 29.4, 29.5, 29.6, 30.6, 31.9, 36.8, 
36.9, 71.0, 91.2, 160.0, 164.1 and 169.0; mass spectrum (APCI), m/z 482.2746 (M + H)+ 
(C25H45 BrN3O2 requires m/z 482.2746).   
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5-Bromo-4-cyclobutoxy-6-hexadecyl-N,N-dimethylpyrimidin-2-amine (3.17).112 To a 
solution of 60.0 mg (0.17 mmol) of 4-cyclobutoxy-6-hexadecyl-N,N-dimethylpyrimidin-
2-amine (3.13) in 3.00 mL of acetonitrile was added 43.6 mg (0.25 mmol) N-
bromosuccinimide at 0 ºC over 5 min. The reaction mixture was stirred for 2 h at room 
temperature. The reaction mixture was then diluted with 5 mL of water and extracted 
with seven 2-mL portions of dichloromethane. The organic layer was washed 
successively with water, brine and dried (Na2 (SO4)2). The excess solvent was 
concentrated under diminished pressure to afford a crude residue. The residue was 
purified by flash column chromatography on a silica gel column (24 × 2 cm). Elution 
with 1:5 ethyl acetatehexane gave 3.17 as a colorless solid: yield- 68 mg (95%); silica 
gel TLC Rf 0.30 (1:2 ethyl acetatehexanes); 1H NMR (CDCl3) δ 1H NMR (CDCl3) δ 
0.87 (t, 3H, J = 7.2 Hz),  1.251.32 (m, 27H), 1.631.65 (m, 1H), 1.661.80 (m, 1H), 
2.082.14 (m, 2H) 2.14 (s, 3H), 2.352.43 (m, 3H), 3.11 (m, 6H); 13C NMR (CDCl3) 
δ13.5, 14.0, 22.6, 27.4, 27.6, 29.0, 29.2, 29.3, 29.3, 29.4, 29.5, 29.6, 29.6, 30.6, 31.9, 
35.9, 36.7, 36.9, 70.9, 91.27 160.0, 164.1 and 168.9; mass spectrum (APCI), m/z 
496.2911 (M + H)+ (C26H47BrN3O requires m/z 496.2902). 
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5-Bromo-4-(cyclopentyloxy)-6-hexadecyl-N,N-dimethylpyrimidin-2-amine (3.18).112 
To a solution of 64.0 mg (0.18 mmol) of 4-cyclopentoxy-6-hexadecyl-N,N-
dimethylpyrimidin-2-amine (3.14) in 3.00 mL of acetonitrile was added 46.0 mg (0.26 
mmol) N-bromosuccinimide at 0 ºC. The reaction mixture was stirred for 2 h at room 
temperature. The reaction mixture was then diluted with 5 mL of water and extracted 
with seven 2-mL portions of dichloromethane. The organic layer was washed 
successively with water, brine and dried (Na2(SO4)2). The excess solvent was 
concentrated under diminished pressure to afford a crude. The residue was purified by 
flash column chromatography on a silica gel column (24 × 2 cm). Elution with 1:5 ethyl 
acetatehexane gave  3.18  as a colorless solid: yield- 62 mg (82%);  silica gel TLC Rf 
0.30 (1:2 ethyl acetatehexanes); 1H NMR (CDCl3) δ 0.87 (t, 3H, J = 7.2 Hz),  1.251.32 
(m, 27H), 1.631.65 (m, 1H), 1.661.80 (m, 1H), 2.082.14 (m, 4H) 2.14 (s, 3H), 
2.352.43 (m, 3H), 3.11 (m, 6H); 13C NMR (CDCl3) δ14.3, 22.8, 23.7, 24.09, 24.1, 24.2, 
25.1, 27.6, 27.8, 29.0, 29.2, 29.4, 29.5, 29.5, 29.5, 29.6, 29.6, 29.7, 29.7, 29.8, 29.8, 32.1, 
32.4, 32.9, 32.9, 34.8, 36.1, 36.2, 36.9, 37.1, 37.1, 79.9, 91.4, 160.3, 164.8 and 168.9; 
mass spectrum (MALDI), m/z 510.3059 (M + H)+ (C27H49BrN3O requires m/z 510.3059). 
 
4-Cyclobutoxy-2-(dimethylamino)-6-tetradecylpyrimidin-5-ol (3.2).112 To a stirred 
solution containing 120 mg (0.25 mmol) of 5-bromo-4-cyclobutoxy-N,N-dimethyl-6-
tetradecylpyrimidin-2-amine (3.15) at 5 ºC in 3.00 mL dry THF was added 390 L (1.6 
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M in hexanes, 0.62 mmol) of n-butyllithium dropwise  over 5 min. The mixture was 
stirred for 20 minutes. To the mixture was added 84.0L (78.0 mg, 0.75 mmol) of 
trimethyl borate and stirred for 1 h.  To the reaction mixture was added 0.55 mL of 30% 
aq H2O2. The reaction mixture was then stirred for 30 min and poured into water. The 
reaction mixture was quenched with 20 mL of saturated NH4Cl and extracted with five 
10-mL portions of ethyl acetate. The organic layer was washed with distilled water, brine 
and dried (MgSO4). The excess solvent was concentrated under diminished pressure to 
afford a crude residue. The crude residue was applied to a silica gel column (6 × 3 cm). 
Elution with 1:4 ethyl acetatehexanes afforded 3.2 as a colorless solid: yield 22 mg 
(22%); silica gel TLC Rf 0.3 (1:1 ethyl etherhexanes); 1H NMR (CDCl3) δ 0.840.87 (t, 
3H, J = 7.2 Hz), 1.28 (m, 24H), 1.601.76 (m, 2H), 1.781.83 (q, 1H, J = 10 Hz), 
2.072.14 (q, 2H, J = 10 Hz), 2.362.40 (m, 2H), 2.442.48 (t, 2H, J = 8 Hz), 3.12 (s, 
6H), 5.075.13 (q, 1H, J = 8 Hz); 13C NMR (CDCl3) δ 13.5, 14.1, 22.6, 28.4, 29.3, 29.3, 
29.4, 29.5, 29.6, 29.6, 29.7, 29.7, 29.7, 30.6, 31.9, 37.07, 38.7, 68.1, 128.7, 156.6, 156.9 
and 157.1; mass spectrum (APCI), m/z 406.3454 (M + H)+ (C24H44N3O2 requires m/z 
406.3434).   
 
4-Cyclobutoxy-2-(dimethylamino)-6-tridecylpyrimidin-5-ol (3.3).112 To a stirred 
solution containing 100 mg (0.21 mmol) of 5-bromo-4-cyclobutoxy-N,N-dimethyl-6-
tridecylpyrimidin-2-amine (3.16) at 5 ºC in 3.00 mL dry THF was added 390 L  (1.6 
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M in hexanes, 0.62 mmol) of n-butyllithium dropwise  over 5 min. The mixture was 
stirred for 20 min. To the mixture was added 84.0L (78.0 mg, 0.75 mmol) of trimethyl 
borate and was stirred for 1 h.  To the reaction mixture was added 0.55 mL of 30% aq 
H2O2. The reaction mixture was then stirred for 30 min and poured into water. The 
reaction mixture was quenched with 20 mL of saturated NH4Cl and extracted with five 
10-mL portions of ethyl acetate. The organic layer was washed successively with distilled 
water, brine and dried (MgSO4). The excess solvent was concentrated under diminished 
pressure to afford a crude. The crude was applied to a silica gel column (6 × 3 cm). 
Elution with 1:4 ethyl acetatehexanes afforded 3.3 as a colorless solid: yield 21 mg 
(25%); silica gel TLC Rf 0.3 (1:1 ethyl etherhexanes); 1H NMR (CDCl3) δ 0.840.87 (t, 
3H, J = 7.2 Hz), 1.28 (m, 25H), 1.601.76 (m, 2H), 1.781.83 (q, 1H, J = 10 Hz), 
2.072.14 (q, 2H, J = 10 Hz), 2.362.40 (m, 2H), 2.442.48 (t, 2H, J = 8 Hz), 3.12 (s, 
6H), 5.075.13 (q, 1H, J = 8 Hz), 6.40 (s, 1H); 13C NMR (CDCl3) δ13.5, 14.0, 14.1, 22.7, 
22.9, 23.7, 27.7, 28.9, 29.3, 29.5, 29.5, 29.6, 29.6, 29.7, 29.8, 30.3, 30.8, 31.9, 37.3, 37.3, 
38.7, 68.1, 126.8, 153.9, 154.6, 156.2;  mass spectrum (APCI), m/z 420.4413, (M + H)+ 
(C25H46N3O2 requires m/z 420.4410).   
 
4-Cyclobutoxy-2-(dimethylamino)-6-hexadecylpyrimidin-5-ol (3.4).112 To a stirred 
solution at –5 °C containing 81.0 mg (0.19 mmol) of 5-bromo-4-cyclobutoxy-6-
hexadecyl-N,N-dimethylpyrimidin-2-amine (3.17) in 3.00 mL of anh THF was added 300 
μL (0.47 mmol) of 1.6 M solution of n-BuLi in hexanes. The reaction mixture was stirred 
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at –5 °C for 20 min. To the mixture was added 64.0 μL (60.0 mg; 0.57 mmol) of 
trimethyl borate and the reaction mixture was stirred for 1 h. To the reaction mixture was 
added 0.42 mL of 30% aq H2O2 followed by 0.13 mL of 3 N aq NaOH. The reaction 
mixture was stirred for 30 min and poured into 15 mL of water. The aq mixture was 
neutralized with dilute aq HCl and extracted with two 5-mL portions of ethyl acetate. The 
combined organic solution was washed successively with 8 mL of brine and distilled 
water, dried (MgSO4). The excess solvent was concentrated under diminished pressure. 
The residue was purified by chromatography on a silica gel column (10 × 3 cm). Elution 
with 2:1 hexanes– ethyl acetate afforded compound 2-(dimethylamino)-4-methyl-6-
(pentadecyloxy) pyrimidin-5-ol  (3.4) as a colorless solid: yield 19 mg (28%); silica gel 
TLC Rf 0.3 (1:1 ethyl etherhexanes) 1H NMR (CDCl3) δ 0.87 (t, 3H, J = 7.2 Hz),  
1.251.32 (m, 25H), 1.51 (s, 3H), 1.621.74 (m, 2H), 1.721.83 (q, 1H, J = 10 Hz), 
2.072.14 (q, 2H, J = 10 Hz), 2.342.39 (m, 2H), 2.442.43 (t, 2H, J = 8 Hz), 3.10 (s, 
6H),  4.09 (br s, 1H); 13C NMR (CDCl3) δ 13.5, 14.1, 22.6, 28.4, 29.3, 29.5, 29.5, 29.6, 
29.6, 30.7, 30.8, 31.9, 37.2, 70.5, 126.8, 151.2, 154.8 and 158.5; mass spectrum (APCI), 




4-(Cyclopentyloxy)-2-(dimethylamino)-6-hexadecylpyrimidin-5-ol (3.5).112 To a 
stirred solution at –5 °C containing 84.0 mg (0.15 mmol) of compound 5-bromo-4-
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cyclopentoxy-6-hexadecyl-N,N-dimethylpyrimidin-2-amine (3.18) in 3.00 mL of anh 
THF was added 210 μL (0.33  mmol) of 1.6 M solution of n-BuLi in hexanes. The 
reaction mixture was stirred at –5 °C for 20 min. To the mixture was added 40.0 μL (36.0 
mg; 0.33 mmol) of trimethyl borate and the reaction mixture was stirred for 1 h. To the 
reaction mixture was added 0.46 mL of 30% aq H2O2 followed by 0.15 mL of 3 N aq 
NaOH. The reaction mixture was stirred for 30 min and poured into 50 mL of water. The 
aq mixture was neutralized with dilute aq HCl and extracted with two 50-mL portions of 
ethyl acetate. The combined organic solution was washed successively with 80 mL of 
brine and distilled water, dried (MgSO4). The excess solvent was concentrated under 
diminished pressure. The residue was purified by chromatography on a silica gel column 
(10 × 3 cm). Elution with 2:1 hexanes– ethyl acetate afforded compound 2-
(dimethylamino)-4-methyl-6-(pentadecyloxy)pyrimidin-5-ol (3.5) as a colorless solid: 
yield 13 mg (18%); silica gel TLC Rf 0.3 (1:1 ethyl etherhexanes) 1H NMR (CDCl3) δ 
0.87 (t, 3H, J = 7.2 Hz),  1.251.32 (m, 28H), 1.631.65 (m, 1H), 1.661.80 (m, 1H), 
2.082.14 (m, 4H) 2.14 (s, 3H), 2.352.43 (m, 3H), 3.11 (m, 6H); 13C NMR (CDCl3) δ 
13.7, 14.3, 22.6, 28.4, 29.3, 29.5, 29.5, 29.8, 29.6, 30.7, 30.8, 31.9, 37.1, 47.2, 70.5, 
128.8, 151.4, 154.2 and 157.5; mass spectrum (APCI), m/z 448.3903 (M + H)+ 
(C27H50N3O2 requires m/z 448.3903). 
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4-Cyclobutoxy-6-methyl-2-(pyrrolidin-1-yl)pyrimidine (3.19).131 To a solution of 117 
mg (0.50 mmol) of cyclobutanol and 120 mg sodium hydride in 3.00 mL of THF stirred 
for 10 minutes; was added 290 mg (3.07 mmol) of 2,4-dichloro-6-methylpyrimidine in 
ice. The reaction mixture was stirred for 27 h at room temperature. The reaction mixture 
was then diluted with 5 mL of water and extracted with seven 2-mL portions of 
dichloromethane. The organic layer was washed with water, brine and dried (Na2SO4). 
The excess solvent was concentrated under diminished pressure to afford a crude of 2-
chloro-4-cyclobutoxy-6-methylpyrimidine. The residue was a yellow oil. The crude was 
used directly in the next step.  
To a solution of 195 mg ( 0.88 mmol) of 2-chloro-4-cyclobutoxy-6-methylpyrimidine in 
6.00 mL of DMF was added 18 mg (0.08 mmol) of 3,4,7,8-tetramethyl-1,10-
phenanthroline, 14.0 mg (0.08 mmol)  CuI, 137 mg (1.69 mmol) dimethylamine. HCl 
salt, 641 mg (1.90 mmol) cesium carbonate in ice. The reaction mixture was then stirred 
for 5 h at 50 ºC. The reaction mixture was then diluted with 5 mL of water and extracted 
with several 2-mL portions of dichloromethane. The organic layer was washed 
successively with water, brine and dried (Na2(SO4)2). The excess solvent was 
concentrated under diminished pressure to afford a crude (3.19). The residue was purified 
by flash column chromatography on a silica gel column (24 × 2 cm). Elution with 1:9 
ethyl acetatehexane gave 3.19 as a colorless oil: yield 147 mg (35%); silica gel TLC Rf 
0.25 (1:9 ethyl acetatehexanes); 1H NMR (CDCl3) δ 1.241.26 (t, 1H, J = 7.2 Hz ), 
1.611.69 (m, 1H), 1.791.84 (m, 1H), 1.931.96 (m, 4H), 2.092.20 (m, 1H) 2.27 (s, 
3H), 2.382.45 (m, 2H), 3.543.57 (m, 4H), 5.095.28 (m, 1H) , 5.76 (s, 1H); 13C NMR 
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(CDCl3) δ14.5, 25.0, 26.3, 31.6, 47.4, 70.7, 94.8, 161.2, 168.7 and 170.0; mass spectrum 




4-Cyclobutoxy-6-methyl-2-(piperidin-1-yl)pyrimidine (3.20).131 To a solution of 175 
mg (0.77 mmol) of cyclobutanol and 184 mg sodium hydride in 3.00 mL of THF stirred 
for 10 minutes at 0 ºC, was added 308 mg (4.70 mmol) of 2,4-dichloro-6-
methylpyrimidine. The reaction mixture was stirred for 27 h at room temperature. The 
reaction mixture was then diluted with 5 mL of water and extracted with seven 2-mL 
portions of dichloromethane. The organic layer was washed successively with water, 
brine and dried (Na2(SO4)2). The excess solvent was concentrated under diminished 
pressure to afford a crude residue of 2-chloro-4-cyclobutoxy-6-methylpyrimidine. The 
residue was a yellow oil. The crude was used directly in the next step.  
To a solution of 308 mg (0.86 mmol) of 2-chloro-4-cyclobutoxy-6-methylpyrimidine in 
6.0 mL of DMF was added 20 mg (0.08 mmol) of 3,4,7,8-tetramethyl-1,10-
phenanthroline, 15.4 mg (0.08 mmol)  CuI, 137 mg (2.12  mmol) dimethylamine. HCl 
salt, 987 mg (2.90 mmol) cesium carbonate in ice. The reaction mixture was then stirred 
for 5 h at 50 ºC. The reaction mixture was then diluted with 5 mL of water and extracted 
with several 2-mL portions of dichloromethane. The organic layer was washed with 
water, brine and dried (Na2SO4). The excess solvent was concentrated under diminished 
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pressure to afford a crude residue (3.20). The residue was purified by flash column 
chromatography on a silica gel column (24 × 2 cm). Elution with 1:9 ethyl 
acetatehexane gave  3.20  as a colourless oil: yield 150 mg (56%); silica gel TLC Rf 
0.25 (1:9 ethyl acetatehexanes); 1H NMR (CDCl3) δ 1.241.26 (t, 1H, J = 7.2 Hz ), 
1.611.69 (m, 1H), 1.791.84 (m, 2H), 1.931.96 (m, 4H), 2.092.20 (m, 2H) 2.27 (s, 
3H), 2.382.45 (m, 2H), 3.543.57 (m, 4H), 5.095.28 (m, 1H) , 5.76 (s, 1H); 13C NMR 
(CDCl3) δ 13.5, 24.1, 30.3, 30.6, 36.8, 69.7, 93.8, 162.2, 167.8 and 169.1; mass spectrum 
(APCI), m/z 248.1766 (M + H)+ (C14H22N3O requires m/z 248.1763). 
 
 
4-Cyclobutoxy-6-hexadecyl-2-(pyrrolidin-1-yl)pyrimidine (3.21).112  To a solution 
containing 160 mg (1.45 mmol) of 4-cyclobutoxy-6-methyl-2-(pyrrolidin-1-yl)pyrimidine 
(3.19) and 50.0 μL (240 mg, 1.45 mmol) tetramethylethylenediamine in 3.00 mL dry 
THF was added 1.22 mL (1.6 M in hexanes, 2.17 mmol) of n-butyllithium dropwise at 
40 ºC over 5 min. The reaction mixture is warmed to 0 ºC over 2 h, 0.70 mL (0.70 g, 
2.75 mmol) of purified 1-bromopentadecane added and the reaction mixture stirred at 
room temperature under an atmosphere of argon for 3 h. The reaction mixture was 
quenched with 20 mL of saturated NH4Cl and extracted with five 10-mL portions of 
diethyl ether. The organic layer was washed with distilled water, brine and dried 
(MgSO4). The excess solvent was concentrated under diminished pressure to afford a 
crude. The crude was applied to a silica gel column (6 × 3 cm). Elution with 1:9 ethyl 
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acetatehexanes afforded 3.21 as a colorless solid: yield 176 mg (58%); silica gel TLC Rf 
0.45 (1:1 ethyl etherhexanes); 1H NMR (CDCl3) δ 0.860.89 (t, 3H, J = 7.2 Hz ), 
1.251.37 (m, 27H), 1.611.71 (m, 3H), 1.711.82 (q, 1H, J = 8 Hz ), 1.911.95 (m, 
4H), 2.152.24 (m, 2H),  2.412.47 (m, 2H), 2.682.71 (m, 2H),  3.493.52 (m, 3H), 
5.145.17 (m, 1H) , 5.76 (s, 1H); 13C NMR (CDCl3) δ 13.56, 14.0, 22.6, 25.4, 27.7, 29.3, 
29.4, 29.4, 29.5, 29.6, 29.6, 29.6, 30.7, 31.8, 36.8, 46.6, 71.0, 91.1, 158.1, 164.1 and 
169.0; mass spectrum (APCI), m/z 444.3963 (M + H)+ (C28H50N3O requires m/z 
444.3954).   
 
4-Cyclobutoxy-6-pentadecyl-2-(piperidin-1-yl)pyrimidine (3.22).112 To a solution 
containing 155 mg (1.40 mmol) of 4-cyclobutoxy-6-methyl-2-(piperidin-1-yl)pyrimidine 
(3.20) and 48.0 μL (232 mg, 1.40 mmol) Tetramethylethylenediamine in 3.00 mL dry 
THF was added 1.18 mL (1.6 M in hexanes, 2.10 mmol) of n-butyllithium dropwise at 
40 ºC over 5 min. The reaction mixture is warmed to 0 ºC over 2 h, 0.67 mL (0.67 g, 
2.66 mmol) of purified 1-bromotridecane added and the reaction mixture stirred at room 
temperature under an atmosphere of argon for 3 h. The reaction mixture was quenched 
with 20 mL of saturated NH4Cl and extracted with five 10-mL portions of diethyl ether. 
The organic layer was washed successively with distilled water, brine and dried 
(MgSO4). The excess solvent was concentrated under diminished pressure to afford a 
crude residue. The crude residue was applied to a silica gel column (6 × 3 cm). Elution 
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with 1:9 ethyl acetatehexanes afforded 3.22 as a colorless solid: yield 186 mg (65%); 
silica gel TLC Rf 0.45 (1:1 ethyl etherhexanes);  1H NMR (CDCl3) δ 0.860.89 (t, 3H, J 
= 7.2 Hz ), 1.241.55 (m, 27H), 1.561.69 (m, 8H), 1.751.83 (q, 1H, J = 8 Hz ), 
2.062.16 (m, 2H),  2.352.74 (m, 4H), 3.713.74 (m, 4H), 5.055.09 (m, 1H) 5.71 (s, 
1H); 13C NMR (CDCl3) δ 13.5, 14.0, 22.6, 24.9, 25.7, 28.4, 29.3, 29.4, 29.5, 29.6, 29.6, 
30.6, 31.9, 37.8, 44.7, 69.6, 93.4, 161.7, 169.2 and 172.0; mass spectrum (APCI), m/z 




To a solution containing 120 mg (0.30 mmol) of 4-cyclobutoxy-6-hexadecyl-2-
(pyrrolidin-1-yl)pyrimidine (3.21) in 5.00 mL chloroform was added 53.3 mg (0.30 
mmol) of N-bromosuccinimide dropwise at 0 ºC over 5 min. The reaction mixture was 
stirred at room temperature under an atmosphere of argon for 15 min. The reaction 
mixture was quenched with 20 mL of saturated NH4Cl and extracted with three 10-mL 
portions of diethyl ether. The organic layer was washed with distilled water, brine and 
dried (MgSO4). The excess solvent was concentrated under diminished pressure to afford 
a crude residue. The crude residue was applied to a silica gel column (6 × 3 cm). Elution 
with 1:20 ethyl acetatehexanes afforded 3.23 as a colorless solid: yield 126 mg (90%); 
silica gel TLC Rf 0.45 (1:10 ethyl etherhexanes); 1H NMR (CDCl3) δ 0.860.89 (t, 3H, 
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J = 7.2 Hz ), 1.251.37 (m, 27H), 1.611.71 (m, 3H), 1.711.82 (q, 1H, J = 8 Hz ), 
1.911.95 (m, 4H), 2.152.24 (m, 2H),  2.412.47 (m, 2H), 2.682.71 (m, 2H),  
3.493.52 (m, 3H), 5.145.17 (m, 1H); 13C NMR (CDCl3) δ 13.5, 14.0, 22.6, 25.4, 27.7, 
29.3, 29.4, 29.4, 29.5, 29.6, 29.6, 29.6, 30.7, 31.8, 36.8, 46.6, 71.0, 91.1, 158.1, 164.1 and 
169.0; mass spectrum (APCI), m/z 522.3046 (M + Na)+ (C28H49 BrN3O requires m/z 
522.3059).   
 
5-Bromo-4-cyclobutoxy-6-pentadecyl-2-(piperidin-1-yl)pyrimidine (3.24).112 
To a solution containing 142 mg (0.35 mmol) of 4-cyclobutoxy-6-pentadecyl-2-
(piperidin-1-yl)pyrimidine (3.22) in 6.00 mL chloroform was added 63.0 mg (0.35 mmol) 
of N-bromosuccinimide dropwise at 0 ºC over 5 min. The reaction mixture was stirred at 
room temperature under an atmosphere of argon for 15 min. The reaction mixture was 
quenched with 20 mL of saturated NH4Cl and extracted with three 10-mL portions of 
diethyl ether. The organic layer was washed successively with distilled water, brine and 
dried (MgSO4). The excess solvent was concentrated under diminished pressure to afford 
a crude. The crude was applied to a silica gel column (6 × 3 cm). Elution with 1:20 ethyl 
acetatehexanes afforded 3.24 as a colorless solid: yield 166 mg (95%); silica gel TLC Rf 
0.45 (1:10 ethyl etherhexanes); 1H NMR (CDCl3) δ 0.860.89 (t, 3H, J = 7.2 Hz ), 
1.241.55 (m, 27H), 1.561.69 (m, 8H), 1.751.83 (q, 1H, J = 8 Hz ), 2.062.16 (m, 
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2H),  2.352.74 (m, 4H), 3.713.74 (m, 4H), 5.055.09 (m, 1H); 13C NMR (CDCl3) δ 
13.5, 14.0, 22.6, 24.9, 25.7, 28.4, 29.3, 29.4, 29.5, 29.6, 29.6, 30.6, 31.9, 37.8, 44.7, 69.6, 
93.4, 161.7, 169.2 and 172.0; mass spectrum (APCI), m/z 536.3216 (M + H)+ (C29H51 
BrN3O requires m/z 536.3215).   
 
4-Cyclobutoxy-6-hexadecyl-2-(pyrrolidin-1-yl)pyrimidin-5-ol (3.6).112 
To a stirred solution containing 75.0 mg (0.15 mmol) of 5-bromo-4-cyclobutoxy-6-
hexadecyl-2-(pyrrolidin-1-yl)pyrimidine (3.23) at 5 ºC in 3.00 mL dry THF was added 
292 µL (1.6 M in hexanes, 0.46 mmol) of n-butyllithium dropwise  over 5 min. The 
mixture was stirred for 20 minutes. To the mixture was added 63.0 L (58.0 mg, 0.56 
mmol) of trimethyl borate and was stirred for 1 h.  To the reaction mixture was added 
0.41 mL of 30% aq H2O2. The reaction mixture was then stirred for 30 min and poured 
into water. The reaction mixture was quenched with 20 mL of saturated NH4Cl and 
extracted with five 10-mL portions of ethyl acetate. The organic layer was washed 
successively with distilled water, brine and dried (MgSO4). The excess solvent was 
concentrated under diminished pressure to afford a crude residue. The crude residue was 
applied to a silica gel column (6 × 3 cm). Elution with 1:4 ethyl acetatehexanes afforded 
3.6 as a colorless solid: yield 12 mg (19%); silica gel TLC Rf 0.3 (1:1 ethyl 
etherhexanes); 1H NMR (CDCl3) δ 0.860.89 (t, 3H, J = 7.2 Hz ), 1.251.37 (m, 28H), 
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1.611.71 (m, 3H), 1.711.82 (q, 1H, J = 8 Hz ), 1.911.95 (m, 4H), 2.152.24 (m, 2H),  
2.412.47 (m, 2H), 2.682.71 (m, 2H),  3.493.52 (m, 3H), 5.145.17 (m, 1H); 13C NMR 
(CDCl3) δ 14.0, 14.1, 22.6, 22.9, 23.7, 28.8, 28.9, 29.2, 29.3, 29.3, 29.4, 29.4, 29.4, 29.4, 
29.5, 29.5, 29.6, 29.6, 30.3, 31.9, 38.7, 68.1, 130.8, 154.7, 158.4 and 159.1; mass 
spectrum (APCI), m/z 460.6176 (M + H)+ (C28H50N3O2 requires m/z 460.6176).   
 
4-Cyclobutoxy-6-pentadecyl-2-(piperidin-1-yl)pyrimidin-5-ol (3.7).112 To a stirred 
solution containing 45.0 mg (0.09 mmol) of 5-bromo-4-cyclobutoxy-N,N-dimethyl-6-
tetradecylpyrimidin-2-amine (3.24) at 5 ºC in 4.00 mL dry THF was added 175 L (1.6 
M in hexanes, 0.27 mmol) of n-butyllithium dropwise  over 5 min. The mixture was 
stirred for 20 min. To the mixture was added 84.0 L (37.0 mg, 0.75 mmol) of trimethyl 
borate and was stirred for 1 h.  To the reaction mixture was added 0.24 mL of 30% aq 
H2O2. The reaction mixture was then stirred for 30 min and poured into water. The 
reaction mixture was quenched with 20 mL of saturated NH4Cl and extracted with five 
10-mL portions of ethyl acetate. The organic layer was washed successively with distilled 
water, brine and dried (MgSO4). The excess solvent was concentrated under diminished 
pressure to afford a crude residue. The crude residue was applied to a silica gel column (6 
× 3 cm). Elution with 1:4 ethyl acetatehexanes afforded 3.7 as a colorless solid: yield 
4.7 mg (12%); silica gel TLC Rf 0.3 (1:1 ethyl etherhexanes); 1H NMR (CDCl3) δ 
0.860.89 (t, 3H, J = 7.2 Hz ), 1.241.55 (m, 28H), 1.561.69 (m, 8H), 1.751.83 (q, 1H, 
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J = 8 Hz ), 2.062.16 (m, 2H),  2.352.74 (m, 4H), 3.713.74 (m, 4H), 5.055.09 (m, 
1H); 13C NMR (CDCl3) δ 14.4, 14.7, 22.6, 22.9, 23.7, 28.8, 28.9, 29.2, 29.3, 29.3, 29.4, 
29.4, 29.4, 29.4, 29.5, 29.5, 29.6, 29.6, 30.3, 31.9, 38.9, 68.1, 129.8, 157.7, 157.4 and 
158.1; mass spectrum (APCI), m/z 474.4039 (M + H)+ (C29H52N3O2 requires m/z 




N, N,4-trimethyl-6-(pentadecyloxy)pyrimidin-2-amine (3.25).131 To a solution of 699 
mg (3.07 mmol) of 1-pentadecanol and 147 mg (6.12 mmol) NaH in 6 mL of THF was 
added 500 mg (3.07 mmol) of 2,4-dichloro-6-methylpyrimidine in ice. The reaction 
mixture was stirred for 27 h at room temperature. The reaction mixture was then diluted 
with 5 mL of water and extracted with seven 2-mL portions of dichloromethane. The 
organic layer was washed with water, brine and dried (Mg SO4). The excess solvent was 
concentrated under diminished pressure to afford a crude residue. The residue was 
purified by flash column chromatography on a silica gel column (24 × 2 cm). Elution 
with 1:5 ethyl acetatehexane gave 2-chloro-4-methyl-6-(pentadecyloxy)pyrimidine as a 
yellow oil. The crude material was directly used in the next step. 
To a solution of 200 mg (0.56 mmol) of 2-chloro-4-methyl-6-(pentadecyloxy)pyrimidine 
in 2 mL of DMF was added 13.0 mg (0.06 mmol) of 3,4,7,8-tetramethyl-1,10-
phenanthroline, 10.0 mg (0.06 mmol), dimethylamine, HCl salt 137 (1.69 mmol), cesium 
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carbonate 641 mg (1.90 mmol) in ice. The reaction mixture was stirred for 5 h at 50 ºC. 
The reaction mixture was then diluted with 5 mL of water and extracted with seven 2-mL 
portions of dichloromethane. The organic layer was washed successively with water, 
brine and dried (Na2 SO4). The excess solvent was concentrated under diminished 
pressure to afford a crude residue. The residue was purified by flash column 
chromatography on a silica gel column (24 × 2 cm). Elution with 1:5 ethyl 
acetatehexane gave  3.25  as a colorless solid: yield- 633 mg (56%); silica gel TLC Rf 
0.30 (1:2 ethyl acetatehexanes); 1H NMR (CDCl3) δ 0.87 (t, 3H, J = 7.2 Hz),  1.251.32 
(m, 26H), 1.51 (s, 3H), 2.01 (s, 6H), 4.09 (t, 2H, J = 6.8 Hz ) 5.25 (s, 1H); 13C NMR 
(CDCl3) δ14.2, 22.7, 24.5, 26.0, 28.7, 28.8, 29.4, 29.4, 29.5. 29.5, 29.5, 29.6, 29.6, 29.7, 
29.7, 29.8, 29.8, 29.9, 29.9, 29.9, 30.0, 30.0, 32.0, 32.7, 37.1, 37.1, 67.1, 94.9, 162.8, 
166.6 and 169.8  mass spectrum (APCI), m/z 364.5510 (M + H)+ (C22H42ClN3O requires 
m/z 364.5508). 
 
5-Bromo-N,N,4-trimethyl-6-(pentadecyloxy)pyrimidin-2-amine (3.26).112 To a 
solution of 60.0 mg ( 0.17 mmol) of N,N,4-trimethyl -6-(pentadecyloxy)pyrimidin-2-
amine (3.25) in 3.00 mL of acetonitrile was added 44.0 mg (0.25 mmol) N-
bromosuccinimide in ice. The reaction mixture was stirred for 2 h at room temperature. 
The reaction mixture was then diluted with 5 mL of water and extracted with seven 2-mL 
portions of dichloromethane. The organic layer was washed successively with water, 
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brine and dried (MgSO4). The excess solvent was concentrated under diminished pressure 
to afford a crude. The residue was purified by flash column chromatography on a silica 
gel column (24 × 2 cm). Elution with 1:5 ethyl acetatehexane gave  3.26  as a colorless 
solid: yield 65 mg (90%); silica gel TLC Rf 0.30 (1:2 ethyl acetatehexanes); 1H NMR 
(CDCl3) δ 0.87 (t, 3H, J = 7.2 Hz),  1.251.32 (m, 26H), 1.51 (s, 3H), 2.01 (s, 6H), 4.09 
(t, 2H, J = 6.8 Hz ); 13C NMR (CDCl3) δ14.2, 22.7, 24.5, 26.0, 28.7, 28.8, 29.4, 29.4, 
29.5. 29.5, 29.5, 29.6, 29.6, 29.7, 29.7, 29.8, 29.8, 29.9, 29.9, 29.9, 30.0, 30.0, 32.0, 32.7, 
37.1, 37.1, 67.1, 91.9, 159.9, 164.9 and 165.6;  mass spectrum (APCI), m/z 442.5002 (M 
+ H)+ (C22H41BrN3O requires m/z 442.5002). 
 
2-(Dimethylamino)-4-methyl-6-(pentadecyloxy)pyrimidin-5-ol (3.8).112 To a stirred 
solution at –5 °C containing 93.0 mg (0.23 mmol) of compound 5-bromo-N,N,4-
trimethyl-6-(pentadecyloxy)pyrimidin-2-amine (3.26) in 3.00 mL of anh THF was added 
362 μL (0.57 mmol) of 1.6 M solution of n-BuLi in hexanes. The reaction mixture was 
stirred at –5 °C for 20 min. To the mixture was added 81.0 μL (72.0 mg; 0.69 mmol) of 
trimethyl borate and the reaction mixture was stirred for 1 h. To the reaction mixture was 
added 0.51 mL of 30% aq H2O2 followed by 0.16 mL of 3 N aq NaOH. The reaction 
mixture was stirred for 30 min and poured into 50 mL of water. The aq mixture was 
neutralized with dilute aq HCl and extracted with two 50-mL portions of ethyl acetate. 
The combined organic solution was washed successively with 80 mL of brine and 
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distilled water and dried (MgSO4). The excess solvent was concentrated under 
diminished pressure. The residue was purified by chromatography on a silica gel column 
(10 × 3 cm). Elution with 2:1 hexanes– ethyl acetate afforded compound 2-
(dimethylamino)-4-methyl-6-(pentadecyloxy)pyrimidin-5-ol 3.8 as colorless solid: yield 
7.9 mg (10%); silica gel TLC Rf 0.3 (1:1 ethyl etherhexanes) 1H NMR (CDCl3) δ 0.87 
(t, 3H, J = 7.2 Hz),  1.251.32 (m, 26H), 1.51 (s, 3H), 2.01 (s, 6H), 4.09 (t, 2H, J = 6.8 
Hz ), 5.09 (br s, 1H); 13C NMR (CDCl3) δ14.7, 22.6, 24.5, 26.2, 28.7, 28.8, 29.4, 29.4, 
29.5. 29.5, 29.5, 29.6, 29.6, 29.7, 29.7, 29.8, 29.8, 29.9, 29.9, 29.9, 30.0, 30.0, 32.0, 32.7, 
37.1, 37.1, 65.1, 129.9, 155.3, 154.8 and 157.2; mass spectrum (APCI), m/z 380.4944 (M 
+ H)+ (C22H42N3O2  requires m/z 380.4940). 
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Cell Lines and Culture Conditions.106 
A Friedreich’s ataxia lymphocyte (GM15850) cell line was obtained from Coriell 
Cell Repositories (Camden, NJ). The lymphocytes were cultured in RPMI-1640 medium 
(Gibco, Life Technologies, Grand Island, NY) with 15% fetal calf serum, 2 mM 
glutamine (HyClone, South Logan, UT) and 1% penicillin–streptomycin antibiotic 
supplement (Cellgro, Manassas, VA). Cells were passaged every other day to maintain 
them in log phase growth and kept at a nominal concentration of 5-10×105 cell/mL. A 
CoQ10 deficient lymphocyte cell line (GM17932) was obtained from Coriell Cell 
Repositories. A nutrient sensitized screening strategy to identify CoQ10 analogues that 
function within the mitochondrial respiratory chain was used by growing the CoQ10-
deficient lymphocyte in galactose containing media to force energy production 
predominantly through oxidative phosphorylation rather than glycolysis. The 
lymphocytes were cultured in RPMI 1640 glucose free medium (Gibco, Grand Island, 
NY) supplemented with 25 mM galactose, 2 mM glutamine and 1% penicillin– 
streptomycin, and 10% dialyzed fetal bovine serum (FBS) (<0.5 μg/mL) (Gemini Bio- 
Product, West Sacramento, CA). 
NADH Oxidase Activity.121 
The effect of the exogenous pyrimidinol analogues (Table 3.1) on the activities of 
complexes I, III and IV within the respiratory chain was evaluated using bovine heart 
mitochondria during the co-oxidation of their respective substrate (NADH) as described 
previously.110-113 Bovine heart submitochondrial particles (SMPs) were prepared as 
described by Matsuno-Yagi21 and stored in a buffer containing 0.25 M sucrose and 10 
mM Tris-HCl, pH 7.4, at –80 °C. SMPs were diluted to 0.5 mg/mL. 
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Mitochondrial complexes I, III, and IV activity were assayed at 30 °C and monitored 
spectrophotometrically using a Beckman Coulter DU-530 (340 nm, ε = 6.22 mM-1cm-1). 
NADH oxidase activity was determined in 50 mM Hepes buffer containing 5 mM MgCl2, 
pH 7.5, in a total volume of 2.5 mL. The final mitochondrial protein concentration was 
30 μg/mL. The initial rates of NADH oxidation were calculated from the linear portion of 
the traces. Data are reported as the mean of three independent experiments each run in 
triplicate. 
Lipid Peroxidation Assay.106 
Lipid peroxidation was measured by a quantitative FACS assay using the 
oxidation-sensitive fatty acid probe C11-BODIPY581/591 (Molecular Probe) as 
described.55-58 The degree of probe oxidation was followed using flow cytometry. 
Briefly, FRDA lymphocytes (5 × 105 cell/mL) were plated (1 mL in 24-well plates), 
treated with the test compounds and incubated at 37 °C for 16 h in a humidified 
atmosphere containing 5% CO2 in air. The following day, cells were treated with 1 μM of 
C11-BODIPY581/591 probe in phenol red-free media and incubated at 37 °C in the dark 
for 30 min. Oxidative stress was induced with 5 mM DEM in phenol red-free RPMI-1640 
media for 120 min. Cells were collected by centrifugation at 300 × g for 3 min and then 
washed with phosphate buffered saline (PBS). Cells were re-suspended in phosphate 
buffered saline and were analyzed immediately by FACS (C6 Accuri, BD Biosciences, 
San Jose, CA), using a 488 nm excitation laser and the FL1-H channel 530 ± 15 nm 
emission filter. The generation of lipid peroxide was detected as a result of the oxidation 
of the polyunsaturated butadienyl moiety of the dye, resulting in a shift of the 
fluorescence emission peak from red to green. In each analysis, 10,000 events were 
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recorded after cell debris were electronically gated out. Data are reported as means ± 
S.E.M. (n = 3). Results were expressed as a percentage of lipid peroxidation scavenging 
activity. 
Cellular ATP Concentration Assay106 
The intracellular ATP content was determined by a bioluminescence assay 
measuring the light output from the luciferin-luciferase reaction as described 
previously.55-58 Briefly, CoQ10 deficient lymphocytes (2 × 10
5 cell/mL) were plated (1 
mL in 24-well plates) in glucose-free media supplemented with galactose and treated 
with the test compounds at final concentrations of 5, 10 and 25 μM, and then incubated at 
37 °C for 48 h in a humidified atmosphere containing 5% CO2 in air. Wells were mixed 
and cells in each well were transferred (100 μL) to 96-well microtiter black-walled cell 
culture plates (Costar, Corning, NY). The total intracellular ATP level was measured in a 
luminator (Clarity™ luminescence microplate reader) using an ATP Bioluminescence 
Assay Kit (ViaLight-Plus ATP monitoring reagent kit, Lonza, Walkersville, MD) 
following the manufacturer’s protocol. The total ATP level was expressed as a 
percentage of untreated control. Data are reported as the mean of at least three 
independent runs. 
Cytoprotection (Trypan Blue Exclusion Assay)105 
The cytoprotection conferred by the pyridinol derivatives was determined in six 
lymphocytes using the trypan blue exclusion method.55-57 This method was used to 
determine the number of viable cells present in cell suspension. It is based on the 
principle that live cells possess intact cell membranes that exclude trypan blue, whereas 
dead cells are not capable of excluding trypan blue. Briefly, lymphocytes were seeded at 
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a density of 5 × 105 cells per mL and treated with different concentrations of the test 
compounds. Cells were incubated at 37 °C in a humidified atmosphere of 5% CO2 in air 
for 16 h. Oxidative stress was then induced by 5 mM diethyl maleate (DEM) treatment 
for 6 h. Cell viability was assessed microscopically by the use of a hemocytometer. The 
number of cells that absorbed the dye and those that excluded the dye were counted, from 
which the percentage of nonviable cell number over total cell number was calculated. 
Cytoprotection by the test compounds was assessed with respect to the untreated controls. 
Cells not treated with DEM had >90% cell viability whereas DEM treatment reduced cell 
viability to <20%. The cell viability was expressed relative to the vehicle control (DMSO 
only) group (n = 3). 
Microsomal Stability Assay.111 
Bovine liver microsomes were prepared from liver of a freshly slaughtered animal. 
Briefly, liver tissues were diced into small pieces and then washed with isotonic sucrose 
buffer (0.25 M sucrose, 10 mM Tris-HCl, 0.5 mM EDTA, pH 7.8). The diced tissue was 
passed through a precooled meat grinder and mixed with three-fold ice cold sucrose 
buffer supplemented with a mixture of protease inhibitors. The suspension was 
homogenized in a waring blender for 25 sec at high speed. At this stage, the pH of the 
suspension was adjusted to 7.4 with 1 M Tris base. The homogenate was centrifuged for 
20 min at 1200 × g to remove cell debris. The supernatant suspension was homogenized 
in a tight fitting Teflon-glass Potter-Elvejhem homogenizer and then centrifuged twice at 
10,000 × g for 20 min, collecting the supernatant each time to remove mitochondria. The 
floating fat layer was carefully removed by filtering the supernatant through layers of 
cheesecloth. The supernatant was centrifuged at 150,000 × g for 30 min (Beckman-
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Coulter ultracentrifuge, XL-100K -01, SW-55 Ti rotor). The pellet (microsomal fraction) 
was suspended in 0.25 M sucrose buffer containing 10 mM Tris-HCl, pH 7.4, with 20% 
(v/v) glycerol, and centrifuged once more at 150,000 × g. The pellet was resuspended in 
sucrose buffer with 20% (v/v) glycerol. The protein concentration after resuspension was 
approximately 20 mg/mL, as determined by BCA protein assay (Pierce Chemical) using 
bovine serum albumin as a standard. Aliquots of microsomal suspensions were stored at –
80 °C. 
  Test compounds were incubated (25 µM) with liver microsomes for 30 min, 
extracted and concentrated for HPLC analysis.  Specifically, microsomal incubations 
were performed in 2 mL eppendorf centrifuge tubes containing 1 mg of microsomal 
protein, 1 mM NADPH, 5 mM MgCl2, in a final volume of 500 µL of phosphate buffer 
(50 mM, pH 7.4).   A positive control assay (without 1 mM NADPH) was prepared by 
using 1-propanol to quench/deactivate the liver microsomal enzymes before the 
incubation was initiated.  The test compounds were dissolved in methanol.  After 30 min 
of microsomal incubation, the reaction was terminated by the addition of 1.2 mL of ice 
cold 1-propanol vortexing for 2 min and centrifugation at 15,000 x g for 20 min.  The 
resulting supernatant was concentrated using a rotavapor.  The concentrated samples 
were reconstituted in minimal amount methanol and analyzed using an HPLC-based 
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CHAPTER 4 
STUDIES ON ENZYMATIC BINDING OF A DIVERSE LIBRARY OF 
MULTIFUNCTIONAL RADICAL QUENCHERS TO MITOCHONDRIAL 
ELECTRON TRANSPORT CHAIN COMPLEXES. 
 
4.1. Introduction 
Mitochondria are membrane bound organelles found in eukaryotic cells.8 It is 
believed that mitochondria were originally independent organelles, which were 
incorporated into cells in an early stage of evolution.2-4,8,16 Mitochondria retains their 
multi-membrane structure and their own DNA, till date, despite of being an integral part 
of the machinery of a modern eukaryotic cell. Many of mitochondrial proteins are 
encoded by nDNA in addition to the ones encoded by mtDNA.70,71 The protein structure 
embedded on the inner membrane of mitochondria is responsible for mitochondrial ATP 
production. ATP is produced by an electron transfer mechanism through membrane 
bound protein complexes called the mitochondrial electron transport chain.  
Mitochondrial dysfunction is often related to a disruption in the mitochondrial electron 
transfer.  
Historically, natural products and antioxidant molecules have been used as 
potential mitochondrial therapeutic agents, individually or as mixtures or cocktail.74,76-
78,80-83 Unsurprisingly, a lack of mechanistic understanding of the interaction between 
target proteins and potential therapeutic agents had limited the efficacy of such drugs.  
A new generation of mitochondrial drugs meant to have better therapeutic activity 
and fewer side effects. To realize the design of better drugs, it is important to understand 
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their interaction with the mitochondrial complexes and hence their effects on 
mitochondrial electron transfer. 
4.2. Submitochondrial Particles 
Submitochondrial particles (SMP) are mitochondrial membrane fragments that are 
isolated from intact mitochondria by sonication followed by differential centrifugation.111 
They can be used to study the effects of exogenously added reagents like NADH and 
cytochrome c and to perform kinetic characterizations on different complexes and 
enzymes inside mitochondrial membrane.61,113  
 
Figure 4.1. Preparation of Submitochondrial Particles from Freshly Isolated Bovine 
Heart. 
 
Sub Mitochondrial Particles are Typically Used for Enzymatic Experiments Involving 
Mitochondrial Complexes.28,137,138 
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4.3. Electron Transport Chain in Mitochondria 
The electron transport chain (ETC) consists of four membrane embedded proteins 
(complex I-IV). The electron transport chain is mainly used in eukaryotic biological 
system to harness energy in usable form as ATP.18,20,139 NADH binds to the flavin 
mononucleotide (FMN) prosthetic group at the binding site on complex I. The co-factor 
gets oxidized and the prosthetic group gets reduced by transferring electrons. Electrons 
are then carried to a lipid-soluble carrier called CoQ10 through Fe-S proteins inside 
complex I.  
 
Figure 4.2.  Mitochondrial Electron Transport Chain in Action.  
 
Coenzyme Q10 binds to the Q site in the complex I. The electron acceptor molecule 
(oxidized CoQ10) has to reach to the binding site is at the end of a long tunnel (Figure 
4.3).20 The reduced CoQ10 molecules so formed transfer their electrons to complex III or 
to coenzyme Q:cytochrome c-oxidoreductase, passing through mitochondrial inner 
membrane where the complexes are embedded.  
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Figure 4.3. Mechanism of Electron Transfer and Substrate Binding Sites in 
Mitochondrial Complex I.20 
The passage of electrons through complex I as well as complex III facilitates proton 
translocation across the inner mitochondrial membrane. The electron transfer process 
from complex II to complex III is completely independent of this process and thus not a 
part of NADH pathway.16 
The mechanism of electron transfer from reduced Coenzyme Q10 to Cytochrome c 
is called the Q cycle.140,141 Coenzyme Q10 binds in the specific site on complex III called 
the Q0 site (Figure 4.4). The electron flow gets distributed between two independent 
pathways, one leading to Qi and the other pathway leading to the cytochrome c binding 
site through iron-sulfur complexes.140,141 
Sometimes, it is also observed that reduced electron carriers from complex I bypass 
complex III and reduces cytochrome c directly.142 
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Figure 4.4. Active Sites and Electron Transfer Mechanism in Complex III.140,141 
Complex IV or cytochrome c oxidase receives four electrons from four molecules 
of cytochrome c and the electrons are transferred through a proton coupled process to the 
active site where molecular oxygen (O2) gets reduced; producing two molecules of water  
(Figure 4.5).143  The transit of electrons through ETC complexes is accompanied by the 
translocation of protons into the mitochondrial intermembrane space. Ten protons are 
translocated for each two electrons introduced into complex I by NADH. The protons are 
returned through the inner mitochondrial membrane at complex V (ATP synthase). It is 
this proton gradient that drives ATP production by ATP synthase. The electron transfer 
system operates such that any inhibition or malfunction at any part of the electron transfer 
chain will disrupt the overall electron transfer process.21 
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4.4. NADH Oxidase and NADH:Ubiquinone Oxidoreductase Activity 
Antioxidant molecules are designed to protect mitochondrial electron transfer 
process from the effects of electrons which have leaked from ETC. During this process 
antioxidants may need to bind to the mitochondrial complexes in order to function. The 
extent of binding varies depending on the functional groups present in the molecule.143 
Molecules may bind to the complexes irreversibly. This process can potentially disrupt 
the electron transfer process in the ETC. As a result total mitochondrial ATP production 
may be reduced. Any disruption in the electron transfer process may also reduce the 
amount of NADH oxidized at complex I. 
 
Figure 4.5. Active Sites and Electron Transfer Mechanism in Complex IV.139 
Accordingly, the overall activity of mitochondrial electron transport chain (complexes I, 
III and IV) in presence of a molecule under investigation can be quantified via the rate of 
oxidation of NADH.112 
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NADH oxidase assay is a fast and initial screening method to verify the inhibitory 
effect of a molecule capable of interacting with the ETC complexes.111,121 This methods 
can be used to quantify the interaction of a MRQ with the complete electron transfer 
chain or individual complexes (complex I in this study).  
As complex I is the largest source of mitochondrial oxidative stress,140 it is 
important to quantify (IC50 value) the binding
121 for molecules of potential therapeutic 
interest to complex I. Interaction with other electron transport chain complexes (complex 
II, III and IV) can also be quantified (togather or individually) (IC50 value).
121 
A high value in NADH oxidase activity assay can sometimes be misleading. If a 
given multifunctional radical quencher does not inhibit the mitochondrial electron 
transport chain, it might simply indicate that it is not interacting with any of the 
mitochondrial ETC complexes. Molecules inducing very low NADH oxidase activity can 
be concluded to be inhibitors of mitochondrial function.111 Drug discovery and lead 
identification can be reinforced by assessing the effects on NADH oxidase and 
NADH:ubiquinone oxidoreductase assays of  potential drug leads.121  
  138 
4.4. Molecular Libraries Selected for Screening 
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Figure 4.6. Series of Idebenone Analogues Evaluated. The Compounds were Synthesized 
by Dr. David Fash and Dr. Pablo Arce.   
 
  140 
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Figure 4.7. Series of Pyridinol and Pyrimidinol Analogues Evaluated. The Compounds 
were Synthesized by Dr. Pablo Arce, Dr. Parvez Alam and Cameron Cripe. 
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Figure 4.8. Series of Bicyclic Pyridinol Analogues Evaluated. The Compounds were 
Synthesized by Dr.Xiaoqing Cai and Dr. Jose Armendariz. 
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Figure 4.9. Series of Alkylaminoquinone Analogues Evaluated. The Compounds were 
Synthesized by Dr.Manikandadas Madathil. 
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Figure 4.10. Series of N-Hydroxypyridone Analogues Evaluated. The Compounds were 
Synthesized by Poulami Talukder. 
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4.5. Results  
4.5.1. Idebenone Analogues 
Potential drug candidates are expected to support electron transfers in the 
mitochondrial electron transport chain. Molecules such as 4.22 support antioxidant 
functions very well but also inhibit the electron transport chain.112 Hence, cannot be an 
ideal therapeutic agent. NADH oxidase inhibition screening of idebenone analogues 
(Figure 4.6), are summarized in Table 4.1 for compounds 4.1-4.16. These compounds 
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Table 4.1. NADH Oxidase Activity of Idebenone Analogues are Shown Relative to 
Untreated Control. 
 
NADH Oxidase (Complex I, III, IV) activity %a 
 
a- Data are expressed as the mean ± SEM (n = 3). 
Compound 1 M 5 M 10 M 
Control 100 100 100 
4.1 90 ± 5 - - 
4.2 93 ± 6 82 ± 2 61 ± 6 
4.3 85 ± 4 66 ± 4 59 ± 1 
4.4 - 70 ± 5 65 ± 5 
4.5 45 ± 1 45 ± 2 35 ± 4 
4.6 45 ± 3 45 ± 2 35 ± 2 
4.7 80 ± 5 60 ± 2 40 ± 5 
4.8 90 ± 6 90 ± 2 90 ± 6 
4.9 98 ± 1 92 ± 4 90 ± 3 
4.10 91 ± 4 - 88 ± 4 
4.11 90 ± 9 83 ± 4 83 ± 9 
4.12 98 ± 1 85 ± 2 65 ± 8 
4.13 - 50 ± 1 50 ± 1 
4.14 98 ± 9 97 ± 4 83 ± 9 
4.15 80 ± 4 80 ± 4 80 ± 4 
4.16 42 ± 2 28.5 ± 1 14 ± 1 
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Compounds 4.1 to 4.28 have the same redox core as idebenone. Compounds 4.1-4.3 are 
idebenone analogues having linear aliphatic side chains. Compounds 4.5 and 4.6 have 
unsaturation and branching on the aliphatic side chain with different sizes. 4.1 to 4.4 have 
little inhibition toward NADH oxidase assay at any tested concentration. In comparison, 
compounds 4.5 and 4.6 were somewhat more inhibitory at all tested concentrations. 
Unsaturation and branching in the side chain of antioxidants can potentially affect the 
efficiency of electron transfer. Compounds 4.7 to 4.16 are molecules with cyclic 
substituents at the end of the side chain. Two of these compounds proved to be strongly 
inhibitory to NADH oxidase activity. One was compound 4.13, which has an anthracene 
moiety attached at the end of the side chain in an orientation orthogonal to the side chain. 
The other was compound 4.16, in which the side chain terminated with an OH functional 
group. Apparently, both planer aromatic surfaces and polar groups both can confer strong 
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Table 4.2. NADH Oxidase Activity of Idebenone Analogues are Shown Relative to 
Untreated Control.  
 
                                                  NADH Oxidase (Complex I, III, IV) activity %a 
a- Data are expressed as the mean ± SEM (n = 3). 









4.17 75 ± 3 30 ± 2 30 ± 4 
4.18 85 ± 1 85 ± 1 70 ± 1 
4.19 60 ± 1 - - 
4.20 89 ± 1 75 ± 1 64 ± 1 
4.21 40 ± 1 - - 
            4.22 50 ± 4 19 ± 2 13 ± 1 
4.23 60 ± 1 - - 
4.24 95 ± 3 67 ± 3 62 ± 3 
4.25 85 ± 3 70 ± 7 42 ± 3 
4.26 95 ± 3 77 ± 3 75 ± 1 
4.27 77 ± 3 70 ± 3 42 ± 7 
4.28 - 85  ± 4 79 ± 5 
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A number of additional idebenone analogues were also studied, and these are 
summarized in Table 4.2. Of these compounds, only two were strongly inhibitory to 
NADH oxidase activity. This included compounds 4.17 and 4.22, both of which have 
polar side chain substituents. Compound 4.17 has an amide group in the side chain while 
4.22 contains an OH group. 
4.5.2. Pyridinol and Pyrimidinol Analogues 
 Table 4.3 summarizes the NADH oxidase activity of pyrimidinol and pyrimidinol 
compounds in Figure 4.7. The compounds in this series show a dose dependent behavior.  
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Table 4.3. NADH Oxidase Activity of Pyridinol and Pyrimidinol Analogues are Shown 
Relative to Untreated Control.  
 
                                                   NADH Oxidase (Complex I, III, IV) activity %a  
  
a- Data are expressed as the mean ± SEM (n = 3). 









4.29 40 ± 2 18 ± 1 4  ± 2 
4.30 62 ±  3 62 ± 1 62 ± 3 
4.31 80 ± 2 70 ± 3 70 ±  3 
4.32 - 73 ± 4  75 ± 2 
4.33 - 70 ± 3 70 ± 2 
4.34 - 69 ± 1 58 ± 1 
4.35 - 46 ± 5 30 ± 1 
4.36 90 ± 8 38 ± 2 20 ± 3 
4.37 - 65 ± 4 50 ± 3 
4.38 50 ± 5 22  ± 4 15 ± 3 
4.39 62 ± 3 50 ± 2 25 ± 1 
4.40 38 ± 2 38 ± 3 10 ± 2 
4.41 66 ± 5 46 ± 5 39 ± 5 
4.42 70 ± 2 55 ± 4 44 ± 2 
4.43 72 ± 4 52 ± 3 31 ± 4 




                                                    NADH Oxidase (Complex I, III, IV) activity %a 
 
a- Data are expressed as the mean ± SEM (n = 3). 
Compound 1 M 5 M 10 M 
Control 100 100 100 
4.44 48 ± 7 23 ± 9 15 ± 7 
4.45 80 ± 5 36 ± 4 20 ± 5 
4.46 27 ± 1 9 ± 1  6 ± 1 
4.47 91± 1 77 ± 1 88 ± 7 
            4.48 80 ± 1 55 ±3 73 ±4 
4.49 27 ± 1 9 ± 1  6 ± 1 
4.50 35 ± 1 28 ± 1 13 ± 1 
4.51 49 ± 1 35 ± 1  8 ± 1 
4.52 81 ± 1 73 ± 1 43 ± 1 
4.53 99 ± 1 96 ± 2 75 ± 2 
4.54 81 ± 1 73 ± 1 43 ± 1 
4.55 88 ± 1 85 ± 1 80 ± 1 
4.56 98 ± 2 95 ± 2 92 ± 1 
4.57 95 ± 1 93 ± 1 86 ± 1` 
4.58 93 ± 1 88 ± 1 85 ± 1 
4.59 98 ± 1 83 ± 1 81 ± 1 
4.60 62 ± 2  57 ± 1 40 ± 1 
4.61 91 ± 1 90 ± 3 91 ± 1 
4.62 85 ± 2 72 ± 3 62 ± 2 
4.63 57 ± 3 37 ± 1 20 ± 1 
4.64 85 ± 2 72 ± 3 62 ± 2 
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                                                    NADH Oxidase (Complex I, III, IV) activity %a  
 
a- Data are expressed as the mean ± SEM (n = 3). 
 
Compounds 4.29-4.34 have pyrimidinol core and an aliphatic side chain. 4.34 has 
an aliphatic cage structure at the end of the chain and an electronegative polar atom in the 
middle of the side chain. Compound 4.29 has a 10-carbon side chain and exhibited 
inhibition at all tested concentrations. While having similar structure, compounds 4.31-
4.33 showed lesser inhibition. Compound 4.34 was not an inhibitor in spite of having a 
polar atom in its side chain. Compound 4.30 differs from 4.31 and 4.32 by the presence 
of an electron donating methoxy substituent on the redox core. Redox cores with similar 









4.65 85 ± 1 85 ± 2 79 ± 2 
4.66 93 ± 4 94 ± 2 95 ± 3 
4.67 95 ± 2 89 ± 2 79 ± 5 
4.68 81 ± 3 78 ± 4 67 ± 5 
            4.69 79 ± 4 73 ± 8 52 ± 6 
4.70 98 ± 1 89 ± 2 83 ± 2 
4.71 79 ± 2 77 ± 2 74 ± 2 
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structures had reduced inhibitory effect when they contain a methoxy substituent 
compared to a methyl substituent. Compounds 4.35–4.46 are the pyridinol and 
pyrimidinol analogues with a polar (-OH) group at the end of the side chain. These 
compounds inhibited the electron transfer. Compound 4.46, with a shorter side chain, 
inhibited electron transfer strongly. Compounds 4.35, 4.36 and 4.37 have similar side 
chains with different redox cores. Compound 4.36 having a redox core similar to that in 
4.37, inhibits electron transport more than 4.37. Compounds 4.35 and 4.37 have similar 
substituents with different redox cores. Compound 4.37, with a pyridinol redox core 
exhibited greater inhibition. Compounds 4.41 and 4.43 have a saturated and unsaturated 
cyclic substituent on the redox core, respectively. Compound 4.43 had a lesser inhibitory 
effect on NADH oxidase at higher concentrations. Compounds 4.45 and 4.46 differ in the 
number of methyl substituents on the pyridinol redox core. Compound 4.46 showed a 
lesser extent of inhibition of NADH oxidase. Compounds 4.46-4.49 are pyridinol and 
pyrimidinol analogues with aliphatic side chains. Shorter side chains (4.49) inhibited the 
electron transfer, while 4.48 did not inhibit electron transfer despite having a polar atom 
in the middle of the side chain. Compounds 4.50-4.71 have pyridinol redox cores with 
variable substituents and side chain sizes. Compounds 4.50 and 4.51 are pyridinol core 
molecules with 10-carbon side chains. Unsurprisingly, they inhibited the electron 
transfer. Compounds 4.53 and 4.54 with a longer side chains, did not inhibit electron 
transfer. Compounds 4.55-4.58 are pyridinol molecules with long (>10-carbon) aliphatic 
side chains. Unsurprisingly, they did not inhibit electron transfer. Compounds 4.59-4.62 
are analogues with long side chain having a cyclic (saturated and unsaturated, aromatic) 
substituents at the end of the side chain. None of them inhibit electron transfer except 
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4.60. Aromatic groups as a substituent at the end of the side chain inhibited NADH 
oxidase activity to a lesser extent compared to the corresponding saturated (cyclohexyl) 
analogues. Compound 4.63 is a compound with a structure similar to 4.55 having a 
branched aliphatic side chain. Compound 4.63 was an inhibitor of electron transfer. 
Compounds 4.65-4.69 are molecules with different heterocyclic substituents on the redox 
core. Smaller hetero-cyclic substituents on the redox core (4.65 and 4.66) made the 
compounds weaker inhibitors of NADH oxidase. Compounds 4.70 and 4.71 have bicyclic 
redox cores. Compound 4.71 did not inhibit the electron transfer despite having a shorter 
side chain. 
 4.5.3. Bicyclic Pyridinol Analogues 
Compounds 4.72-4.93 are bicyclic pyridinol antioxidants which have been 
evaluated for inhibition in NADH oxidase activity (Table 4.4). All of them showed dose 


























Table 4.4. NADH Oxidase Activity of Bicyclic Pyridinol Analogues are Shown Relative 
to Untreated Control. 
 
                                                   NADH Oxidase (Complex I, III, IV) activity %a 
 
a- Data are expressed as the mean ± SEM (n = 3). 
 
Compound 10 M 5 M 1 M 
Control 100 100 100 
4.72 - - 55 ± 1 
4.73 - - 50 ± 7 
4.74 - - 78 ± 4 
4.75 - - 77 ± 6  
4.76 - - 74 ± 2 
4.77 54 ± 2 64 ± 1 73 ± 1 
4.78 - - 40 ± 2 
4.79 42 ± 1 49 ± 2 62 ± 2 
4.80 38 ± 1 51 ± 2 58 ± 3 
4.81 26 ± 2 41 ± 1 47 ± 1 
4.82 42 ±1 48 ± 1 53 ± 3 
4.83 19 ±1 32 ± 2 39 ± 1 
4.84 54 ± 2 60 ± 1 66 ± 3 
4.85 15 ± 1 26 ± 1 31 ±2 
4.86 67 ±1 82 ± 1 86 ±2 
4.87 41 ± 2 51 ±1 58 ±3 
4.88 63 ±1 91 ± 4 92 ± 1 
4.89 76 ± 3 92 ± 4 93 ± 5 
4.90 68 ± 3 76 ± 2 78 ±1 
4.91 88 ± 3 92 ± 1 93 ± 4 
4.92 39 ± 3 43 ± 2 49 ± 1 
4.93 51 ± 2 63 ± 1 68 ± 3 
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Compounds 4.72 and 4.73 are analogues having short side chain attached to the 
redox core. The polar (-OH) group is protected on the redox core of 4.73. Unsurprisingly, 
both of these compounds inhibited the electron transfer. Compounds 4.74 and 4.75 did 
not demonstrate any difference in inhibition despite a protected polar group on the redox 
core of 4.74. Compound 4.78 has a 10-carbon side chain with a polar (OH) group at the 
end of the chain. Unsurprisingly, it inhibited the electron transfer. Compounds 4.79-4.85 
are molecules with variable aliphatic side chains and a polar (OH) group on the redox 
core. All of them moderately inhibited electron transfer. Compound 4.83, with a 10-
carbon side chain inhibited the electron transfer. Compounds 4.86-4.91 and 4.93 having 
the polar (-OH) group protected on the redox core, were not strongly inhibitory to NADH 
oxidase activity. Compound 4.92, with a 10-carbon side chain inhibited the electron 
transfer. 
4.5.4. Alkylaminoquinone Analogues 
Compounds 4.94-4.104 are alkylaminoquinone analogues (Figure 4.8). The 
molecules show dose dependent behavior as inhibitors of NADH oxidase activity (Table 
4.5). 
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Table 4.5. NADH Oxidase Activity of Alkylaminoquinone Analogues are Shown 
Relative to Untreated Control.  
 
                                                  NADH Oxidase (Complex I, III, IV) activity %a 
a- Data are expressed as the mean ± SEM (n = 3). 
All of the analogues in this library have 13-carbon side chain. Variations were 
made at the vinylogous amide substituent in the side chain and the methoxy or hydroxyl 
substituent on the redox core. The ester groups at the end of the vinylogous amide side 
chain varied as a linear, branched aliphatic chain or as a cyclic aromatic group. 









4.94 - 77 ± 4 84 ± 1 
4.95 - 62 ± 3 77 ± 4 
4.96 - 48 ± 3 67 ±6 
4.97 - 27 ± 3 54 ± 5 
4.98 - 39 ± 1 67 ±6 
4.99 - 47 ± 3 74 ± 1 
4.100 18 ± 1 36 ±1 82 ± 2 
4.101 17 ± 1 33 ± 1 81 ± 1 
4.102 5 ± 1 6.6 ± 1 18 ± 1 
4.103 15 ± 1 34 ±1 70 ± 2.1 
4.104 70 ± 1  85 ± 1 95 ± 1 
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Compound 4.97 inhibited the electron transfer. Compounds with a polar (-OH) group on 
the redox core (4.98) showed greater inhibition compared to the corresponding acetylated 
analogue (4.99). Compound 4.102 having a dimethylamine as a vinylogous amide, was 
an inhibitor of NADH oxidase. Compound 4.104, having an aliphatic cyclic side chain 
similar to geldanamycin, did not inhibit NADH oxidase activity. 
4.5.5. N-Hydroxypyridone Analogues 
The N-hydroxy pyridines (4.105-4.121) described in Figure 4.9 were evaluated; 
the results are shown in the Table 4.6. The analogues in this table showed dose dependent 
behavior in all concentration ranges. 
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Table 4.6. NADH Oxidase Activity of N-Hydroxy Pyridone Analogues are Shown 
Relative to  Untreated Control.  
 
 
                                                          NADH Oxidase (Complex I, III, IV) activity %a 
 
a- Data are expressed as the mean ± SEM (n = 3). 
 Compounds 4.105-4.110 were strong inhibitors of electron transfer. They were 
evaluated at a lower concentration range contrary to the libraries of analogues evaluated 
so far. Compound 4.108 has a 10-carbon side chain and a polar group on the redox core. 
It is a strong inhibitor of electron transfer at sub-micro molar concentration. All other 
compounds were strong inhibitors at higher concentrations. 







4.105 70 ± 2 67 ± 1 
4.106 60 ± 3 55 ± 1 
4.107 64 ± 1 61 ± 2 
4.108 44 ± 1 42 ± 1 
4.109 79 ± 2 75 ± 1 
4.110 85 ± 3 79 ± 2 
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Table 4.7. NADH Oxidase Activity of N-Hydroxy Pyridone Analogues (4.111- 4.121) 
are Shown Relative to Untreated Control.  
 
                                                    NADH Oxidase (Complex I, III, IV) activity %a 
 
a- Data are expressed as the mean ± SEM (n = 3). 
 
Compounds 4.111-4.121 are strong inhibitors of electron transfer at higher 
concentrations. Compounds 4.112 and 4.113 have an alkenenyl substituent on the 
terminal position of the side chain. They are strong inhibitors of electron transfer. 









4.111 75 ± 7 45 ± 4 34 ± 2 
4.112 30 ± 4 21 ± 2 13 ± 1 
4.113 20 ± 1 12 ± 1 12 ± 2 
4.114 93 ± 1 77 ± 7 70 ± 6 
4.115 17 ± 1 13 ± 2 11 ± 1 
4.116 74 ± 5 64 ± 4 60 ± 1 
4.117 78 ± 1 75 ± 9 67 ± 2 
4.118 37 ± 1 33 ± 5 10 ± 1 
4.119 89 ± 2 85 ± 3 89 ± 2 
4.120 74 ±3 69 ± 1 50 ± 1 
4.121 96 ± 2 94 ± 2 92 ± 1 
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Compound 4.115 has a polar amine and a polar (OH) group on the redox core. It is a 
strong inhibitor of electron transfer at lower concentrations. Compounds 4.119 and 4.121 
have long alkyl chain substituents and a protected polar amine (dimethylamine) group. 
They did not inhibit NADH oxidase strongly.  
4.5.6. IC50 Measurements 
Determination of IC50 Values for Complex I with Selected Analogues161 
Complex I (a large 40 sub-unit protein)71 being an important part of the 
functioning of NADH oxidase, is also a major source of ROS.71 It is important to 
understand the interaction of analogues of therapeutic interest with complex I. 
Accordingly, we measured the IC50 values for selected compounds (Table 4.8). 
Table 4.8. Determination of IC50 Values for Complex I with Selected Analogues 
(Scheme 4.6- 4.9) are Shown Relative to Untreated Control.  
 
                                                                            NADH:ubiquinone oxidoreductasea 
 
a- Data are expressed as the mean ± SEM (n = 3). 
Compound IC50  (µM) 
  
4.2 >100 
4.22 7 ± 1 
4.28 27 ± 3 
4.46 0.86 
4.94 > 30 
4.104 >30 
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Compound 4.2 has an idebenone core and a 10-carbon aliphatic side chain. It does 
not inhibit NADH oxidase activity, and therefore it also did not inhibit complex I activity 
at 100 µM. This is a very high concentration range for therapeutic interest. Compound 
4.22 is idebenone. It is strongly inhibitory towards NADH oxidase activity; 
unsurprisingly, it inhibited complex I activity with a 7 µM value. Compound 4.28 has a 
high IC50 value for complex I, consistent with the fact that it did not inhibit NADH 
oxidase activity. Compound 4.46 is a pyridinol analogue, which was a strong inhibitor of 
NADH oxidase activity. It also very strongly inhibited complex I. Compounds 4.94 and 
4.104 were not inhibitory in the NADH oxidase activity. Similarly, they did not inhibit 
complex I activity even at 100 µM concentration. If electron transfer has been inhibited 
due to irreversible binding, complex I may be a probable target. Binding to other 
complexes can be studied individually, which may reveal greater details of the electron 
transfer and inhibition mechanisms of a potential therapeutic agents.  
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Determination of IC50 Values for NADH Oxidase with Selected Analogues56, 161 
Comparison of the IC50 values for NADH oxidase and the individual complexes 
for a given antioxidant can provide insight into the inhibition mechanism. Compound 4.2 
did not inhibit NADH oxidase activity or complex I activity and has a high IC50 value. 
Compound 4.3 did not inhibit NADH oxidase activity and had an IC5o value >30 µM, 
which is beyond the range of therapeutic interest. Compounds 4.5 and 4.8 had moderate 
NADH oxidase activity, which is reflected in their IC5o values. Compound 4.20 did not 
inhibit the NADH oxidase activity and the IC5o value lies in a region beyond our 
therapeutic interest. Interestingly, the IC5o value for 4.22 was lower than IC5o found for 
complex I. 
Table 4.10. Determination of IC50 Values for NADH Oxidase Performed with Selected 
Analogues (Scheme 4.6-4.9) are Shown Relative to Untreated Control.  
 
                                                                             NADH Oxidase (Complex I, III, IV)a 
 
a- Data are expressed as the mean ± SEM (n = 3).




4.5 14 ± 2 
4.8 14 ± 1 
4.20 >30 
4.22 5 ± 1 
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4.6. Discussion 
Idebenone analogues had inhibitory effects toward the NADH oxidase when they 
had a shorter carbon chain, (10 carbon or less, except 4.2) or a polar group (-OH or -NH2) 
at the end of the side chain (4.22). An alkenyl group in the middle of the side chain or at 
the terminal position of the side chain inhibited electron transfer. Cyclic substituents at 
the end of the side chain did not result in inhibition of NADH oxidase activity. Phytol 
side chains resulted in partial inhibition of electron transfer. Polar atoms in the middle of 
the side chain and branched side chain did not result in inhibition of electron transfer by 
NADH oxidase. 
Pyridinol and pyrimidinol antioxidants showed similar behavior as the idebenone 
analogues. They inhibited electron transfer if the side chain was 10-carbon atoms or 
shorter. Polar substituents at the end of the side chain resulted in inhibition electron 
transfer. Analogues with 16-carbon side chains exhibited limited inhibition at higher 
concentrations. Methoxy groups as a substituent on the redox core resulted in reduced 
inhibition compared to the comparable methyl analogues. Analogues with longer 
aliphatic side chains did not inhibit the electron transport. Analogues having cyclic 
substituents on the redox core exhibited reduces extent of inhibition. Small nitrogenous 
heterocycles on the redox core resulted in compounds exhibiting moderate inhibition at 
the higher concentration ranges tested. 
The general observations made for pyridinol and pyrimidinol analogues were also 
valid for bicyclic pyridinol analogues. Analogues with shorter 10-carbon side chains on 
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the redox core, and having a polar group at the end of the side chain inhibited electron 
transfer. Compounds having longer side chains exhibited lesser inhibition.  
Alkylaminoquinone analogues with longer ester substituent on the vinylogous 
amides inhibited electron transfer. Analogues with polar groups at the end of the side 
chains also inhibited electron transfer. Unsurprisingly, the cyclic side chain analogue, 
similar to geldanamycin (4.104), exhibited the least amount of inhibition.  
The series of compounds bearing a N-hydroxy pyridone redox core were strong 
inhibitors of NADH oxidase. Analogues with protected polar groups on the redox core 
and longer side chain exhibited reduced inhibition. 
4.7. Experimental 
Preparation of Bovine Heart Mitochondria21 
 
Freshly cut bovine heart was collected from slaughter house. After cleaning, they 
were minced and diced. Tissues were suspended in buffer followed by differential 
centrifugation for the isolation of Bovine Heart Mitochondria (BHM).  
Briefly, heart tissues were diced into small pieces and then washed with isotonic 
sucrose buffer (0.25 M sucrose, 10 mM Tris-HCl, 0.5 mM EDTA, pH 7.8). The diced 
tissue was passed through a precooled meat grinder and mixed with three-fold ice cold 
sucrose buffer supplemented with a mixture of protease inhibitors. The suspension was 
homogenized in a waring blender for 25 sec at high speed. At this stage, the pH of the 
suspension was adjusted to 7.4 with 1 M Tris base. The homogenate was centrifuged for 
20 min at 1200 × g to remove cell debris. The floating fat layer was carefully removed by 
filtering the supernatant through layers of cheesecloth. The supernatant suspension was 
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homogenized in a tight fitting Teflon-glass Potter-Elvejhem homogenizer and then 
centrifuged at 26,000 × g for 20 min, collecting the pellet of mitochondria. The pellet was 
resuspended in sucrose buffer with 20% (v/v) glycerol. The protein concentration after 
resuspension was approximately 20 mg/mL, as determined by BCA protein assay (Pierce 
Chemical) using bovine serum albumin as a standard. Aliquots of mitochondrial 
suspensions were stored at –80 °C. 
 
Preparation of Submitochondrial particles (SMP)21 
 
Bovine heart mitochondria is thawed from the storage and then suspended in 
buffer (50 mM Hepes, 5 mM MgCl2, pH 7.5). The suspended mitochondria were 
sonicated at 7X speed for 30 sec. The homogenate was centrifuged for 7 min at 20,000 × 
g to remove mitochondrial debris. The supernatant suspension was then centrifuged at 
30,000 × g for 30 min. (Beckman-Coulter ultracentrifuge, XL-100K -01, SW-55 Ti 
rotor). The pellet (sub-mitochondrial particles) was suspended in buffer (50 mM Hepes, 5 
mM MgCl2, pH 7.5). The protein concentration after resuspension was approximately 20 
mg/mL, as determined by BCA protein assay (Pierce Chemical) using bovine serum 
albumin as a standard. Aliquots of microsomal suspensions were stored at –80 °C. 
NADH Oxidase Assay121  
 
 Inverted submitochondrial particles (SMP) were stored in a buffer containing 0.25 M 
sucrose and 10 mM Tris–HCl (pH 7.4) at −80 °C. Inhibitory effects of compounds on 
bovine heart mitochondrial complexes (I, III, IV) were evaluated by modification of a 
method described previously.19 Stock solutions (2 mg/mL in dimethylsulfoxide) of 
compounds were prepared and kept in the dark at −80 °C. Maximal dimethyl sulfoxide 
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concentration never exceeded 2% and had no influence on the control enzymatic activity. 
Beef heart SMP were diluted to 0.5 mg/mL. The enzymatic activities were assayed at 
30 °C and monitored spectrophotometrically with a Molecular Device SPECTRA Max-
M-5 (340 nm, ε = 6.22 mM−1 cm−1 for NADH). NADH oxidase activity was determined 
in a reaction medium (2.5 mL) containing 50 mM Hepes, pH 7.5, containing 5 mM 
MgCl2. The final mitochondrial protein concentration was 30 μg. The reaction was 
initiated by adding 50 μM NADH after the pre-equilibration of SMP with inhibitor for 
5 min. The initial rates were calculated from the linear portion of the traces. 
NADH: Ubiquinone Oxidoreductase Assay121 
NADH: ubiquinone oxidoreductase activity was measured using SMPs. The 
inhibition of NADH-ubiquinone oxidoreductase activity was determined under the same 
experimental conditions reported. 25 micrograms of SMPs were incubated at 37 °C for 5 
min with the test compound in 1 mL of 0.25 M sucrose containing 1 mM MgCl2, 2 μM 
antimycin A, 2 mM KCN, and 50 mM phosphate buffer, pH 7.4. The reaction was 
initiated by the addition of 50 μM NADH and 50 μM coenzyme Q1. The enzymatic 
activity, at 37 °C, was monitored at 340 nm.   
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